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CHAPTER 1 
 
INTRODUCTION 
 
Addiction 
Drug addiction can be defined as a chronically relapsing disorder 
characterized by compulsive drug use and loss of control over intake (Koob, 
2008).  In the United States alone, the economic cost of drug abuse in 2002 was 
estimated to be $180.9 billion.  This amount includes the loss in productivity from 
disability, death, and withdrawal from the workforce as well as the cost due to 
health and crime consequences.  Loss in productivity accounted for about 71% of 
the economic cost of drug abuse, while health care costs totaled about $16 billion 
(Harwood et al., 2004).  The costs of addiction reach much further than one’s 
pocketbook, however, and include emotional and physical devastation to the 
diseased individuals as well as their families, friends, and communities.  There 
are currently few effective treatments for helping addicted individuals remain 
abstinent from drugs of abuse.  Our lab is focused on understanding how the 
stress and reward systems of the brain interact, so that we may aid others in 
finding more effective treatments to prevent relapse in addicted individuals who 
are trying to become and remain drug free. 
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Synaptic Transmission 
 Drugs of abuse are known to mediate many of their effects on individuals 
by altering normal physiologic mechanisms of signaling in the brain.  The brain is 
made up of many networks of neurons which form synapses with one another in 
very organized, consistent patterns, resulting in various sets of nuclei that have 
similar connections and properties.  These sets of nuclei are often grouped by 
scientists together as brain regions and subnuclei within each region.  In a simple 
model, a neuron consists of an information-receiving end, the dendrite, a cell 
soma, and an information output end, the axon.  One cell soma can have many 
dendrites and axons.  A simple synapse is formed by one neuron’s axon terminal 
(the presynaptic terminal) and another neuron’s dendritic spine (the postsynaptic 
terminal).  Other types of synapses also exist such as axoaxonal or axosomatic.  
When a neuron is excited, it depolarizes from a negative resting membrane 
potential and this signal propagates down the axon to the axon terminal 
(presynaptic terminal), leading to calcium (Ca2+) influx in the presynaptic terminal 
via opening of voltage-gated Ca2+ channels.  Intracellular calcium levels thus 
rise, and Ca2+ signaling results in fusion of vesicles containing neurotransmitter 
with the cell membrane, resulting in release of neurotransmitter into the synaptic 
cleft (the space between the axon terminal and the dendritic spine).  The 
neurotransmitter then binds to receptors on the postsynaptic side of the synapse, 
leading to either a hyperpolarization (inhibition) or depolarization (excitation) of 
the postsynaptic cell.  If the cell is depolarized strongly enough, it too will fire an 
action potential and release neurotransmitter at its axons, thus propagating the 
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signal to yet other neurons (Kandel et al, 2000).  Thus, “synaptic transmission” is 
a relay of information from one neuron to another via neurotransmitter-mediated 
signaling at a synapse. 
 There are three primary types of synaptic transmission, including 
excitatory, inhibitory, and modulatory.  Excitatory transmission is primarily 
mediated by the neurotransmitter glutamate.  Inhibitory transmission is primarily 
mediated by the neurotransmitter GABA, although the neurotransmitter glycine 
also mediates inhibitory transmission.  Finally, many modulatory 
neurotransmitters such as norepinephrine (NE), corticotropin releasing factor 
(CRF), and dopamine (DA), can modulate glutamatergic and GABAergic 
transmission. 
 Glutamate is an excitatory neurotransmitter and leads to a depolarization 
at the postsynaptic terminal.  Glutamate acts on both ionotropic and metabotropic 
glutamate receptors (Kandel et al, 2000).  Kainate receptors (KAR), α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPAR), and N-methyl-D-
aspartic acid receptors (NMDAR) are the three ionotropic receptors and mediate 
fast excitatory transmission.  These receptors are ion channels, and when 
activated by glutamate, result in the flux of Na+ and K+, which depolarizes the 
postsynaptic membrane (Kandel et al, 2000).  This depolarization can be 
measured as an excitatory postsynaptic potential (EPSP) or an excitatory 
postsynaptic current (EPSC).  The NMDAR contains Mg2+ that blocks the pore at 
normal resting potentials.  This Mg2+ block is only relieved when the membrane is 
sufficiently depolarized (usually, via activation of AMPARs and KARs).  After the 
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Mg2+ block is removed, glutamate can bind and open the NMDAR ion channel 
(Kandel et al, 2000).  Importantly, NMDARs and some AMPARs can also flux 
Ca2+ in addition to Na+ and K+, resulting in activation of Ca2+-dependent 
intracellular signaling cascades.  Glutamate also binds at metabotropic glutamate 
receptors (mGluRs), and these receptors are linked to G-coupled proteins, and 
are therefore considered to be modulatory in nature (Bellone et al, 2008). 
 In the adult brain, GABA and glycine are inhibitory neurotransmitters and 
their release leads to a hyperpolarization at the postsynaptic terminal.  GABA is 
the primary inhibitory neurotransmitter in the brain, and binds at two receptors, 
GABAA and GABAB receptors.  The GABAAR is an ionotropic receptor and 
mediates fast inhibitory transmission.  Its activation leads to the influx of Cl-, 
which normally causes a hyperpolarizing response in adult neurons.  This 
hyperpolarization can be measured as an inhibitory postsynaptic potential (IPSP) 
or an inhibitory postsynaptic current (IPSC).  GABABRs are metabotropic, are 
therefore considered modulatory in nature (Kandel et al, 2000). 
 Finally, many neuromodulatory neurotransmitters exist that can alter 
glutamatergic and GABAergic mediated synaptic transmission.   These 
neurotransmitters include dopamine (DA), norepinephrine (NE), serotonin (5-HT), 
corticotropin releasing factor (CRF), as well as many others, and all modulatory 
neurotransmitters act on receptors that are coupled to G-proteins (Kandel et al, 
2000).  NE, for example, acts on several receptors such as the α2-adrenergic 
receptor (α2-AR).  NE acting through this receptor is known to depress excitatory 
transmission in regions such as the prefrontal cortex, bed nucleus of the stria 
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terminalis (BNST), and central nucleus of the amygdala (CeA) (Delaney et al, 
2007; Egli et al, 2005; Ji et al, 2008).  G-coupled protein receptors (GPCRs), via 
their coupling to G-proteins, exert their effects on neurons through second 
messenger signaling systems.  α2-ARs, for example, are coupled to Gi proteins 
that lead to inhibition of adenylate cyclase and decreased levels of the second 
messenger cAMP, resulting in signaling cascades that decrease glutamate 
release or the postsynaptic response to glutamate (Delaney et al, 2007; Egli et 
al, 2005; Ji et al, 2008).  Additionally, glutamate and GABA can act on 
metabotropic GPCRs that alter transmission through these second messenger 
systems (Kandel et al, 2000). 
 Learning is thought to occur when changes in synaptic transmission 
become long term, rather than transient in nature.  That is to say that a synaptic 
response remains altered, even hours, days, weeks, or months after the stimulus 
is gone (Kandel et al, 2000).  These changes are due to altered levels or altered 
composition of receptors at the membrane surface, changes in enzyme activity, 
changes in neuronal dendritic spine structure, or altered release of 
neurotransmitter.  Long term depression (LTD) and long term potentiation (LTP) 
are examples of these long term alterations at a glutamate synapse (Kandel et al, 
2000).   
 
Alterations in synaptic transmission by drugs of abuse 
As just described, the current theory maintains that sustained alterations 
in synaptic transmission in the brain are responsible for learning and memory.  
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The process of addiction involves many types of learning such as learning 
associations between drugs and the context in which the drugs are taken or 
received, as well as memory of both positive and negative experiences 
associated with drug intake.  These associations lead to craving in situations 
such as when an addict is in the environment where he/she used to take or buy 
drugs, and craving is exacerbated by stress.  Learned associations also include 
positive associations with experiencing drugs’ effects and negative associations 
of withdrawal when the actions of drugs wear off or when drugs are not available. 
Importantly, drugs of abuse hijack natural physiological signaling 
mechanisms by binding to endogenous receptors and transporters in the brain.  
For example, cocaine intake leads to alterations in dopamine (DA) release in the 
nucleus accumbens (NAc) and other regions of the brain by blocking the DA 
transporter (DAT) (Robbins et al, 2008).  As a result, metabolic and molecular 
processes occur that attempt to counteract these changes and bring DA levels 
back to normal, and therefore maintain homeostasis.  The term homeostasis 
encompasses the mechanisms that maintain stability within physiological 
systems and hold all parameters of the organism’s internal milieu within limits 
that allow an organisms to survive (Koob and Le Moal, 2001).  Chronic drug 
intake disrupts the ability of the brain to return to its normal homeostatic set point, 
leading to permanent changes in synaptic transmission over time (Koob et al, 
2001).  These changes have many physiologic consequences that lead to 
physiological and behavioral dependence on the drug of abuse (Koob et al, 
2001).  Thus, in many ways, drugs of abuse disrupt the brain’s natural 
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homeostatic set points over time, a mechanism described as allostasis, or the 
process of achieving stability through change (Koob et al, 2001)  The result is an 
allostatic state in which there is a chronic deviation of the regulatory systems in 
the body from their normal operating levels (Koob et al, 2001).   
Drugs of abuse essentially hijack the brain’s natural learning and memory 
mechanisms, as well as overwhelm the brain’s ability to maintain homeostasis, 
leading to permanent changes in the brain that result in behavioral addiction.  
Thus, addiction is truly a disease of the brain. 
 
Reward Pathway of the brain 
Addiction is a disease that alters the neural mechanisms involved in 
reward sensation and motivation.  The prefrontal cortex (PFC), nucleus 
accumbens (NAc), and ventral tegmental area (VTA) are three brain regions that 
make up the basic reward pathway of the brain.  Dopaminergic neurons from the 
VTA project to the NAc, and the VTA additionally sends a projection to the PFC.  
The PFC has glutamatergic projections that terminate in the NAc.  The NAc 
additionally sends afferent fibers to the VTA (Kandel et al, 2000).  Thus, these 
three regions are highly interconnected and make up the basic reward pathway 
(see Figure 1).  Many other brain regions modulate this basic reward pathway, 
including areas involved in emotions, stress, and motivational behavior.  These 
will be discussed in a later section.  Importantly, drugs of abuse all have different 
mechanisms of action that lead to their common effect of activating the VTA, 
thereby allowing high levels of DA to be released into the NAc (Koob et al, 2001).  
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Figure 1.  Basic reward pathway.  
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Mechanism of action for common drugs of abuse 
Common drugs of abuse include cocaine, amphetamines, alcohol, and 
opiates, and each have unique effects on the brain.  Cocaine acts by blocking the  
DA, 5-HT, and NE transport proteins (DAT, SERT, and NET respectively), that 
are responsible for removing neurotransmitter from the synapse.  Cocaine leads 
to an increase in DA in the NAc primarily by blocking the DAT, prolonging DA’s 
presence in the synaptic cleft (Nestler, 2005).   Amphetamines, on the other 
hand, reverse the DAT, causing an efflux of dopamine into the synaptic cleft 
(Koob et al, 2001).  The effects of alcohol on the reward circuitry are more 
complex, but its effects are thought to be due to enhancement of the GABAA 
receptor function and decreased NMDAR function (Koob et al, 2001).  Opiates 
act at endogenous opiate receptors including the µ, δ, and κ opioid receptors, 
and the addictive properties of opiates are typically attributed to the effects of 
opiates on µ opioid receptors (Koob et al, 2001).  Similarly, nicotine acts at 
endogenous nicotine receptors (nAChRs), and cannabinoids act at the 
endogenous cannabinoid receptors, CB1 and CB2  (Koob et al, 2001).  
 
Stages of Addiction   
Initiation, continued use, and tolerance 
Addiction is typically broken down into stages based on both biochemical 
changes in the brain and behavior.  These stages include initiation, continued 
use, tolerance, withdrawal, dependence, abstinence, and relapse.  The first time 
a person obtains and uses a drug is described as initiation.  Typically, those who 
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continue to take drugs of abuse do so because the initial experience was 
pleasurable.  For example, cocaine can induce intense feelings of euphoria and 
well-being, and can often increase the intensity of emotions and sexual feelings 
(Gawin, 1991; Johanson and Fischman, 1989).  As an individual continues to use 
drugs, he/she often develops tolerance, in which greater and greater amounts of 
drug are needed to achieve the positive effects of the drug.   
Withdrawal and Dependence 
Withdrawal is a negative state of being that is associated with cessation of 
drug intake and effectiveness.  Dependence on a drug of abuse is described as 
adaptations that result in withdrawal symptoms when the drug of abuse is 
discontinued (Koob, 2009b).  Physical symptoms of withdrawal depend on the 
drug being abused.  For example, common signs of withdrawal for opiates can 
include sweating, vomiting, shaking, nausea, dilated pupils, agitation, diarrhea, 
restlessness, insomnia, and more (Perez 2008).  Cocaine, on the other hand, 
may have less obvious physical symptoms of withdrawal, but symptoms include 
depressed mood, increased appetite, fatigue, restlessness, and agitation, nausea 
and vomiting, shaking, muscle pain, and disturbed sleep (Perez 2008).   
Anxiety is a classic symptom of withdrawal, and severe anxiety during 
withdrawal is one reason many drug abusers continue using drugs.  As users 
continue their use of a drug, they begin to do so to avoid the negative symptoms 
and signs associated with withdrawal, rather than for the pleasurable experience 
they had on their first few uses (Koob et al, 2001).  When an individual has lost 
control over his/her drug intake, he/she is considered an addict. Addicted 
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individuals will continue to abuse drugs despite serious adverse social 
consequences such as loss of a job or dissolution of their marriage or other close 
relationships, and health consequences such as cancer or liver damage.  
Addiction is typically described as a compulsive uncontrollable use despite these 
types of social and health consequences (Koob, 2009a).   
Abstinence and Relapse 
Individuals not using drugs for prolonged periods of time are said to be 
abstinent.  Addicted individuals maintaining abstinence from drugs of abuse, 
however, are at great risk for relapse to drug seeking even many years after they 
quit taking drugs.  Relapse is the return to drug seeking or drug intake by an 
addicted individual after a period of abstinence.  Relapse tends to occur in part 
due to intense craving or desire for more drugs. 
Relapse can occur due to re-exposure to the environment in which the 
addict abused drugs (context), exposure to drug cues such as drug 
paraphernalia, reexposure to the drug itself, and stress (Stewart, 2008).  Stress 
has been implicated as a major driving force in drug addiction, playing a 
significant role in relapse to drug- and alcohol-seeking (Brown et al, 1995; Le et 
al, 2000; Sinha et al, 1999).  In clinical studies, stress has been cited as the 
number one reason for relapse to drug addiction (Sinha et al, 1999).  
 
Animal models of addiction  
Several rodent models have been developed to study and model addiction 
as seen in humans.    
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Acquisition of drug preference and dependence, and effects of withdrawal 
Conditioned place preference (CPP) is a model in which researchers 
attempt to determine an animal’s preference or craving for a drug of abuse by 
pairing injection or availability of drug with one side (compartment) of a two-sided 
chamber.  The chamber consists of two compartments with different contexts, 
such as differences in scent, color of walls, texture of flooring or lighting, such 
that the animal can tell one compartment from the other.  Before the animal 
receives injections, it is allowed to roam freely between the two compartments 
and time spent in each side is monitored.  Following drug pairing episodes of 
varying periods of time, the animal is again monitored for its time spent and 
activity in each side of the chamber.  An increase in the drug-paired side is 
interpreted as the animal having obtained preference for the drug (Koob, 2008). 
Self-administration is another model for examining drug preference.  In 
this model, one of two levers available within an enclosed chamber is associated 
with an i.v. infusion of drug or some other mechanism of drug delivery.  This lever 
is designated the active lever, and a second lever which does not result in any 
action if pressed is termed the inactive lever.  In this paradigm, preference or 
desire for a drug can be measured by how much the animal presses the active 
lever to obtain the drug, and the ratio of active versus inactive lever pressing 
(Koob, 2008). 
Once an animal has obtained preference for a drug of abuse, animals can 
then be tested for dependence by looking at somatic signs of withdrawal, and 
also by being placed into a chamber similar to that used for CPP and tested for 
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aversion to a side of the two-compartment chamber associated with withdrawal 
(Koob and Le Moal, 2008).  For example, precipitated-withdrawal to opiate 
dependence is often accomplished by pairing a side of the chamber with 
naloxone injections.  Naloxone is an opiate-receptor antagonist that quickly leads 
to the withdrawal state in an animal dependent on an opiate such as morphine 
(Delfs et al, 2000; Fuentealba et al, 2000).  If the animal is forced to undergo 
withdrawal in only one side of the chamber, the animal will avoid that side of the 
chamber, thus indicating an aversion to withdrawal. Thus conditioned place 
aversion (CPA) measures the avoidance of the withdrawal-associated side of the 
chamber as compared to a pre-test in which the animal has no preference for 
either side of the chamber.  The measure of avoidance in this model is correlated 
to the animal’s aversion to the withdrawal state (Koob et al, 2008). 
Many experimental models of anxiety have been developed, and these 
are often used to assess changes in an animal’s anxiety levels following intake of 
drugs of abuse and during a withdrawal period.  Two commonly used models are 
the elevated plus maze and open field test (Ramos, 2008).  In the elevated plus 
maze model, animals are placed on an elevated maze that has open and closed 
arms resulting in the shape of a plus sign.  Animals described as anxious when 
placed in the center of the maze typically stay in the closed arms of the maze; 
where as animals described as less anxious are more likely to explore the open 
arms (Rodgers and Dalvi, 1997).  Similarly, animals can be monitored for their 
exploration in a novel, open field, environment.  In this model, anxious animals 
stay toward the edges of the compartment, where as less anxious animals are 
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likely to spend more time in the center of the compartment (Prut and Belzung, 
2003).   
Extinction 
Abstinence is modeled in rodents by simply not providing the animal with 
drug for extended periods of time, and typically the animal is no longer placed in 
the environment where it previously obtained the drug.  On the other hand, 
during extinction, the animal learns that a behavior previously required to obtain 
drug no longer provides the animal with the drug of abuse.  Extinction can be 
modeled using either the CPP chamber or self-administration model (Shaham et 
al, 2003).  In the CPP model, following acquisition of CPP, the animal is allowed 
back into the chamber over multiple sessions, but only saline is provided on the 
previously drug-paired side (as well as the previously non-drug-paired side 
(Shaham et al, 2003).  Thus, the animal eventually loses preference for the 
previously drug-paired side.  In the self-administration model, after acquiring 
preference for the drug-paired lever, the animal is placed back into the chamber 
over multiple sessions in which no drug is available.  Eventually the animal learns 
that no drug will be delivered following pressing on the previously drug-paired 
lever, and the animal will lower responding on the lever system to that of pre-
drug baseline responding (Shaham et al, 2003).  In both of these models, when 
the animal learns that the previously learned behavior will no longer bring about 
drug acquisition and the animal stops attempts to obtain drug, it is said to have 
achieved extinction.  Animals are often trained for extinction in order to further 
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understand learned behaviors; and importantly for treating addiction, animals are 
trained for extinction in order to learn more about relapse.   
Relapse and Craving 
Relapse and craving can be modeled in animals in several ways.  Animals 
may be primed with an injection of drug, and then placed back into a CPP 
chamber or self-administration chamber.   An animal previously trained to lever-
press for cocaine, for example, will reinstate lever pressing following a priming 
i.p. injection of cocaine (Koob, 2008).  Animals will also reinstate drug-seeking 
when given cues associated with a drug (Koob, 2008).  Stress-induced relapse is 
an important model for reinstatement of drug-seeking, but in response to a 
stressor rather than re-exposure to the drug (Shaham et al, 2003).  People cite 
stress as the number one reason they relapse to drugs of abuse (Sinha et al, 
1999).  Thus, understanding the mechanisms that lead to stress-induced relapse 
are extremely important when thinking about treatment for addicts.  Using the 
self-administration system, rats can be trained to lever press for access to a drug 
of abuse, such as an i.v. infusion of cocaine.  Following extinction, if a rat is 
placed back into the chamber and given a footshock stress, it will immediately 
resume responding on the active lever (Erb et al, 1996; Shaham et al, 2000a; 
Shalev et al, 2001).  Similarly, following a stressor, an animal will resume 
preference for the previously drug-paired side of a CPP chamber (Wang et al, 
2001).  Potential pharmacological therapies can be tested for their ability to 
prevent or induce reinstatement to drug-seeking in response to a stressor.  
These studies will be discussed in detail in a later section.   
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Stress  
Stress is defined in many ways, but all definitions convey the concept that 
stress is a demand placed on an animal.  Some describe stress simply as any 
alteration in psychological homeostatic processes (Burchfield, 1979).  Others 
define stress as any threat, either real or perceived, to the homeostasis and well-
being of an organism (Morilak et al, 2005). 
 
Acute, Chronic, Unconditioned, and Conditioned Stress 
Stressors can be acute or chronic, unconditioned or conditioned.  Acute 
stressors are of short duration and typically have a defined onset and offset, and 
an animal’s stress response recovers following cessation of the stressor (Morilak 
et al, 2005).  Chronic stressors, on the other hand, can continue for indefinite 
periods of time, often leading an animal to experience prolonged anxiety 
(Hammack et al, 2009; Walker et al, 2003).  Unconditioned stressors cause an 
animal distress without any previous learned behavior (Morilak et al, 2005).  
Examples of acute unconditioned stressors in rodent behavioral models include 
restraint stress, inescapable footshock stress, and forced-swim stress (Leao et 
al, 2009; Tanaka et al, 2000).  Chronic unconditioned stress is often modeled in 
rodents using long term intermittent housing in a cold environment (Ma and 
Morilak, 2005), or using a series of unconditioned stressors such as cage tilt, wet 
bedding, food restriction, cold environment, footshock, forced swim, and restraint 
stress at random intervals over several days (Hammack et al, 2009; Mineur et al, 
2006).  Conditioned stressors come about when a previously unconditioned 
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stimulus, such as a tone, is paired with an unconditioned stress such as 
footshock (Garakani et al, 2006).  The animal learns to associate the tone with 
the footshock, and will then have an anxiety-like response to the tone alone.  
Thus, stressors may be categorized based on their duration (acute or chronic) as 
well as whether or not they require learning of an association (conditioned or 
unconditioned). 
 
Processive vs Systemic Stressors 
Stressors on an animal or person can also be described as processive or 
systemic (Morilak et al, 2005).  Systemic stressors require no conscious thinking, 
and are real, imminent physical threats to health and well-being (Morilak et al, 
2005).  Thus, systemic stressors could be extreme heat or cold, massive blood 
loss, hypoglycemia, or any other stress that subconsciously activates the 
peripheral stress response (Morilak et al, 2005).  Processive stressors, on the 
other hand, require higher order brain processing to evoke a stress response in 
an animal and depend upon perception, cognitive processing and interpretation 
of the stimulus (Morilak et al, 2005).  For example, restraint stress is a 
prototypical processive stressor (Morilak et al, 2005).  Importantly, both 
processive and systemic stressors activate the stress circuitry in the brain and 
periphery, albeit via different pathways and mechanisms.  Both types of stressors 
importantly lead to activation of the paraventricular hypothalamus (PVN) which 
activates the peripheral stress system (Morilak et al, 2005). 
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Peripheral Stress Circuitry 
Although pathways and mechanism may differ, activation of the PVN is 
common to stress-evoking stimuli. When activated, the PVN releases 
corticotropin releasing factor (CRF) to the pituitary gland.  In response the 
pituitary gland releases adrenocorticotropic hormone (ACTH) to the adrenal 
glands.  The adrenal glands then release cortisol into the bloodstream, which 
leads to systemic stress responses such as increased blood pressure, increased 
blood glucose, and decreased immune responses (Koob, 2008).  Importantly, 
certain regions in the central stress circuitry contain receptors for cortisol and 
therefore provide a means of interaction and feedback between the central and 
peripheral stress circuits.  These include a direct negative feedback inhibition of 
the PVN and pituitary gland by cortisol (Koob, 2008).  Together, this circuitry is 
referred to as the hypothalamic-pituitary-adrenal (HPA) axis. 
 
Central Stress Circuitry 
Many brain regions have been shown to be involved in stress and reward 
circuitry, and are implicated in addiction.  These regions and their general role in 
stress and reward will be briefly reviewed here.   
Activation of the VTA is critical for mediating natural reward, and the VTA 
is one of the major sources of DA in the reward pathway of the brain (Wise, 
2009).  DA in the brain is important for conditioned preferences, synaptic 
plasticity in learning and memory, as well as in reinforcement of response habits.  
Perturbations in VTA DA function are attributed to anhedonia and anxiety from 
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various stressors including withdrawal from drugs of abuse, and alterations in 
VTA function are critical in mediating relapse to drug-seeking in addicted 
individuals (Wise, 2009).   
The NAc is also critically involved in reward processing, and mediates the 
addictive properties of drugs of abuse (Koob et al, 2001).  Lesions of the NAc 
lead to decreased self-administration of cocaine, opiates, alcohol, and other 
drugs of abuse (Wang et al, 2008). 
The limbic system, a set of regions involved in emotional regulation, is 
intricately involved in both stress and reward.  Parts of the hypothalamus, septal 
area, nucleus accumbens, frontal cortex, and the amygdala make up the limbic 
system and these regions are highly interconnected (Feltenstein and See, 2008; 
Lopez et al, 1999).  The limbic system is involved in fear and anxiety (Walker et 
al, 2003), and alterations in function of these regions by chronic stressors are 
thought to lead to anxiety disorders such as post-traumatic stress disorder 
(PTSD) (Shekhar et al, 2005).  Drugs of abuse also alter synaptic transmission of 
various neurotransmission systems throughout the limbic circuitry, leading to 
anxiety and craving during withdrawal from drugs of abuse (Feltenstein et al, 
2008).   
The amygdala, a critical mediator of behavioral response to emotions, can 
be divided into several general regions.  The central nucleus of the amygdala, 
CeA, is part of the extended amygdala critical for responses to short-term fear-
evoking stimuli, and is one central source of the neuropeptide CRF (Walker and 
Davis, 2008b).  The bed nucleus of the stria terminalis (BNST), which will be 
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discussed in detail in a later section, on the other hand, is critical in response to 
long-term fear- and anxiety-evoking stimuli (Walker et al, 2008b).  The 
basolateral amygdala (BLA) is extremely important in the formation, 
consolidation, and extinction of fear and emotional memory, and is therefore 
critical in the initiation of response to stressful events (Akirav and Maroun, 2007).  
Thus, the BLA plays a pivotal role in classical conditioning of learned fear (Akirav 
et al, 2007).   
The PFC is important for integration of affective states with autonomic and 
neuroendocrine regulation of stress, and it is critical in long-term fear extinction 
memory (Akirav et al, 2007; Hefner et al, 2008; Milad and Quirk, 2002).  
Importantly, the PFC regulates expression of amygdala-dependent memories 
(Quirk and Mueller, 2008).  It can be subdivided into the prelimbic and infralimbic 
cortices, and the infralimbic cortex is important for consolidation of extinction 
learning in rodent models (Quirk et al, 2008).   
Studies have shown that the insular cortex is important in processing 
emotional and homeostatic information, and is thought to be involved in drug 
addicts’ negative affective states during abstinence (Contreras et al, 2007).  For 
example, the insular cortex is critical for conscious aspects of needs and desires 
such as craving in drug-addicted individuals (Contreras et al, 2007, 2008; Naqvi 
et al, 2007). 
The lateral hypothalamus (LH) is also involved in regulation of feeding 
behaviors and reward, and chemical activation of the LH can induce 
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reinstatement to drug-seeking via an orexin-containing projection to the VTA 
(Harris et al, 2005).   
The periaqueductal gray (PAG) is a region of the midbrain involved in 
defensive behaviors, and the PAG regulates behaviors such as freezing, running, 
jumping, immobility and tachycardia, that are typical of a rodent under predator 
stress (Brandao et al, 2008).  The PAG additionally is involved in regulating 
conscious recognition of pain via inhibition of ascending pain pathways (Wood, 
2008). 
Finally, the nucleus tractus solitarus (NTS) is highly involved in stress, 
anxiety, and stress-induced relapse to drug-seeking.  This region contains a 
large NE projection to the limbic and reward circuitry, and is activated when an 
animal is under physiological or environmental stress (Walker et al, 2003).  The 
locus coeruleus (LC) is also a large source of NE in the brain, and is activated 
under stress (Lopez et al, 1999), although its projections are not critical in 
mediating stress-induced relapse to drug-seeking (Olson et al, 2006). 
 
Stress messengers 
Corticotropin-releasing factor (CRF) 
Corticotropin-releasing factor (CRF) is a 41 amino acid neuropeptide 
secreted in response to stress.  There are two known CRF receptors, CRF1R 
and CRF2R, and each is made by a separate gene (Bale and Vale, 2004).  CRF 
receptors are Gs GPCRs that lead to activation of adenylate cyclase.  Secretion 
of CRF by the PVN is important in activating the peripheral stress system.  CRF 
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released into the hypophyseal portal system by the PVN acts on CRF1Rs in the 
anterior pituitary leading to the secretion of ACTH, which acts on the adrenal 
gland leading to secretion of the stress hormone cortisol into the blood stream 
(Koob, 2008).  CRF is also expressed by extrahypothalamic brain regions such 
as the CeA and BNST as well as in hindbrain regions, and in peripheral tissues 
such as the gut, skin, and adrenal gland (Bale et al, 2004).  CRF is inactivated 
via binding to the CRF binding protein (CRF BP) in the liver and circulation.  
Another hormone, urocortin, also binds to CRFRs and is involved in the stress 
response, although its distinct functions are not clear (Bale et al, 2004). 
Central CRF has been implicated in many studies as a key stimulator of 
the stress response as well as a major player in mediating anxiety-like behaviors.  
Intracerebroventricular (ICV) infusions of CRF are known to decrease food 
intake, increase adrenal gland weight, reduce thymus and spleen weights, and 
increase cortisone and free fatty acid (FFA) levels.  CRF KO mice, CRF1R KO 
mice, and CRF2R KO mice have confirmed the critical role of CRF in the stress 
response and the role of the CRF1R in mediating this response.  The CRF2R, on 
the other hand, has been suggested to play a role in modulating the response 
mediated by CRF1Rs [for review, see (Bale et al, 2004)].   
CRF is known to play a role in anxiety, and potentially the development of 
anxiety disorders. (Waddell et al, 2008).  ICV infusion of the CRF antagonist α-
helical CRF9-41 increase latency and decrease time spent in the defense 
burying model of fear (Korte et al, 1994), and attenuate light-enhanced acoustic 
startle (de Jongh et al, 2003) and CRF-enhanced acoustic startle (Liang et al, 
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1992).  Central infusions of CRF increase anxiety-like behaviors in the elevated 
plus maze (Moreau et al, 1997), potentiate the acoustic startle response 
(Swerdlow et al, 1986), decrease punished responding in the conflict test (Britton 
et al, 1985), decrease exploratory behavior in novel environments (Britton et al, 
1982),  and reduce exploratory behavior in a novel open field, increase 
circulating corticosterone levels, and disrupt social interaction behavior 
(Campbell et al, 2004).  ICV infusions of CRF also block reinstatement to 
extinguished fear responses using a fear-potentiated startle model (Waddell et al, 
2008).  These and other anxiety measures have been shown to be mediated 
primarily via the CRF1R [for review see (Bale et al, 2004)].  CRF1R antagonists 
are currently being investigated for their anxiolytic role in alleviating anxiety 
disorders (Risbrough and Stein, 2006; Valdez, 2006).  Importantly, 
extrahypothalamic CRF and in particular, amgydaloid CRF, is implicated in 
mediating effects of anxiety (Berridge and Dunn, 1989a; Gray, 1993).   
ICV infusions of CRF antagonists have been shown to reverse ethanol 
and cocaine withdrawal-induced increases in anxiety.  Alcohol-withdrawn rats 
injected with a CRF antagonist attenuate alcohol self-administration and show 
decreased anxiety in an elevated plus maze paradigm (Valdez et al, 2002).  
Additionally, animals pretreated daily with ICV injections of immunoserum raised 
against CRF display reduced anxiety-like behavior during cocaine withdrawal 
(Sarnyai et al, 1995).    
Extrahypothalamic CRF has also been shown to mediate reinstatement of 
stress-induced drug-seeking behaviors.  ICV CRF infusions can reinstate self-
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administration of heroin and alcohol, and footshock stress- induced reinstatement 
to heroin- and alcohol-seeking can be attenuated by the CRF antagonists, alpha-
helical CRF or d-phe-CRF (Le et al, 2000; Shaham et al, 1997).  Similar findings 
were found in models of reinstatement for cocaine-seeking (Erb et al, 1998) and 
morphine-seeking (Lu et al, 2000), and CRF actions on reinstatement have been 
shown to be mediated by the CRF1R (Lu et al, 2000; Shaham et al, 1998).  CRF 
antagonists do not, however, block drug-priming reinstatement to drug-seeking, 
implicating a selective role of CRF in stress interactions with drug-seeking (Erb et 
al, 1998; Shaham et al, 1997).  CRF in the BNST specifically has been implicated 
in mediating stress-induced relapse to drug seeking behaviors and these studies 
will be reviewed in a later section.  
Norepinephrine (NE) 
Norepinephrine (NE) has additionally been implicated in mediating the 
stress response.  NE is synthesized by the enzyme dopamine beta-hydroxylase 
(DBH), which converts dopamine (DA) to NE.  NE is packaged into synaptic 
vesicles at presynaptic terminals by the vesicular monoamine transporter 
(VMAT).  Once released into the synapse, it is able to activate noradrenergic 
receptors (discussed later in this section).  NE is cleared from the synapse via 
uptake by the NE transporter (NET) for recycling, or is rapidly degraded into 
metabolites by the enzymes catechol-O-methyl-transferase (COMT), monoamine 
oxidase (MAO) and phenylethanolamine N-methyltransferase (PNMT) (Kandel et 
al, 2000).   
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NE is converted to epinephrine by PNMT, and it is released into the 
bloodstream by the adrenal medulla where it can modulate peripheral stress 
responses.   It is released in response to activation of the sympathetic nervous 
system and is an important part of the “flight or fight” response.  Epinephrine 
increases heart rate, triggers release of glucose from energy stores, and 
increases blood flow to skeletal muscle and away from areas such as the 
digestive system.  Thus, epinephrine released into the periphery prepares the 
animal to respond to a stressful situation (Kandel et al, 2000). 
Centrally, NE is extremely important as a neuromodulator for mediating 
and modulating responses to processive and systemic stressors, focused 
attention, the sleep-wake cycle, motivation, and other functions.  Many studies 
have shown that central NE is activated by a range of stressful stimuli such as 
immobilization, loud acoustic stimuli, electric foot-shock, cold exposure, and 
other stimuli (Morilak et al, 2005).  NE is implicated in anxiety-related disorders 
and mediation of stress-induced relapse to drugs of abuse.  Stress and 
withdrawal from drugs of abuse have been shown to increase NE levels 
throughout the brain (Koob, 2008).  Additionally, mice lacking DBH have been 
shown to be resistant to the anxiogenic effects of cocaine (Schank et al, 2008). 
There are two sources of NE in the brain, the locus coeruleus (LC) and the 
nucleus tractus solitarus (NTS) (Figure 3).  The LC projects via the dorsal 
noradrenergic bundle to areas of the brain such as the thalamus, hippocampus, 
cerebellum, and prefrontal cortex, and areas of the hypothalamus.  Early studies 
focused on the LC in response to stressful stimuli, and physiological stressors do 
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activate NE neurons in the LC (Page et al, 1992; Svensson, 1987; Valentino et 
al, 1993).  Lesions of the LC, however, do not alter naloxone-induced CPA in 
opiate-dependent rats, or the expression of withdrawal symptoms following 
naloxone-precipitated withdrawal (Caille et al, 1999).   
The NTS is a much smaller NE nucleus and projects via the ventral 
noradrenergic bundle (VNAB) to areas implicated in anxiety and stress-behaviors 
such as the amygdala, BNST, and PVN.  Lesions of the VNAB have been shown 
to inhibit footshock-induced reinstatement of morphine-seeking (Wang et al, 
2001), and block opiate withdrawal-induced conditioned place aversion (Aston-
Jones et al, 1999) implicating the NE from the NTS in stress and anxiety 
behaviors.  Additionally, mice lacking DBH were used to demonstrate that viral 
restoration of DBH in the NTS but not LC restored CPP for morphine, thus 
implicating NE from the NTS, but not LC, as critical for drug-seeking behaviors 
(Olson et al, 2006).   
  
27 
 
Figure 2.  Illustration of norepinephrine (NE) projections in the brain 
 
 
 
Figure 2.  Illustration demonstrating projections of NE from the locus coeruleus 
through the dorsal noradrenergic bundle and from the nucleus tractus solitarus 
through the ventral noradrenergic bundle.  Adapted from Fundamental 
Neuroscience (Zigmond, 1999). 
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β-adrenergic receptors 
NE acts on several G-protein coupled adrenergic receptors (ARs), found 
throughout the brain and periphery.  These include the α1-ARs, α2-ARs, and β-
ARs.  The β-ARs are composed of three isoforms, β1-ARs, β2-ARs, and β3-ARs, 
and all are Gs-coupled GPCRs (Koob, 2008).  Thus, activation of these receptors 
leads to activation of adenylate cyclase.  Alcohol withdrawal signs and symptoms 
are alleviated in both human and rodent models by administration of β-AR 
antagonists (Romach and Sellers, 1991; Trzaskowska and Kostowski, 1983).  
Increased anxiety following cocaine and morphine is also blocked by β-AR 
antagonists  (Harris and Aston-Jones, 1993).  Also, systemic injection of β-AR 
antagonists attenuates stress-induced reinstatement to cocaine seeking (Leri et 
al, 2002) as well as anxiogenic responses to cocaine administration (Rudoy and 
Van Bockstaele, 2007; Schank et al, 2008).   ICV administration of β-AR 
antagonists can also attenuate stress-induced behaviors such as restraint stress-
induced decreases in exploration on the elevated plus maze (Gorman and Dunn, 
1993).    
α1-adrenergic receptors 
α1-ARs are Gq coupled GPCRs and mediate their signaling through the 
phospholipase C (PLC) 2nd messenger cascade.   There are three subtypes of 
the α1-AR, α1A-ARs, α1C-ARs, and α1D-ARs (Koob, 2008).  α1-AR antagonists can 
reduce signs of withdrawal from alcohol in rodents (Trzaskowska et al, 1983).  
Additionally, the α1-AR antagonist prazosin can reduce heroin self-administration 
in rats given extended access (Greenwell et al, 2009), and can attenuate self-
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administration of cocaine in those given long term access (Wee et al, 2008; 
Zhang and Kosten, 2007).  The α1-AR antagonist prazosin can also attenuate 
ethanol self-administration in ethanol-dependent rats (Walker et al, 2008a).  
Thus, α1-ARs appear to play a significant role in mediating aspects of addiction. 
α2-adrenergic receptors 
 α2-ARs are Gi coupled GPCRs and their activation leads to inhibition of 
adenylate cyclase.  The α2-AR family is comprised of three isoforms, α2A-ARs, 
α2B-ARs, and α2C-ARs, in mammals (Bylund et al, 1994).  The α2A-AR has a 
widespread mRNA distribution in the brain including, but not limited to, regions 
involved in mediation of stress and anxiety, such as the NTS, amygdala, 
hippocampus, hypothalamus, and cortex (Scheinin et al, 1994; Tavares et al, 
1996; Wang et al, 1996).  The α2C-AR has a similar though not as widespread 
mRNA distribution as compared to the α2A-AR, whereas α2B-AR mRNA 
expression is mainly limited to the thalamus (Scheinin et al, 1994; Tavares et al, 
1996; Wang et al, 1996).  Both α2C-ARs and α2A-ARs are suggested to act as 
autoreceptors regulating the release of NE (Altman et al, 1999; Bucheler et al, 
2002; Devoto et al, 2004; Hein et al, 1999; Trendelenburg et al, 1999; 
Trendelenburg et al, 2001), although data also implicates α2-ARs as 
heteroreceptors regulating the release of other neurotransmitters such as 5-HT 
(Ansah et al, 2003; Gobert et al, 1998; Maura et al, 1992; Numazawa et al, 1995; 
Scheibner et al, 2001), DA (Bucheler et al, 2002; Gobert et al, 1998; Ihalainen 
and Tanila, 2002), and glutamate (Carey and Regehr, 2009; Delaney et al, 2007; 
Glass et al, 2001; Milner et al, 1998; Milner et al, 1999; Yamanaka et al, 2006).   
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Interestingly, peripheral administration of blood-brain-barrier permeant, but 
not impermeant, α2-AR agonists such as clonidine and lofexidine blocks stress-
induced reinstatement of heroin-seeking (Shaham et al, 2000b), cocaine-seeking 
(Erb et al, 2000), speedball- (mixture of heroin and cocaine) seeking (Highfield et 
al, 2001), nicotine-seeking (Zislis et al, 2007), and alcohol-seeking in rodent 
models (Le et al, 2005).  Lofexidine also decreases alcohol self-administration 
(Le et al, 2005).  ICV injections of the α2-AR agonist clonidine also blocks stress-
induced reinstatement to heroin-seeking (Shaham et al, 2000b).  These studies 
implicate central α2-ARs and NE rather than peripheral α2-ARs and NE in 
mediating stress-induced relapse to drug-seeking (Shaham et al, 2000b).   
It is clear that activation of central α2-ARs decreases anxiety during 
withdrawal and can prevent stress-induced relapse to drug seeking behaviors 
(Morilak et al, 2005).   In agreement with these findings, many studies have 
reported that the α2-AR antagonist yohimbine evokes anxiety in both human 
(Holmberg and Gershon, 1961; Murburg et al, 1991; Redmond and Huang, 1979) 
and animal studies (Davis et al, 1979; Holmes et al, 2002; Lang and Gershon, 
1963).   Cain and others found that yohimbine can facilitate extinction of 
conditioned fear in mice (Cain et al, 2004), while other groups concluded that 
yohimbine has no effect on extinction of conditioned fear (Mueller et al, 2009). 
Other studies have shown that yohimbine can enhance development of CPP for 
morphine (Zarrindast et al, 2002).  Additionally, intraperitoneal (IP) injections of 
yohimbine can reinstate methamphetamine-seeking following extinction in the 
self-administration model (Shepard et al, 2004), as well as alcohol-seeking (Le et 
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al, 2005; Marinelli et al, 2007; Richards et al, 2009) and cocaine-seeking (Lee et 
al, 2004).  Thus, yohimbine, through its putative action at α2-ARs appears to 
enhance anxiety-like behaviors.   
Other studies, however, have suggested that the anxiogenic effects of 
yohimbine are partially mediated through 5-HT1A receptors.  Powell and others 
have shown that yohimbine disrupts prepulse inhibition of acoustic startle in rats 
through the 5-HT1A receptor, and not α2-ARs, as the effects of yohimbine were 
blocked by a 5-HT1A-R antagonist but not an α2-AR agonist, and the effect of 
yohimbine was not mimicked by the more selective α2-AR antagonist 
atipamezole (Powell et al, 2005).  Studies looking at selectivity of yohimbine 
indicates that yohimbine has about a 10-fold selectivity for the α2A-AR over the 5-
HT1A-R, whereas atipamezole displays negligible effects on the 5-HT1A-R 
(Newman-Tancredi et al, 1998).  Thus it is likely that blockade of α2-ARs cannot 
account for all of the anxiogenic effects of yohimbine, though further work is 
needed to differentiate the roles of yohimbine and α2-ARs in stress and anxiety. 
  
The Bed Nucleus of the Stria Terminalis (BNST) 
 
General anatomy of BNST 
 The BNST, a part of the extended amygdala, is a very diverse region, 
involved in many physiological and behavioral functions such as modulation of 
stress, anxiety, and fear responses, relapse to drug seeking, maternal behavior, 
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reproductive behavior, aggression and defensive behaviors, analgesia and 
regulation of pain, and regulation of fluid homeostasis.   
 The BNST has been divided into multiple subnuclei as described in Tables 
1 and 2.  Our laboratory focuses on regulation of the anterior division of the 
BNST, as this region has been shown to be involved in anxiety and relapse to 
drug-seeking.  The laboratory uses a simplified classification of subregions within 
the anterolateral BNST, with the subregions being the dorsal anterolateral, dorsal 
anteromedial, and ventral subregions.  The dorsal anterolateral region 
encompasses the oval and juxtacapsular nuclei, and the dorsal anteromedial 
region encompasses the central core of the BNST.  Our ventral BNST recordings 
and localization encompass the subcommissural, fusiform, dorsomedial, and 
parastriatal nuclei.  Ju and Swanson have extensively characterized these 
subnuclei anatomically (Ju and Swanson, 1989b; Ju et al, 1989c), and much 
work has been done in recent years to further identify the efferents and afferents 
of various subnuclei (Alheid et al, 1998; Dong et al, 2000; Dong et al, 2001a; 
Dong et al, 2001b; Dong and Swanson, 2004a, b, 2006a, b, c).   
 Recently, Choi and others have shown that different subregions of the 
BNST differentially modulate the HPA axis.  Lesions of the posterior BNST 
elevated plasma ACTH and corticosterone levels in response to acute stress, 
and increased stress-induced PVN c-fos mRNA and CRF mRNA relative to 
controls (Choi et al, 2007).  Lesions of the dorsomedial and fusiform nuclei in the 
anteroventral BNST, on the other hand, attenuated the plasma corticosterone 
response and decreased c-fos mRNA in the PVN in response to acute stress 
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(Choi et al, 2007).  More recent studies by this group, however, did not support 
critical roles for the posterior and anteroventral BNST in response to chronic 
variable stress (Choi et al, 2008a; Choi et al, 2008b).  These data begin to 
suggest that the posterior BNST nuclei are normally involved in inhibition of the 
HPA axis, whereas anteroventral nuclei activate the HPA axis (Choi et al, 2007), 
although more work needs to be done to elucidate the roles of various 
subregions in the BNST on HPA axis activation. 
Our lab has primarily focused on afferents and efferents to the dorsal 
anterolateral (dBNST) and ventral (vBNST) regions of the BNST. 
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Table 1.  Anterior Division of the Bed Nucleus of the Stria Terminalis  
(adapted from Ju and Swanson, 1989) 
 
Anterior 
Division 
Subnuclei Description of Location Cytoarchitecture 
Anterodorsal 
 
 Dorsal to the AC, contiguous with 
the anteroventral area rostral and 
caudal to the AC 
Dense population of small 
and round/oval shaped 
cells; although central 
core contains high density 
of large triangular and 
multipolar cells 
Anterolateral  Borders the anterodorsal region 
rostrally and the posterior division 
caudally; merges with 
anteroventral area without clear 
boundary 
 
 Oval Lies dorsal to the AC, mid-level 
rostro-caudally, just medial to the 
internal capsule 
Uniform medium-sized 
round-oval neurons 
 Juxtacapsular Narrow vertical strip of cells just 
medial to the internal capsule 
Smaller but similar to 
neurons in oval nucleus 
 Rhomboid Caudal and ventral to the oval and 
juxtacapsular nuclei; lies between 
internal capsule and ventromedial 
running stria terminalis 
Uniform sized neurons 
that are round-to-
multipolar; contains 
substance P and 
somatostatin-
immuoreactive neurons 
Anteroventral  Bordered dorsally by AC, ventrally 
and medially by the substantia 
innominata and preoptic areas, 
caudally by the lateral and medial 
hypothalamic areas 
 
 Subcommissural 
zone 
Just ventral to the AC, similar to 
region just dorsal to the AC 
Generally small neurons 
 Fusiform Lies along ventrolateral border of 
the anteroventral area 
Small to medium-sized, 
oval-to-spindle-shaped 
neurons 
 Dorsomedial Bordered caudally and laterally by 
the dorsolateral nucleus; adjacent 
to the anteroventral area 
anteriorally 
Ill-defined nucleus; 
contained scattered 
medium-sized multipolar 
cells that are oriented 
dorsomeidial to 
ventrolateral 
 Dorsolateral Ventral to the AC, lateral to the 
dorsomedial nucleus, and 
dorsomedial to the magnocellular 
nucleus 
Medium-sized cells; many 
triangular or multipolar 
 Magnocellular Rostrally, it is ventrolateral to 
crossing of the AC, lateral to the 
dorsolateral nucleus; extends 
dorsolaterally to ventral border of 
the anterolateral area 
Darkly stained, large and 
plump cells 
 Ventral  Triangular are ventral to the 
magnocellular nucleus; caudally 
becomes narrow 
Medium-sized multipolar 
neurons 
 Related nuclei Parastrial and posteriordorsal Lie at interface between 
preoptic area and BNST  
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Table 2.  Posterior Division of the Bed Nucleus of the Stria Terminalis  
(adapted from Ju and Swanson, 1989) 
 
 
Posterior 
Division 
Subnuclei Description of Location Cytoarchitecture 
 Principal Sausage-shaped nucleus; rostrally, is 
ventral to tip of LV; caudally, spreads 
ventrally and medially 
Round-oval small densely 
packed neurons 
 Interfascicular Scattered cells that lie among the 
fibers of the stria terminalis and lateral 
to the principal nucleus 
Round-oval small densely 
packed neurons 
 Transverse Mid-dorsoventral levels in lateral 
portion of posterior diffusion; thin sheet 
of cells within the interfascicular and 
lateral principal nuclei 
More heterogeneous in 
shape and size than 
interfascicular  and principal 
nuclei 
 Premedullary Narrow sparse region of cells ventral 
to the obliquely running fibers of the 
stria at the caudal end of the BNST 
Transversely oriented 
fusiform nuclei 
 Dorsal  Ventral to the lateral ventricle, extends 
anteriorly over the anterodorsal area, 
caudally runs continuously with the 
stria extension of the BNST 
Dense small round neurons 
 Cell-sparse zone Ventral to the floor of the LV, medial to 
the dorsal nucleus 
Few cells 
 Related cell groups   
  Strial extension of the BNST – extends 
caudally along the dorsal border of the 
stria terminalis 
 
  Magnocellular neurosecretory cells – 
scattered within BNST along lateral 
border of fornix and stria medullaris 
and medial edge of internal capsule 
and stria terminalis 
 
  Bed nucleus of the AC – lateral to the 
region where the fornix passes caudal 
to the AC 
Small densely packed 
neurons with a few larger 
cells scattered  
 
AC = anterior commissure 
LV = lateral ventricle 
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Afferents to the BNST (see Figure 3 for a simplified illustration) 
Previous anatomical studies characterizing the inputs to the BNST have 
been completed almost exclusively in rat brain, with sparse studies also 
completed in cat, monkey, and opossum.   
Anterograde and retrograde tracer studies, as well as in vivo 
electrophysiology studies, have been used to identify glutamatergic afferents to 
the BNST.  Glutamatergic inputs to the lateral BNST include the infralimbic cortex 
(Massi et al, 2008; McDonald, 1998; McDonald et al, 1996; McDonald et al, 
1999; Room et al, 1985; Shin et al, 2008; Vertes, 2004; Weller and Smith, 1982), 
insular cortex (Shin et al, 2008; Weller et al, 1982), the basolateral amygdala 
(Dong et al, 2001a; McDonald, 1991; McDonald and Culberson, 1986; Shin et al, 
2008; Walker et al, 2003), as well as the ventral subiculum of the hippocampus 
(Canteras and Swanson, 1992; Cullinan et al, 1993; Dong et al, 2001a; Weller et 
al, 1982), lateral hypothalamus (Dalsass and Siegel, 1987; Goto et al, 2005), and  
parabrachial nucleus of the hypothalamus (PBN) (Alden et al, 1994; Pritchard et 
al, 2000; Saper and Loewy, 1980).  
While most studies examining infralimbic inputs to the BNST have been 
completed using anterograde tracer studies (McDonald, 1998; McDonald et al, 
1996; McDonald et al, 1999; Room et al, 1985; Vertes, 2004), Massi and others 
have shown that the infralimbic cortex directly enhances activation of 
dopaminergic neurons in the VTA through a relay in the BNST, and that this 
activation is modulated by cannabinoid CB1-receptors in the BNST (Massi et al, 
2008).    
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Other groups have used retrograde tracers to examine inputs to the BNST, and 
found that not only the infralimbic cortex, but also the insular cortex projects to 
the BNST (Shin et al, 2008; Weller et al, 1982).  Two other groups completed 
anterograde tracer studies in rat confirming this projection (McDonald et al, 1999; 
Yasui et al, 1991).   
In the adult brain, glutamatergic projections from one region to the other 
typically contain only one of two types of vesicular glutamate transporters 
(VGLUT1 or VGLUT2), as VGLUT1 and VGLUT2 have complementary patterns 
of expression in the brain (Fremeau et al, 2001; Herzog et al, 2001).  VGLUTs 
are responsible for packaging glutamate into presynaptic vesicles (Hayashi et al, 
2001).  VGLUT1 is typically found in cortical regions such as the infralimbic 
cortex and insular cortex, as well as the BLA and hippocampus; whereas 
thalamic and striatal regions and hypothalamic areas such as the parabrachial 
nucleus are shown to express primarily VGLUT2 (Boulland et al, 2004; Fremeau 
et al, 2001; Herzog et al, 2001; Islam and Atoji, 2008; Varoqui et al, 2002).  
Therefore, VGLUTs are potentially good markers to identify subsets of 
glutamatergic inputs to the BNST. 
The BNST also receives a strong GABAergic input from the CeA  (Dong et 
al, 2001a; McDonald, 1991; McDonald et al, 1999; Price and Amaral, 1981; Shin 
et al, 2008; Sun et al, 1991; Weller et al, 1982; Zahm et al, 1999), and this 
projection contains the neuropeptide CRF (Asan et al, 2005; Erb et al, 2001; 
Sakanaka et al, 1986).   
38 
 
The BNST receives noradrenergic projections from both the NTS and LC.  
In fact, the BNST, and in particular, the vBNST, receives the densest innervation 
of NE in the brain (Forray and Gysling, 2004).  Most NE in the BNST arises from 
the NTS (Delfs et al, 2000; Geerling and Loewy, 2006; Ricardo and Koh, 1978; 
Roder and Ciriello, 1994), and this projection is critical in stress-induced 
reinstatement to drug-seeking behaviors (Aston-Jones et al, 1999; Olson et al, 
2006; Shaham et al, 2000b; Wang et al, 2001).  The BNST also receives a much 
more modest projection from the LC (Dahlstrom and Fuxe, 1964; Forray et al, 
2004; Forray et al, 2000; Weller et al, 1982), although this projection is not critical 
for stress-induced reinstatement to drug-seeking (Olson et al, 2006; Shaham et 
al, 2000b; Wang et al, 2001).  Additionally, the A1 noradrenergic cell group from 
the ventrolateral medulla projects to the BNST (Woulfe et al, 1990). 
 Finally, the BNST receives dopaminergic innervations (Eliava et al, 2003; 
Phelix et al, 1992a) from the VTA (Hasue and Shammah-Lagnado, 2002; Zahm 
et al, 2001) and PAG (Hasue et al, 2002; Meloni et al, 2006; Shin et al, 2008), 
and dopamine has been shown to modulate neurons in the BNST (Kash et al, 
2008).  The BNST also receives a serotonergic input from the raphe nucleus 
(Phelix et al, 1992a, b). 
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Figure 3 
 
 
Figure 3.  Illustration of afferents and efferents in the BNST that are related to 
stress and reward processing. 
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Efferents of the BNST (see Figure 3, page 39 for a simplified illustration ) 
Anterograde tracer studies examining projections from the anterolateral 
and juxtacapsular nuclei of the BNST show that the BNST sends projections to 
the NTS, PBN, VTA, CeA, LH, BLA, PAG, and NTS, and infralimbic cortex (Dong 
et al, 2000; Dong et al, 2004a).  All of these regions innervate the BNST (see 
previous section), indicating reciprocal connections between these nuclei and the 
BNST. 
Both retrograde and anterograde tracer studies demonstrate a projection 
from the BNST to the NTS that is predominantly ipsilateral (Kang and Lundy, 
2009; van der Kooy et al, 1984).  Many studies demonstrate a projection from the 
BNST to the PBN, which is an important projection concerning gustatory 
sensation and feeding (Dong et al, 2000; Kang et al, 2009; Moga et al, 1989; 
Saggu and Lundy, 2008; Tokita et al, 2009).  The BNST additionally sends a 
GABAergic projection to the PVN, and this projection is critical in regulation of the 
HPA axis by the BNST (Cullinan et al, 1993; Dunn, 1987; Herman et al, 1994). 
The BNST also contains a reciprocal connection with the VTA (Dong et al, 
2004a; Georges and Aston-Jones, 2001).  Output from the BNST is typically 
assumed to be GABAergic  due to the large density of GABAergic interneurons 
present (McDonald, 1983; Sun and Cassell, 1993), and limited functional studies 
support a GABAergic projection from the BNST to the VTA (Eiler and June, 
2007).  Other studies, however, indicate that an excitatory projection from the 
BNST to the VTA exists (Dumont and Williams, 2004; Georges and Aston-Jones, 
2002).  Additionally, a CRF(+) projection from the BNST to the VTA has been 
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identified (Rodaros et al, 2007).  Despite the controversy over the makeup of the 
projection from the BNST to the VTA, it is generally accepted that activation of 
the BNST results in overall excitation of the VTA. 
The BNST also contains a dense reciprocal connection with the CeA.  
Together, the CeA and BNST are considered to make up the extended 
amygdala.  Like the projection from the CeA to the BNST, the projection from the 
BNST to the CeA (Dong et al, 2000; Dong et al, 2004a) is considered to be a 
GABAergic CRF(+) projection (Smith and Aston-Jones, 2008). 
 Finally, studies show that the anterolateral BNST also projects to multiple 
other regions in the brain, where it may modulate function.  These regions 
include the NAc, prelimbic cortex, substantia innominata, thalamocortical 
feedback loops, ventral CA1 area of the hippocampus, medial amygdaloid nuclei, 
midbrain reticular nucleus, as well as well as many other areas of the BNST itself 
(Dong et al, 2004a).  The BNST is a very diffuse region with many subnuclei.  
Additional studies completed in the magnocelluar division of the BNST, posterior 
BNST, and medial BNST indicate that regions of the BNST are also important for 
control of reproductive behavior, social behavior,  feeding behavior, and maternal 
behavior, in addition its involvement in the stress and reward pathway (Dong et 
al, 2004b, 2006a, b, c). 
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Role of the BNST in mediating anxiety and relapse to drug seeking 
behaviors 
 
The BNST has long been implicated in mediating responses to stress, and 
in particular anxiety, where anxiety is a response to an unconditioned stressor or 
long-term conditioned stressor (the closely related nucleus, the CeA, on the other 
hand is thought to be responsible for fear behavior, where fear is the response to 
a short-term conditioned stressor) (Alheid, 2003; Heimer, 2003; Henke, 1984; 
Walker et al, 2003).  Both restraint stress and stimulation of the BNST produce 
similar changes in locomotor, exploratory, and stereotypic behavior, and 
stimulation of the BNST also leads to vigorous escape behavior and biting 
(Casada and Dafny, 1991).  Similarly, lesion of the BNST in rats prior to a forced 
swim stress causes increased immobility and decreased escape behaviors, 
without changes in general motor behavior in an open field test, thus implicating 
the BNST in modulating responses to uncontrollable stress (Pezuk et al, 2008; 
Schulz and Canbeyli, 2000).  Studies also demonstrate a role for the BNST, but 
not the CeA, in light-enhanced startle, where light is an unconditioned stressor 
(Davis et al, 1997).  Additionally, inactivation of the BNST but not the more lateral 
amygdaloid nuclei, results in inhibition of TMT-induced freezing behavior (TMT is 
a component of fox odor (Fendt et al, 2003).  Lesions of the BNST also reduce 
freezing and escape latency to an inescapable shock (Hammack et al, 2004; 
Schulz and Canbeyli, 1999). Thus, the BNST appears to play a role in behavioral 
responses to unconditioned stressors [but see (Gray et al, 1993; Pezuk et al, 
2008; Treit et al, 1998)].   
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The BNST may also play a role in contextual fear responses to acute 
conditioned stressors, as lesions of the BNST produce anxiolytic-like effects in 
the Vogel conflict test and in contextual fear conditioning (Resstel et al, 2008; 
Sullivan et al, 2004).  Lesions of the BNST also prevent enhanced classical 
eyeblink conditioning following footshock stress (Bangasser et al, 2005), and 
inactivation of the BNST impairs retention in a one-trial step-through inhibitory 
avoidance task (Liang et al, 2001).  These studies demonstrate a role for the 
BNST in stress during learning.  Finally, the BNST is known to also be involved in 
acute responses to visceral and somatic pain (Deyama et al, 2007). 
Anxiety related to chronic stress, conditioned or unconditioned, also 
appears to be mediated by the BNST.  Interestingly, Pego and others showed 
that chronic unpredictable stress increases measures of anxiety in the elevated 
plus maze, and also leads to increased volume and dendritic hypertrophy in the 
BNST (Pego et al, 2008).  Lesions of the BNST block long term sensitization to 
the startle reflex and conditioned freezing to context (rather than cue) (Davis et 
al, 1997; Sullivan et al, 2004).  Lesions of the BNST also block sensitization of 
the acoustic startle reflex produced by repeated stress (Gewirtz et al, 1998).  
Additionally, lesions of the BNST attenuate reinstatement of extinguished fear, 
but not fear conditioning to a short-term conditioned stimulus (Waddell et al, 
2006).  Data further supporting this role for the BNST show that lesions of the 
BNST do not block fear-potentiated startle or conditioned freezing using an 
explicit cue, suggesting that the BNST is not involved in modulating stress 
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responses to acute conditioned fear stimuli (Hitchcock and Davis, 1991; LeDoux 
et al, 1988).   
The BNST is clearly involved in mediating anxiety-like responses to 
stressful unconditioned stimuli and long term responses to conditioned stimuli, 
and studies have also demonstrated a role for the BNST in stress-induced 
relapse to and withdrawal from drugs of abuse.  Relapse to cocaine-seeking is 
blocked when the BNST is inhibited by infusion of GABA agonists (McFarland et 
al, 2004).  Additionally, lesions of the BNST will block conditioned place aversion 
(CPA) to precipitated morphine withdrawal (Nakagawa et al, 2005). Finally, 
morphine-dependent abstinent rats, but not non-dependent rats, show elevated 
Fos expression in the BNST, and this expression negatively correlates with food 
preference in abstinent animals (morphine abstinent rats show reduced CPP for 
food-associated environments as compared to non-dependent rats) (Harris and 
Aston-Jones, 2003, 2007).  Thus, it is clear that the BNST plays an important role 
in stress-induced relapse to drug-seeking, as well as anxiety stress and altered 
hedonic values during withdrawal (Aston-Jones and Harris, 2004).   
 
Cell types, neurotransmitters in the BNST and their roles in stress and 
relapse 
 Glutamate and GABA are classic neurotransmitters, providing excitatory 
and inhibitory neurotransmission in the BNST.  Using in vitro whole cell 
recordings of BNST brain slices, Rainnie first demonstrated that electrical 
stimulation of cells in the BNST could evoke both excitatory and inhibitory post-
synaptic potentials (EPSP and IPSC respectively), and showed that EPSPs could 
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be abolished by application of an AMPAR antagonist, while IPSPs could be 
nearly abolished by a GABAA-R antagonist (Rainnie, 1999).  These and other 
findings were confirmed by Egli and Winder (2003).  These investigators went on 
to show that a substantial number of cells exhibited a low-threshold spike (LTS) 
driven by T-type Ca2+ channels, an Ih channel-dependent depolarization, and 
inward rectification in response to increasing current injection steps.  Egli and 
others also found regional differences in cells exhibiting these properties: cells in 
the vBNST typically exhibited a faster τ, exhibited a LTS (74.5% vs only 22.9% in 
the dBNST), and were less likely to exhibit an Ih-current (15.7% vs 48.6% in the 
dBNST) (Egli and Winder, 2003).  Hammock and Rainnie have gone further to 
describe three types of neurons in the dorsal anterolateral BNST, designated 
Types I, II, and III, based on characterization of electrical properties (Hammack 
et al, 2007).  Dumont and Williams recorded from projection neurons in the 
vBNST that were retrogradely labeled from the VTA.  They found that these 
neurons exhibited different properties from non-labeled neurons in the vBNST 
and had a higher membrane resistance (Rm), lower membrane capacitance, and 
were inwardly-rectifying as compared to nonlabeled neurons (Dumont et al, 
2004).   
Glutamatergic transmission can be regulated by a variety of glutamate 
receptors, including the ionotropic AMPARs and NMDARs which act as cation 
channels when activated, leading to depolarization and excitability changes; as 
well as metabotropic glutamate receptors (mGluRs) which are GPCRs.  Group I 
mGluRs (mGluR1 and mGluR5) act via the Gq coupled pathway, where as group 
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II (mGluR 2 and mGluR3) and group III mGluRs (mGluR4, mGluR6, mGluR7, 
and mGluR8) act via Gi/o coupled pathways.  Fast excitatory transmission in the 
BNST can be abolished with AMPAR and NMDAR antagonists (Egli et al, 2003; 
Rainnie, 1999).   High frequency stimulation can invoke an NMDAR-dependent 
LTP in the BNST which does not require the NR2A subunit of the NMDAR, and 
the early portion of this LTP is reduced by acute exposure to ethanol in a 
GABAAR-dependent manner (Weitlauf et al, 2004; Weitlauf et al, 2005).   
Dumont additionally showed that chronic morphine treatment selectively 
increases AMPA-dependent EPSCs in the dBNST of neurons projecting to the 
VTA (Dumont et al, 2008).  Finally, rats trained to self-administer cocaine or food 
pellets show an increase in excitability of vBNST neurons via alterations in 
AMPAR/NMDAR ratios (Dumont et al, 2005).  In animals receiving cocaine or 
food reward passively, however, these alterations were not observed, suggesting 
that the change in the AMPAR/NMDAR ratio could not have resulted from direct 
actions of these stimuli on the synapse but were likely mediated by alterations in 
synapses of the reward circuitry (Dumont et al, 2005). 
Activation of group II and group III mGluRs has been shown to 
presynaptically decrease glutamate transmission in the BNST (Grueter and 
Winder, 2005; Muly et al, 2007), and activation of group II mGluRs leads to LTD, 
indicating a role for them in synaptic plasticity of the BNST (Grueter et al, 2005).  
Moreover, activation of mGluR5, a type I mGluR, leads to an extracellular signal-
regulated kinase (ERK) 1-dependent LTD (Grueter et al, 2006a; Grueter et al, 
2008).  Additionally, this LTD is postsynaptically maintained as interference with 
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postsynaptic machinery via a dynamin-inhibitory peptide disrupts the late phase 
of the LTD (Grueter et al, 2008).  The early phase of this LTD is CB1 receptor 
dependent (Grueter et al, 2006a).  MGluR5 LTD in this region is disrupted 24 
hours but not 10 days following multiple cocaine exposures through animals self-
administering cocaine or via multiple noncontingent i.p. injections (Grueter et al, 
2006a; Grueter et al, 2008).  Grueter and colleagues were additionally able to 
show that cocaine promotes activation of the mGluR signaling pathway in vivo in 
the BNST resulting in occlusion or desensitization of mGluR5 (Grueter et al, 
2008).   
 GABAergic transmission in the BNST has not been as extensively 
characterized as glutamatergic transmission in this region, though 70-90% of 
neurons in the BNST are thought to be GABAergic (Cullinan et al, 1993; 
McDonald, 1983; Sun et al, 1993) and the BNST receives a dense GABAergic 
input from the CeA (Dong et al, 2001a; Price et al, 1981; Weller et al, 1982).  
Studies to date are limited in their exploration of alterations in GABAergic 
transmission by stress or drugs of abuse.  Neurotransmitters such as NE have 
been shown to modulate GABAergic transmission, however, and these studies 
will be discussed later in this section. 
The BNST contains several neurotransmitters including DA, NE, and 5HT, 
that can potentially modulate glutamatergic and GABAergic synaptic 
transmission in this region.  NE will be discussed later in this section.  DA is 
distributed throughout the BNST, with its highest concentration found in the 
dorsolateral and ventral BNST, as inferred by the density of TH labeling (Phelix 
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et al, 1992a).  Acute exposure to various drugs of abuse increases DA in the 
BNST (Carboni et al, 2000), and causes a DA-dependent activation of neurons in 
the BNST (Valjent et al, 2004).  D1R antagonists but not D2R antagonists can 
reduce alcohol-motivated responding in rats trained to self-administer alcohol 
(Eiler et al, 2003).  On the other hand, D1R antagonists injected in the dBNST of 
rats increase the rate of cocaine self-administration, indicating a role for D1Rs in 
self-administration (Epping-Jordan et al, 1998).  DA application enhances 
excitatory transmission in the dBNST through activation of D1 and D2 receptors, 
and this enhancement is activity dependent and requires downstream activation 
of CRF1Rs (Kash et al, 2008).  Both in vivo and ex vivo cocaine have been 
shown to induce a DA receptor- and CRF1R-dependent enhancement of 
NMDAR dependent short-term potentiation (Kash et al, 2008).  The effect of DA 
on inhibitory transmission has not been examined.   
 The BNST receives a serotonergic input from the raphe nucleus, which is 
concentrated more heavily in the medial BNST and innervates CRF(+) nuclei of 
the BNST (Phelix et al, 1992a, b).  Infusion of a 5-HT1R agonist into the BNST 
reduces the acoustic startle response, indicating an anxiolytic role for 5-HT in the 
BNST (Levita et al, 2004).  Alterations in 5-HT fiber density in the BNST have 
also been suggested following cocaine exposure in hamsters (DeLeon et al, 
2002).  Rainnie has shown that 5-HT can postsynaptically modulate excitability of 
cells in the medial and lateral dBNST, and that 5-HT can also modulate neurons 
presynaptically, although the response of cells was variable (Rainnie, 1999).  The 
49 
 
hyperpolarization response that many cells in the lateral dBNST exhibit in 
response to 5-HT is likely mediated through the 5-HT1AR  (Levita et al, 2004).   
The BNST also contains several neuropeptides including galanin (Morilak 
et al, 2003), neurotensin (Day et al, 2002; Ju et al, 1989b; Rainnie, 1999), orexin 
(Baldo et al, 2003; Nambu et al, 1999) , enkephalin (Ju et al, 1989b; Kozicz, 
2002; Rainnie, 1999), neuropeptide Y (NPY) (Walter et al, 1991), substance P 
(Walter et al, 1991), and oxytocin (Uhl-Bronner et al, 2005; Wilson et al, 2005).  
Many have of these are known to modulate synaptic transmission in the BNST. 
NPY, a neuropeptide suggested to have anxiolytic effects (Bannon et al, 2000; 
Heilig et al, 1989), is known to inhibit GABAergic transmission in the BNST, likely 
by regulating GABA release via activation of the Y2R (Kash and Winder, 2006).  
Galanin in the BNST is anxiogenic, as a galanin antagonist can attenuate anxiety 
behaviors and ACTH plasma levels in response to immobilization stress (Morilak 
et al, 2003).  Orexins have also been implicated in stress and anxiety and 
relapse to drug-seeking (Boutrel et al, 2005; Harris et al, 2005; Lawrence et al, 
2006), although the role of orexin in the BNST has not been elucidated.  
Enkephalin is another neuropeptide in the BNST that is known to be involved in 
reward, positive mood, and euphoria, and the BNST contains high levels of the 
endogenous µ-opioid receptor, which mediates the addictive properties of opiate 
drugs (Koob et al, 2001). 
Perhaps most interesting is a large set of data pointing to the role of the 
stress messengers CRF and NE in the BNST on anxiety, stress of withdrawal 
from drugs of abuse, and stress-induced relapse to drug-seeking. 
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CRF 
 The stress neuropeptide CRF in the BNST is critical for anxiety-like 
responses to stressful stimuli as well as for relapse to drug-seeking behaviors.  
Numerous studies have identified cell bodies expressing CRF throughout the 
BNST (Cummings et al, 1983; Ju and Han, 1989a; Moga et al, 1989; Olschowka 
et al, 1982; Phelix et al, 1992b; Sakanaka et al, 1987).  Additionally, the BNST 
receives a CRF(+) projection from the CeA (Sakanaka et al, 1986).  CRF mRNA 
is increased in the BNST following exposure to chronic mild uncontrollable stress 
(Kim et al, 2006).  Infusion of the CRF antagonist, α-helical CRF9-41, blocks 
reinstatement of extinguished fear (Waddell et al, 2008).  Lesions of the BNST 
block CRF-enhanced acoustic startle, and infusions of a CRF antagonist into the 
BNST block CRF-enhanced acoustic startle and CRF-enhanced startle to bright 
lights, but not fear-potentiated startle (Davis et al, 1997; Lee and Davis, 1997).  
Additionally, infusions of CRF into the BNST mimic anxiety effects produced by 
ICV infusions of CRF (Lee et al, 1997).  Infusions of CRF enhance retention of a 
one-trial step-through inhibitory avoidance task (Liang et al, 2001), and 
additionally lead to anorexia in food-deprived rats (Ciccocioppo et al, 2003).  
CRF antagonists injected into the BNST, on the other hand, attenuate stress-
induced behaviors such as submissive-defensive behaviors following social 
defeat (Jasnow et al, 2004).  Intra-BNST infusions of CRF increase anxiety as 
measured by the elevated plus maze, and these effects are blocked by co-
infusion of a CRF1R, but not a CRF2R, antagonist (Sahuque et al, 2006).  Rats 
also demonstrate conditioned place aversion (CPA) to a CRF-paired 
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environment, and this aversion is blocked by both CRF1R and CRF2R 
antagonists infused into the BNST (Sahuque et al, 2006).   
 CRF in the BNST also plays a role in relapse to cocaine-seeking, as 
infusion of the CRF antagonist D-Phe CRF12-41 block stress-induced 
reinstatement of cocaine-seeking (Erb and Stewart, 1999).  Injections of CRF1R 
antagonists in the BNST also block stress-induced reinstatement of morphine 
CPP (Wang et al, 2006). Interestingly, ethanol-withdrawn animals have increased 
levels of CRF in the BNST, and this is reversed when animals are given access 
to ethanol but not control diet (Olive et al, 2002).   
CRF projections from the CeA to the BNST are thought to be critical in 
CPA and relapse to drug-seeking behaviors (Smith et al, 2008).  Lesions of these 
projections can block stress-induced reinstatement to cocaine-seeking behavior 
(Erb et al, 2001).  Also, lesions of the CeA reduce opiate-withdrawal induced Fos 
activation in the BNST, but BNST lesions have no effects on Fos in the CeA, thus 
indicating a role for the projection of the CeA to the BNST in effects of opiate 
withdrawal (Nakagawa et al, 2005). 
 Electrophysiology studies looking at the effects of CRF on synaptic 
transmission in the BNST have also shed some light on how CRF modulates this 
region.  In whole-cell recordings in the vBNST, bath application of CRF enhances 
the amplitude of evoked and miniature IPSCs (eIPSCs and mIPSCs, 
respectively), but does not alter the paired-pulse ratio (PPR) of eIPSCs or the 
frequency of mIPSCs (Kash et al, 2006).  These and other findings suggest that 
the effects of CRF are mediated by postsynaptic CRF1Rs (Kash et al, 2006).  
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Interestingly, it appears that CRF and DA interact in the BNST.  Whereas 
activation of CRF1R does not appear to alter eEPSCs in the vBNST, as 
demonstrated by lack an effect of the CRF1R agonist urocortin I (Kash et al, 
2006); data from Kash and others does demonstrate an activity-dependent 
enhancement by DA on excitatory transmission in the dBNST that requires 
downstream activation of the CRF1R (Kash et al, 2008).   
NE (see Table 3) 
 The BNST has one of the densest innervations of NE in the brain (Forray 
et al, 2004; Phelix et al, 1992a), and this projection comes primarily from the 
NTS, the NE nucleus responsible for stress-induced relapse to drug-seeking 
behaviors (see section on Afferents to the BNST).   Immobilization stress, as well 
as chronic morphine treatment and withdrawal, significantly increase NE release 
into the BNST as measured by in vivo microdialysis (Cecchi et al, 2002a; 
Fuentealba et al, 2000; Pacak et al, 1995).  Additionally, exposure to 
trimethylthiazoline (TMT), a component of fox odor, leads to increased NE in the 
BNST, and lesion of the BNST blocks freezing in response to the odor (Fendt et 
al, 2005).  Infusion of NE into the BNST enhances retention in a one-trial step-
through avoidance task (Liang et al, 2001).   Also, increased NE in the BNST 
elicited by visceral and somatic pain stimuli is important for the negative affective 
component of these types of pain (Deyama et al, 2007).   
 In vivo recordings in the BNST of anesthetized rats have shown that 
infusion of NE in the BNST suppresses neuronal firing (Casada and Dafny, 
1993).  Additionally, microdialysis studies in ex vivo minislices of the BNST show 
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that NE inhibits glutamate release (Forray et al, 1999), and that NMDA, an 
agonist at NMDARs, increase NE release (Aliaga et al, 1995; Forray et al, 1995).  
In field recordings in the dorsal BNST, bath application of NE causes both 
excitation and inhibition of glutamatergic transmission, whereas bath application 
of NE in the vBNST always results in a depression of glutamatergic transmission 
(Egli et al, 2005).  Further work using whole recordings demonstrate that NE 
causes a depression of glutamate transmission in the dorsal BNST, and with 
prolonged application leads to an α1-AR dependent LTD (McElligott and Winder, 
2008).  Work by Dumont and Williams looking at inhibitory transmission revealed 
that NE causes an increase in spontaneous GABAA-mediated IPSCs, and this is 
not altered in rats sacrificed following naloxone-precipitated withdrawal from 
morphine (Dumont et al, 2004). 
 Thus, NE appears to play a significant role in regulation of the BNST, and 
in particular anxiety and addiction behaviors.  The adrenergic receptor subtypes 
mediating these effects have been parsed out to some extent.  Current findings 
will be reviewed next. 
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Table 3.  Known effects of norepinephrine (NE) in the BNST. 
NE Behavioral Findings Electrophysiological Findings 
 Increases in NE in the BNST 
are elicited by 
 Immobilization stress   
(Cecchi et al, 2002a; 
Pacak et al, 1995) 
 Chronic morphine 
treatment and 
withdrawal (Fuentealba 
et al, 2000) 
 Exposure to TMT 
(Fendt et al, 2005) 
 Visceral and somatic 
pain stimuli (Deyama 
et al, 2007) 
Infusion of NE into the BNST 
 Enhances retention in 
a one-trial step-through 
avoidance task (Liang 
et al, 2001) 
 Suppresses neuronal 
firing in in vivo 
recordings of 
anesthetized rats 
(Casada et al, 1993) 
NE causes 
 Inhibition of glutamate release in ex 
vivo minislices of the BNST in 
studies employing microdialysis 
(Forray et al, 1999) 
 Both excitation and inhibition of 
glutamatergic transmission in field 
recordings in the dorsal BNST (Egli 
et al, 2005) 
 A depression of excitatory 
transmission that results in an α1-
AR dependent LTD with prolonged 
NE application in whole cell 
recordings (McElligott et al, 2008) 
 A depression of glutamatergic 
transmission in the ventral BNST 
(Egli et al, 2005) 
 An increase in sIPSCs, that is 
unaltered in rats following naloxone-
precipitated withdrawal from 
morphine (Dumont et al, 2004) 
NMDA infused into the BNST increases 
release of NE in microdialysis studies 
(Aliaga et al, 1995; Forray et al, 1995) 
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β-adrenergic receptors (see Table 4) 
 Infusion of a mixture of β1-AR and β2-AR antagonists into the BNST 
attenuates immobilization stress-induced reduction in open arm exploration in the 
elevated plus maze (Cecchi et al, 2002a).  In animals showing high-reactivity to 
opioid withdrawal as measured by teeth chattering, eye twitching, and somatic 
signs, infusion of the β1-AR antagonist betaxolol into the BNST dose-dependently 
reduces teeth chattering to levels similar to animals with low-reactivity to opioid 
withdrawal (Cecchi et al, 2007).  Betaxolol injected into the BNST also blocks 
CPA to morphine withdrawal in high-reactivity animals (Cecchi et al, 2007).  
Additionally, infusion of β-AR antagonists into the BNST attenuates stress-
induced reinstatement to cocaine-seeking (Leri et al, 2002), as well as opiate-
withdrawal-induced CPA (Delfs et al, 2000).  Intra-BNST infusion of the β1/2-AR 
antagonist timolol prevents the development of behavioral sensitization to 
amphetamine (Colussi-Mas et al, 2005).  β-AR antagonists in the BNST also 
block the affective component of pain elicited by visceral and somatic pain stimuli 
(Deyama et al, 2009; Deyama et al, 2008).  β-ARs do not appear to be involved, 
however, in stress and learning as measured by retention of a one-trial step-
through inhibitory avoidance task (Liang et al, 2001).   
 Electrophysiological recordings have been used to examine the effects of 
β-ARs on transmission in the BNST.  Egli and others (2005) have shown that the 
β1/2-AR agonist isoproterenol causes an increase in the N2 amplitude in field 
recordings, and an increase in sharp microelectrode EPSP slope, with no change 
in eEPSC amplitude in whole cell recordings in the dBNST.  Interestingly, there 
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was no effect of isoproterenol in field recordings in the vBNST.  They also saw a 
dual effect of NE on excitatory transmission, and found that the increase in 
excitatory transmission caused by application of NE is blocked by the β1/2-AR 
antagonist timolol, but not the β1-AR antagonist betaxolol.  Application of the β2-
AR antagonist ICI-118,551 blunted the NE-induced increase of excitatory 
transmission.  Interestingly, when application of NE caused an increase in 
excitatory transmission, subsequent application of the β1/2-AR agonist 
isoproterenol led to a further increase in transmission.   On the other hand, when 
NE led to a decrease in excitatory transmission, application of isoproterenol had 
no effect.  These studies demonstrate a role for postsynaptic modulation of 
BNST neurons by activation of β2-AR receptors in the dorsal, but not ventral, 
BNST (Egli et al, 2005).  Dumont and Williams found that the β1/2-AR antagonist 
propranolol reduced a NE-mediated increase in GABAA-IPSCs during acute 
morphine withdrawal, but that propranalol had no effect on this measure in 
control slices, demonstrating recruitment of β-ARs during opioid withdrawal  
(Dumont et al, 2004). 
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Table 4.   Known functions of β-adrenergic receptors in the BNST 
 
Adrenergic 
Receptor 
Behavioral Findings Electrophysiological Findings 
β-ARs Infusion of β1/2-AR antagonists 
in the BNST 
 attenuates 
immobilization stress-
induced reduction in 
open arm exploration in 
the elevated plus maze 
(Cecchi et al, 2002a) 
 attenuates stress-
induced reinstatement 
to cocaine-seeking 
(Leri et al, 2002) and 
opiate withdrawal-
induced CPA (Delfs et 
al, 2000) 
 prevents the 
development of 
behavioral sensitization 
to amphetamine 
(Colussi-Mas et al, 
2005) 
 blocks the affective 
component of pain 
elicited by visceral and 
somatic pain stimuli 
(Deyama et al, 2009; 
Deyama et al, 2008) 
Infusion of a β1-AR antagonist 
in the BNST 
 reduces signs of opioid 
withdrawal (Cecchi et 
al, 2007) 
 blocks CPA to 
morphine withdrawal in 
high-reactivity animals 
(Cecchi et al, 2007) 
NE can both increase and decrease 
excitatory transmission in the BNST (Egli 
et al, 2005) 
 The β1/2-AR antagonist timolol 
blocks the increase in excitatory 
transmission elicited by NE in 
field recordings, and the β2-AR 
antagonist ICI-118,551 blunts this 
NE induced increase in excitatory 
transmission, but the β1-AR 
antagonist betaxolol has no effect 
(Egli et al, 2005) 
 When NE increases excitatory 
transmission, isoproterenol 
further increases transmission, 
but when NE decreases 
excitatory transmission, 
isoproterenol has no effect (Egli 
et al, 2005) 
The β1/2-AR agonist isoproterenol in the 
dorsal BNST 
 increases the N2 amplitude in 
field recordings 
 increases the EPSP slope in 
sharp microelectrode recordings 
 has no effect on eEPSC 
amplitude in whole cell recordings 
(Egli et al, 2005) 
The β1/2-AR agonist isoproterenol in the 
ventral BNST 
 has no effect on N2 amplitude in 
field recordings (Egli et al, 2005) 
The β1/2-AR antagonist reduces a NE-
mediated increase in GABAA-IPSCs 
during acute morphine withdrawal, but 
not in control conditions (Dumont et al, 
2004) 
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α1-adrenergic receptors (see Table 5) 
 
 Involvement of α1-ARs in the BNST has also been demonstrated in some 
studies.  Blockade of α1-ARs in the BNST blocks the reduction in open-arm 
exploration in the elevated plus maze induced by acute immobilization stress, as 
well as reduces plasma levels of ACTH following immobilization stress (Cecchi et 
al, 2002a).  Additionally, infusion of the α1-AR antagonist prazosin into the BNST 
impairs retention in a one-trial step-through avoidance task (Liang et al, 2001).  
Prazosin can also decrease self-administration in rats given long term, but not 
short term, access to cocaine, and rats given long term extended access to 
cocaine show decreased α1-AR-like immunoreactivity in neurons of the BNST, 
(Wee et al, 2008). 
In vivo microdialysis studies show that infusion of prazosin in the BNST 
reduces NE but not glutamate or GABA levels in the BNST; and that prazosin 
increases K+-induced glutamate release and decreases K+-induced NE release 
(Forray et al, 1999) in the BNST.  Activation of α1-ARs in whole cell recordings 
increases spontaneous IPSC frequency in the vBNST of animals exposed to 
morphine (Dumont et al, 2004). Using whole cell recordings, McElligott and 
Winder (2008) have shown that activation of α1-ARs in the BNST leads to LTD of 
excitatory transmission, and that blockade of α1-ARs can inhibit NE-induced LTD.  
Interestingly, whereas α1-AR mediated LTD is intact following acute cocaine 
exposure in mice, both NET KO and α2A-AR KO mice show disrupted α1-AR 
mediated LTD (McElligott et al, 2008), indicating a potential disruption of α1-AR 
function following chronic but not acute stress. 
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α2-adrenergic receptors (see Table 5) 
 Infusion of α2-AR agonists in the BNST leads to decreased anxiety and 
drug-seeking.  Injection of the α2-AR agonist clonidine into the BNST disrupts 
both acquisition and expression of fear-potentiated startle, and well as light-
enhanced startle (Schweimer et al, 2005).  Clonidine in the BNST also blocks 
increases in NE release elicited by TMT exposure (Fendt et al, 2005).  α2-AR 
agonists in the BNST also block opiate withdrawal-induced CPA (Delfs et al, 
2000), as well as stress-induced reinstatement of morphine-seeking (Wang et al, 
2001).  Activation of α2-ARs in the BNST also decreases extracellular NE levels 
in chronic morphine treated and 48hr withdrawn rats (Fuentealba et al, 2000).  
Interestingly, activation of α2-ARs decreases extracellular glutamate only in 
control, but not morphine-treated or withdrawn rats, suggesting morphine and 
withdrawal from morphine may lead to an increase in glutamatergic activity in the 
BNST (Fuentealba et al, 2000). 
 Forray and others have done multiple studies in the BNST examining the 
effect of α2-AR agonists on extracellular NE and glutamate levels using in vivo 
microdialysis, and have shown that infusion of the α2-AR agonist UK-14,304 in 
the BNST decreases extracellular NE and glutamate levels, while an α2-AR 
antagonist increases NE and glutamate levels (Forray et al, 1999).  α2-AR 
agonists also decrease K+-induced release of NE and glutamate, whereas α2-AR 
antagonists have the opposite effect (Forray et al, 1997, 1999).  Work using 
minislices containing vBNST also demonstrated that α2-AR agonists decrease 
K+-induced release of NE and glutamate in the BNST (Forray et al, 1995). 
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 Using field and whole cell recordings, Egli and others have shown that the 
α2-AR agonist UK-14,304 causes a depression of excitatory transmission in both 
the dorsal and ventral BNST, and that this effect is absent in the dBNST and 
greatly reduced in the vBNST of α2A-AR KO mice (Egli et al, 2005).  Application 
of UK-14,304 causes an increase in PPR, suggesting that α2-ARs modulate 
glutamatergic transmission presynaptically (Egli et al, 2005).   
Limited studies have examined the role of α2-ARs on inhibitory 
transmission in the BNST.  In vivo microdialysis studies in the BNST have shown 
that the α2-AR agonist UK-14,304 does not alter extracellular GABA levels in this 
region (Forray et al, 1999).  Additionally, clonidine, a partial α2-AR agonist, does 
not alter GABAA receptor-mediated spontaneous transmission in the vBNST 
(Dumont et al, 2004).  Further work is needed, however, to fully examine the 
potential role of α2-AR activation on modulation of GABAergic transmission. 
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Table 5.  Known functions of α-adrenergic receptors in the BNST 
 
Adrenergic 
Receptor 
Behavioral Findings Electrophysiological Findings 
α1-ARs Infusion of α1-AR antagonists in the 
BNST 
 blocks the reduction in open-
arm exploration in the 
elevated plus maze induced 
by acute immobilization 
stress (Cecchi et al, 2002a) 
 impairs retention in a one-
trial step-through avoidance 
task (Liang et al, 2001) 
 decreases self-
administration in rats given 
long-term, but not short-
term, access to cocaine 
(Wee et al, 2008) 
Rats given long-term extended 
access to cocaine show decreased 
α1-AR-like immunoreactivity in 
neurons of the BNST (Wee et al, 
2008) 
The  α1-AR antagonist prazosin  
 reduces NE but not glutamate or 
GABA levels in the BNST with in 
vivo microdialysis experiments 
(Forray et al, 1999) 
 increases K
+
-induced glutamate 
release and decreases K
+
-induced 
NE release in the BNST in in vivo 
microdialysis experiments (Forray et 
al, 1999) 
 inhibits NE-induced LTD in whole 
cell recordings (McElligott et al, 
2008) 
α1-AR agonists in the BNST 
 increases sIPSC frequency in the 
ventral BNST of animals exposed to 
morphine (Dumont et al, 2004) 
 causes an LTD of excitatory 
transmission in the dorsal BNST in 
whole cell recordings (McElligott et 
al, 2008) 
α1-AR-mediated LTD is absent in NET KO 
and α2A-AR KO mice, but is intact following 
acute exposure to cocaine in wild type mice 
(McElligott et al, 2008) 
α2-ARs Infusion of α2-AR agonists in the 
BNST 
 disrupts acquisition and 
expression of fear-
potentiated startle and light-
enhanced startle 
(Schweimer et al, 2005) 
 blocks opiate-withdrawal 
induced CPA (Delfs et al, 
2000) 
 attenuates stress-induced 
reinstatement of morphine-
seeking (Wang et al, 2001) 
 decreases extracellular NE 
levels in chronic morphine 
treated and 48 hr withdrawn 
rats (Fuentealba et al, 2000) 
 decreases extracellular 
glutamate levels in control, 
but not morphine-treated or 
withdrawn rats (Fuentealba 
et al, 2000) 
 blocks increases in NE 
release elicited by TMT 
exposure (Fendt et al, 2005) 
 
α2-AR agonists in the BNST 
 decrease extracellular NE and 
glutamate levels but do not alter 
GABA levels in in vivo microdialysis 
studies (Forray et al, 1999) 
 decrease K
+
-induced release of NE 
and glutamate (α2-AR antagonists 
have the opposite effect) in in vivo 
microdialysis studies (Forray et al, 
1999) and in minislices containing 
the ventral BNST (Forray et al, 
1995) 
 depress excitatory transmission in 
the dorsal BNST and this effect is 
absent in the α2A-AR KO mice (Egli 
et al, 2005) 
 depress excitatory transmission in 
the ventral BNST and this effect is 
diminished in the α2A-AR KO mice 
(Egli et al, 2005) 
 cause an increase in the PPR of 
excitatory transmission in whole cell 
recordings (Egli et al, 2005) 
 have no effect on GABAA-receptor 
mediated sIPSCs in the ventral 
BNST 
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Finally, despite data implicating a tonic NE tone in the BNST (Forray et al, 
1999), effects of α2-AR antagonists alone have not been examined using field or 
whole cell electrophysiology methods to determine the effects of potential tonic 
α2-AR activity in the BNST. 
Potential role of the α2A-AR subtype  
To date, no studies have examined which subtype of the α2-AR mediates 
behavior and physiological findings of α2-AR agonists and antagonists in the 
BNST.  A lack of effect of UK-14,304 in the α2A-AR KO mice suggests this 
subtype may be responsible, although α1-AR mediated LTD is also absent in this 
mouse (McElligott et al, 2008), indicating potential desensitization of remaining 
ARs, and therefore α2C-AR contributions to the effect of UK-14,304 cannot be 
ruled out.  Similar findings in hippocampal and cortical tissue from α2A-AR KO 
mice have shown that α2-AR agonist-mediated inhibition of NE is disrupted in 
these mice, thus indicating an autoreceptor role of the α2A-AR (Trendelenburg et 
al, 1999; Trendelenburg et al, 2001).  Therefore, the α2A-AR has been 
hypothesized to regulate stress and relapse behaviors due to its ability to 
regulate NE release (Stewart, 2000; Trendelenburg et al, 2001).   
 Recently, however, data has indicated that α2A-ARs may also regulate 
neurotransmission in the brain heterosynaptically, by modulating 
neurotransmitters other than NE.  Gilsbach and others found that mice 
expressing the α2A-AR only under the DBH-promotor (and therefore presumably 
only in noradrenergic cells) could not rescue behavioral deficits in α2A-AR KO 
mice that are typically attributed to α2A-AR autoreceptors, such as analgesia, 
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hypothermia, sedation and anesthetic-sparing (Gilsbach et al, 2009).  In the CeA, 
a structure closely related to the BNST, α2-ARs heterosynaptically regulate 
glutamate transmission via a direct interaction of the βγ subunit of the G-protein 
coupled receptor (GPCR) complex with release machinery (Delaney et al, 2007).  
Carey and Regehr have also demonstrated that activation of the α2-AR on 
climbing fiber-Purkinje cell synapses in the cerebellum can alter associative 
learning by disrupting LTD elicited via near-simultaneous activation of parallel 
fiber-Purkinje cell and climbing fiber-Purkinje cell synapses (Carey et al, 2009).  
They demonstrate that α2-ARs heterosynaptically modulate glutamatergic 
transmission selectivity at climbing fiber-Purkinje cell synapses via a presynaptic 
mechanism (Carey et al, 2009).  Additionally, α2A-ARs in the prefrontal cortex 
mediate depression of excitatory transmission, although likely through a post-
synaptic mechanism (Ji et al, 2008).  The α2A-AR selective agonist guanfacine 
improves performance on working memory tasks via inhibition of postsynaptic 
cAMP-HCN channel signaling in the prefrontal cortex (Wang et al, 2007), and 
other studies support these findings (Barth et al, 2008; Carr et al, 2007). 
Studies using electron microscopy to localize the α2A-AR also support a 
potential heterosynaptic role for the receptor.  In the NTS, ventrolateral medulla, 
and hippocampus, α2A-ARs have been noted on presynaptic autoreceptor and 
heterosynaptic terminals, as well as postsynaptically, and on glial cells (Glass et 
al, 2001; Milner et al, 1998; Milner et al, 1999).  Thus, it is possible that α2-ARs 
may regulate excitatory synaptic transmission in the BNST indirectly by 
regulating NE release (as a presynaptic autoreceptor), directly by regulating 
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glutamate release (as a presynaptic heteroreceptor), and/or by altering the 
response to glutamate postsynaptically (as a postsynaptic receptor) (see Figure 
4). 
Potential CRF-NE interactions in the BNST 
 Finally, several authors have proposed that CRF and NE interact in the 
brain, and data indicate that NE may regulate CRF release through activation of 
the α1-AR (Berridge and Dunn, 1989b; Forray et al, 2004; Smith et al, 2008; 
Stewart, 2000), although an interaction between α2A-ARs or β-ARs and CRF 
cannot be ruled out.   Authors have pointed to the BNST as a potential region for 
this interaction (Forray et al, 2004; Stewart, 2000), yet no studies to date have 
looked at co-distribution of ARs and CRF.   
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Figure 4 
 
 
Figure 4.  α2A-ARs may potentially regulate glutamate transmission in the BNST 
indirectly by altering NE release at NE terminals (as an autoreceptor), or more 
directly by regulating release of glutamate at glutamatergic terminals (as a 
heteroreceptor), or by altering the postsynaptic response to glutamate (as a 
postsynaptic receptor). 
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Summary 
The BNST is a critical relay in mediating behavioral and physiological 
responses to stress and anxiety.  Stressors such as withdrawal from drugs of 
abuse lead to increases in NE in the BNST, and α2-AR agonists infused in the 
BNST block stress-induced reinstatement to many drugs of abuse.  
Electrophysiology studies have examined the role of α2-ARs on excitatory 
transmission in the BNST, but the role of the α2A-AR subtype is currently unclear.  
In addition, although studies using the α2-AR antagonist yohimbine indicate that 
systemic injections of yohimbine indeed elicit anxiety-like behaviors, the exact 
mechanism of the action of yohimbine is debated.  Finally, most studies 
elucidating the anatomical inputs to the BNST have been conducted in rat, and 
despite many behavioral and physiology studies conducted in mouse, no 
anatomical studies have confirmed these inputs to the BNST in the mouse 
model. 
 
Hypothesis 
NE modulates glutamatergic and GABAergic transmission of cells in the dBNST 
through heterosynaptic α2A-ARs. 
 
Specific Aims 
Specific Aim 1  To test the hypothesis that activation of α2A-ARs in the dBNST 
modulates glutamatergic and GABAergic transmission of cells in the dBNST.   
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Specific Aim 2  To test the hypothesis that α2A-ARs localize to heterosynaptic 
terminals in the dBNST.  
 
Specific Aim 3  To test the hypothesis that yohimbine affects glutamate 
transmission in the dBNST through a non-α2-AR dependent mechanism.  
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CHAPTER II 
 
THE α2AAR HETEROSYNAPTICALLY MODULATES GLUTAMATERGIC 
TRANSMISSION IN THE BNST 
This chapter describes work completed toward the fulfillment of Aims I and 
II of my thesis project.   
 
Introduction 
Stress has been implicated as a major driving force in drug addiction, 
playing a significant role in relapse to drug- and alcohol seeking (Brown et al, 
1995; Le et al, 2000; Sinha et al, 1999).  Relapse to drug-seeking can be 
modeled in rodents using behavioral paradigms such as stress-induced 
reinstatement of drug-seeking (Shaham et al, 2000a) and conditioned place 
preference (Wang et al, 2001).  The bed nucleus of the stria terminalis (BNST), 
part of a region known as the extended amygdala, has been suggested to play 
an important role in general anxiety and relapse to drug abuse (Walker et al, 
2003).  The BNST is well-situated to process inputs from other brain regions 
involved in stress and reward pathways, such as the insular and infralimbic 
cortices, hippocampus, and the central and basolateral nuclei of the amygdala 
(Chiba et al, 2001; Shin et al, 2008; Weller et al, 1982).  The BNST sends 
projections to many brain regions, including the hypothalamus (Conrad and Pfaff, 
1976; Swanson and Cowan, 1979), a region involved in the stress response; and 
the ventral tegmental area (VTA) (Georges et al, 2002; Swanson et al, 1979), a 
region involved in reward and motivation.  Thus, the BNST is an important center 
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for processing inputs from stressful stimuli and integrating them into stress and 
reward circuitry. 
 The noradrenergic system is a key mediator of the stress response, and 
has been implicated in relapse to drug addiction.  The BNST receives one of the 
densest noradrenergic (NE) inputs in the brain (Brownstein et al, 1974).  This 
input arises primarily from the nucleus tractus solitaris (NTS) which makes up 
part of the ventral noradrenergic bundle (VNAB) (Aston-Jones et al, 1999).  
Lesions of the VNAB result in the inhibition of footshock-induced reinstatement of 
morphine-seeking (Wang et al, 2001) and heroin-seeking (Shalev et al, 2001).  
Withdrawal from chronic morphine treatment increases extracellular 
norepinephrine (NE) levels in the rat BNST (Fuentealba et al, 2000).  Lesions of 
the VNAB have also been shown to block opiate withdrawal-induced conditioned 
place aversion (Aston-Jones et al, 1999).  Also, mice lacking the enzyme 
dopamine beta-hydroxylase (DBH) do not exhibit morphine-induced conditioned 
place preference (CPP).  Viral restoration of DBH in the NTS but not the locus 
coeruleus (the source of NE in the dorsal noradrenergic bundle) of these mice 
can restore CPP for morphine, indicating the importance of NE in this paradigm 
(Olson et al, 2006).   Importantly, NE has been shown to suppress neuronal firing 
in the BNST and studies indicate that the BNST output is under noradrenergic 
tone (Casada et al, 1993; Dumont et al, 2004; Egli et al, 2005; Forray et al, 
1997).  In total, these data strongly implicate NE in the BNST in stress-reward 
related behaviors. 
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 NE is known to act through β-adrenergic receptors (β-ARs), α1-adrenergic 
receptors (α1-ARs), and α2-adrenergic receptors (α2-ARs) in the BNST (Dumont 
et al, 2004; Egli et al, 2005; Matsui and Yamamoto, 1984; McElligott et al, 2008).  
Evidence suggests that α2-ARs within the BNST play important roles in stress-
addiction interactions.  Peripheral administration of blood-brain-barrier permeant 
α2-AR agonists blocks foot-shock induced reinstatement of heroin seeking 
(Shaham et al, 2000b), and alcohol-seeking in rats (Le et al, 2005).  Intra-BNST 
injections of α2-AR agonists block morphine withdrawal-induced conditioned 
place aversion (Delfs et al, 2000), and stress-induced reinstatement of morphine-
conditioned place preference (Wang et al, 2001).  Intra-BNST injection of the α2-
AR agonist clonidine also blocks stress-induced freezing behavior induced by the 
innate stressor trimethylthiazoline, a component of fox feces (Fendt et al, 2005). 
 Previous electrophysiology studies have implicated α2-ARs in the 
modulation of glutamatergic and potentially GABAergic transmission in the 
BNST.  The non-subtype specific α2-AR agonists UK-14,304 and clonidine cause 
a decrease in evoked excitatory transmission in the BNST and this effect is 
absent in brain slices prepared from α2A-AR knockout (KO) mice (Egli et al, 
2005).  Paired-pulse ratios of evoked synaptic responses are increased by UK-
14,304, suggesting a presynaptic modulation of glutamate release by α2-ARs 
(Egli et al, 2005).  Although NE is known to modulate both glutamatergic and 
GABAergic transmission in the BNST through α1-AR and β-ARs (Dumont et al, 
2004; Egli et al, 2005; McElligott et al, 2008), the modulation of inhibitory 
transmission by α2-ARs in naïve mice has not been extensively studied.  The α2-
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AR partial agonist clonidine does not alter GABAA receptor-mediated 
spontaneous transmission in the ventral BNST, suggesting that α2-ARs may not 
modulate GABA transmission (Dumont et al, 2004). 
 There are three known α2-AR subtypes, α2A-AR, α2B-AR, and α2C-ARs, in 
mammalian brain tissues (Bylund et al, 1994).  The α2A-AR has a widespread 
mRNA distribution in the brain including, but not limited to, regions involved in 
mediation of stress and anxiety, such as the NTS, amygdaloid complex, 
hypothalamus, and cortex (Scheinin et al, 1994; Wang et al, 1996).  The α2C-AR 
has a similar though not as widespread mRNA distribution as compared to the 
α2A-AR, whereas α2B-AR mRNA expression is mainly limited to the thalamus 
(Scheinin et al, 1994; Wang et al, 1996).  Studies have implicated the α2A-AR as 
a major subtype utilized by NE to modulate neuronal function in the brain, 
although the α2C-AR also plays a role in this modulation (Trendelenburg et al, 
2001).  Egli and others have shown that the effects of the α2-AR agonist UK-
14,304 on excitatory transmission are absent in the dBNST and dramatically 
reduced in the vBNST of the α2A-AR knockout mouse (Egli et al, 2005).  
However, additional data indicate that actions of other ARs in BNST are also 
absent in these knockout mice, raising the possibility that these phenotypes may 
be more related to autoreceptor rather than heteroreceptor roles of the α2A-AR 
(Egli et al, 2005; McElligott et al, 2008).  Similarly, hippocampal and cortical 
tissue from α2A/D-AR KO mice show substantial loss of α2-AR agonist-mediated 
inhibition of NE release, suggesting that these mice have disruptions in 
autoreceptor-mediated inhibition of NE (Trendelenburg et al, 1999; 
72 
 
Trendelenburg et al, 2001).  Recently, however, research in mice expressing the 
α2A-AR in only adrenergic neurons (autoreceptors), has suggested that many 
functions previously attributed to the role of autoreceptors such as analgesia, 
hypothermia, sedation, and anesthetic-sparing, may actually be mediated by α2A-
ARs on non-noradrenergic (heterosynaptic) neurons (Gilsbach et al, 2009).  
Studies in the central nucleus of the amygdala also point to a heterosynaptic 
function of α2-ARs in the brain (Delaney et al, 2007).  We have therefore focused 
our current studies on the α2A-AR subtype, with the hypothesis that 
heterosynaptic α2A-ARs modulate acute synaptic transmission in the BNST. 
 We have taken advantage of a hemagglutinin α2A-AR knockin (HA α2A-AR 
KI) mouse to localize the α2A-AR within the BNST.  Using the α2A-AR selective 
agonist guanfacine, we have characterized the ability of α2A-ARs to modulate 
both excitatory and inhibitory transmission in the dorsal BNST.  We provide 
evidence that the α2A-AR functions in the BNST as a heteroreceptor regulating 
glutamate release presynaptically, with a more modest action on GABAergic 
transmission.   
 
Experimental Procedures 
 
All procedures were performed according to Institutional Animal Care and Use 
Committee approved procedures. 
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Light Microscopy Level Immunohistochemistry Studies 
Fluorescent Immunohistochemistry 
A minimum of 10 adult male 6-14 week old C57BL/6J mice (Jackson 
Laboratory), a minimum of 10 male and female 6-14 week old HA-tagged α2A-AR 
knockin (KI) mice (backcrossed to C57BL/6 background for 10 generations, 
provided by Qin Wang at University of Alabama), and two male 6-14 week old 
NET KO mice (provided by Randy Blakely at Vanderbilt University) were 
transcardially perfused with phosphate-buffered saline (PBS), followed by 4% 
paraformaldehyde.  Brains were post-fixed in 4% paraformaldehyde for 2-3 days 
at 4°C, and were then transferred to 30% sucrose until fully impregnated. 
Following post-fixation, 30 μm coronal or 30 μm sagittal sections of brain were 
sliced on a cryostat (Leica CM3050S).  Sections containing the BNST were then 
free-floated for immunolabeling.  Sections were blocked with 4% normal donkey 
serum containing 0.2% Triton-X-100 in PBS.  Sections were then incubated with 
primary antibody for 48 hours at 4°C, followed by incubation with cyanine dye- or 
Alexa fluorophore-conjugated secondary antibody for 24 hours at 4°C.  Sections 
were mounted on slides, sealed with PolyAquamount, and left overnight to dry.   
Reagents used 
Mouse anti-HA from Chemicon was used at 1:500-1:1000, guinea-pig anti-
VGLUT1 from Chemicon was used at 1:8000, mouse anti-NET contributed from 
Randy Blakely was used at 1:1000, rabbit anti-TH from Chemicon was used at 
1:1000.  Secondary antibodies used from Jackson ImmunoResearch included: 
cy2- and cy3-conjugated donkey anti-mouse (1:1000), cy5-conjugated donkey 
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anti-guinea pig (1:2000), and cy3-conjugated donkey anti-rabbit (1:1000).  
Secondary antibodies used from Molecular Probes included: Alexa 568-
conjugated goat anti-mouse IgG2b and Alexa 488-conjugated goat anti-mouse 
IgG1.  
In the first immunohistochemistry experiment (Figure 2), mouse anti-HA 
was used at 1:500 and cy2-conjugated donkey anti-mouse was used at 1:1000.  
In the second immunohistochemistry experiment (Figure 4A-C), mouse anti-HA 
(IgG1) was used at 1:1000 and mouse anti-NET (IgG2b) was used at 1:1000.  
Alexa-488-conjugated goat anti-mouse IgG1 was used at 1:1000, and Alexa-568-
conjugated goat anti-mouse IgG2b was used at 1:1000.  In the third 
immunohistochemistry experiment (Figure 4D-F, 5D-F), mouse anti-HA was used 
at 1:1000 and rabbit anti-TH was used at 1:1000.  Cy2-conjugated donkey anti-
mouse was used at 1:2000, and cy3-conjugated donkey anti-rabbit was used at 
1:1000.  In the final immunohistochemistry experiment (Figure 4G-I, 5A-C), 
mouse anti-HA was used at 1:1000 and guinea pig anti-VGLUT1 was used at 
1:8000.  Cy2-conjugated donkey anti-mouse was used at 1:1000, and cy5-
conjugated donkey anti-guinea pig was used at 1:2000. 
Imaging 
Images were taken with an LSM510 confocal microscope using a 10x 
objective and a 63x/1.4 NA planapochromat objective (Carl Zeiss, Inc.).  
Laser excitation was kept constant between genotypes and primary/no primary 
controls.  High-power (63x) images (optical sections) were taken at 0.5 µm focus 
intervals.  Under conditions identical for those used to obtain sample images, 
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we imaged microscopic fluorescent latex beads (Multispeck, Molecular Probes, 
Inc.) with spectral properties similar to the three sample probes (Cy2, Cy3, and 
Cy5) in order to calibrate the three-channel registration and subsequently 
compensate for instrument-induced positional shifts in the data.  Measured shifts 
were minor and used to apply precise offsets to the image data using the 
LSM software, thus providing accurate probe positions to within the diffraction 
limit of the microscope (less than 0.25 µm in x and y).  Using CorelDraw12, 
images in Figure 2 were converted to monochrome, and intensity, brightness, 
and contrast were altered to allow clear presentation of signal.  Using ImageJ 
software, Figures 4 and 5 were subtracted for background and were then altered 
in brightness and contrast to allow clear presentation of signal. 
Electrophysiological recordings in BNST slices 
Animals 
6-12 week old male C57BL/6J mice (The Jackson Laboratory) or HA α2A-
AR KI mice were housed in cages of two to five animals on a 12 h light/dark cycle 
with food and water ad libitum.  The number of animals used in each experiment 
is indicated in the text and figure legends. 
Brain slice preparation  
Methods were as described previously (Grueter et al, 2005; Grueter et al, 
2006b). Briefly, mice were decapitated under isofluorane anesthesia. Brains were 
quickly removed and placed in an ice-cold, low-sodium/high-sucrose dissecting 
solution. Hemisected (300 µm) coronal brain slices containing anterior portions of 
BNST (bregma 0.26–0.02 mm) were prepared on a Leica vibratome and 
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transferred to either an interface chamber (field potential recordings) or a holding 
chamber (whole cell recordings) containing oxygenated and heated artificial 
cerebrospinal fluid (ACSF) composed of the following (in mM): 124 NaCl, 4.4 KCl, 
2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 10 glucose, and 26 NaHCO3. 
Field potential recordings 
 Field potential recordings were performed as previously reported 
(McElligott et al, 2008).  Briefly, slices were transferred immediately after slicing 
to interface chambers where they rested for at least 30 min in a humidified and 
oxygenated environment while continuously being perfused with oxygenated and 
heated (approximately 28–30°C) ACSF at a rate of 2 ml/min. Next, 25 μM 
picrotoxin was added to the bath to block GABAA receptors and slices were 
rested another 30 min prior to recording.  Picrotoxin was included during the 
entirety of all experiments to isolate excitatory transmission. Recording 
electrodes of approximately 1 MΩ resistance were pulled on a Flaming/Brown 
micropipette puller (Sutter Instruments, Novato, CA) and filled with ACSF. A 
bipolar Nichrome (A-M Systems, Carlsborg, WA) stimulating electrode was 
placed dorsal to the recording electrode within the dorsal lateral BNST such that 
stimulation of the field resulted in two distinguishable negative shifts in potential: 
N1 (the TTX sensitive fiber volley estimate) and N2 (CNQX sensitive synaptic 
response) as previously reported (Egli et al, 2005; Grueter et al, 2005; Weitlauf et 
al, 2004). The amplitude (voltage) of the N2 was measured at a stimulation 
intensity that resulted in a voltage approximately 50% of the maximum N2 
response. Slices were stimulated at a frequency of 0.05 Hz. Field potentials were 
77 
 
recorded using Clampex 8.2 (Molecular Devices, Sunnyvale, CA). All drugs were 
bath applied at their final concentrations. 
Reagents used   
UK-14,304 (Sigma) stock solution was made in DMSO and added directly 
to the ACSF. 
Analysis of Field Recordings 
All recorded data were analyzed via Clampfit 9.0 (Molecular Devices). All 
field recordings contain a 20 min baseline recording prior to agonist application 
(with the exception of one 10 μM UK-14,304 experiment completed in wildtype 
C57BL/6J, which had a 10 min baseline) and all data points were normalized to 
the baseline 5 min prior to the agonist application. Plotted time courses for field 
experiments are represented as 1 min averages. Minutes 21-25 post-drug 
application were also averaged for statistical analysis and comparison to 
baseline. 
Whole-cell voltage-clamp recordings 
Whole-cell recordings were performed as previously reported (Grueter et 
al, 2006a; Grueter et al, 2005; Kash et al, 2006). Briefly, following slicing on the 
vibratome, slices were allowed to recover for a minimum recovery period of 60 
minutes in a submerged holding chamber (25°C) containing oxygenated ACSF.  
Slices were then removed from the holding chamber and placed in the recording 
chamber, where they were continuously perfused with oxygenated (95% O2/5%
 
CO2) and heated (approximately 24-25°C) ACSF at a rate of 2 ml/min.   
 
78 
 
Experiments examining excitatory transmission in the BNST 
Electrodes of 2.5–7.0 MΩ were filled with the following for experiments 
examining excitatory transmission (in mM): 117 Cs gluconate, 20 HEPES, 0.4 
EGTA, 5 TEA, 2 MgCl, 4 Na2ATP,
 0.3, Na2GTP (pH 7.2-7.4, Osm 290-295).  Two 
experiments looking at the effect of 1 µM UK-14,304 were conducted using 
electrodes filled with (in mM): 135 K+-gluconate, 5 NaCl, 10 HEPES, 0.6 EGTA, 4 
Na2ATP, 0.4 Na2GTP (pH 7.2-7.4, Osm 290-295), but no difference was noted, 
so results were combined.  EPSCs of 100–400 pA were recorded at a frequency 
of 0.17 Hz while voltage-clamped at –70 mV in the presence of the GABAA 
receptor antagonist, picrotoxin (25 µM).  After whole-cell configuration was 
achieved, cells were allowed to equilibrate a minimum of 10 minutes before 
baseline recordings were started. Postsynaptic parameters were monitored 
continuously throughout the duration of the experiments. Data are represented as 
an average of the peak amplitudes of ten sweeps (1 min).  A paired-pulse ratio 
(PPR) was acquired by applying a second stimulus of equal intensity 50 ms after 
the first stimulus, where PPR = EPSC2/EPSC1.  
Experiments examining inhibitory transmission in the BNST 
For IPSC experiments, electrodes of 2.5–7.0 MΩ were filled with 70 K+-
gluconate, 70 Cs gluconate, 1 EGTA, 5 HEPES, 4 Na2ATP, 0.3 Na2GTP (pH 7.2-
7.4, Osm 290-295).  IPSCs of 100-400 pA were recorded at frequency of 0.10Hz 
while voltage-clamped at -70 mV in the presence of 4 mM kynurenic acid to block 
excitatory transmission. After whole-cell configuration was achieved, cells were 
allowed to equilibrate a minimum of 10 min before baseline recordings were 
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started. Postsynaptic parameters were monitored continuously throughout the 
duration of the experiments. Data are represented as an average of the peak 
amplitudes of six sweeps (1 min).  A paired-pulse ratio (PPR) was acquired by 
applying a second stimulus of equal intensity 50 ms after the first stimulus, where 
PPR = EPSC2/EPSC1.  
Reagents used   
UK-14,304 (Sigma) stock solution was made in DMSO, guanfacine 
hydrochloride (Tocris) stock solution was made in water, picrotoxin (Tocris) stock 
solution was made in DMSO, and atipamezole hydrochloride (Pfizer Animal 
Health) and kynurenic acid (Sigma) were added directly to ACSF. 
Analysis of whole-cell recordings 
Recorded data were analyzed via Clampfit 9.2 (Molecular Devices). 
Recordings contain a 5-10 min baseline recording prior to agonist application, 
and all data points were normalized to the baseline 5 min prior to agonist 
application. Plotted time courses for whole-cell experiments are represented as 
1 min averages. Minutes 16-20 post-drug application were also averaged for 
statistical analysis and comparison to baseline. 
Statistics 
All data points were reported as the mean +/- SEM and significance (determined 
by paired and unpaired Student's t-test).  Experiments examining a difference as 
compared to baseline were analyzed using a paired Student’s t-test.  
Experiments comparing relative effects of a drug across separate conditions 
were analyzed using an unpaired student’s t-test (Figure 1B comparing effects of 
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UK-14,304 between HA KI and WT mice, Figure 7 comparing effects of 
guanfacine between excitatory and inhibitory transmission).  Results are reported 
in the text and figure legends. Significant differences were defined as having a p 
< 0.05. 
 
Results 
 
The HA α2A-AR KI mouse contains functional α2A-ARs 
The HA α2A-AR KI mouse is a recently described line (Lu et al, 2009) in 
which an α2A-AR with an N-terminal HA tag is inserted into the endogenous 
allele.  Lu et al. have demonstrated that the N-terminal HA tag on the α2A-AR 
does not appreciably alter receptor density or coupling (Lu et al, 2009).  Thus this 
mouse affords a model for genotypically-controlled analysis of α2A-AR expression 
and localization.   
We have previously reported that the α2-AR agonist UK-14,304 causes a 
depression in excitatory transmission in the BNST and that this response is 
absent in slices prepared from the α2A-AR KO mouse (Egli et al, 2005).  To 
grossly assess whether α2-AR function in the BNST is normal in the knock-in line, 
we assessed the ability of the α2-AR agonist UK-14,304 (10 µM) to depress 
synaptic transmission.  Using extracellularly recorded field potentials (Egli et al, 
2005; Grueter et al, 2005; McElligott et al, 2008; Weitlauf et al, 2005) we show 
that 10 µM UK-14,304 depresses excitatory transmission in both wildtype mice 
(68.4 +/- 9.9% from baseline, n = 4, p < .01, t = 7.50, df = 3) and HA KI mice 
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(90.7 +/- 5.1% from baseline, n = 4, p < .001, t = 17.47, df = 3), and that the HA 
KI mouse has functional α2-ARs, as the response to 10 µM UK-14,304 was not 
different from that observed in slices prepared from wildtype animals (p > .07, t = 
-2.14, df = 5) (Figure 5B). 
 
  
82 
 
Figure 5 
 
 
 
Figure 5.  The HA α2A-adrenergic receptor knockin mouse (HA α2A-AR KI) 
contains functional α2-ARs. A) Coronal brain section demonstrating placement of 
stimulating and recording electrodes for field electrophysiology experiments. B) A 
10 min 10 µM UK-14,304 application causes a depression in excitatory 
transmission in the HA α2A-AR KI (red, n = 4) that is not different from wild type 
C57BL/6J mice (black n = 4).  
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The α2A-AR is highly expressed in the BNST  
We examined the distribution of the α2A-AR in the knockin mouse at the 
light microscopy level utilizing an anti-HA antisera.  High levels of HA labeling 
(presumptive α2A-AR immunoreactivity) were found in the locus coeruleus, NTS, 
hippocampus, and lateral septum, as expected based on previous findings 
(Glass et al, 2001; Lee et al, 1998; Milner et al, 1998; Scheinin et al, 1994; Wang 
et al, 1996) (see Figure 6A).  In addition, intense labeling was observed in the 
BNST.  The α2A-AR immunoreactivity was present throughout both the dorsal and 
ventral portions of the anterior BNST, with brightest labeling in the stria terminalis 
(Figure 6B).  Wildtype tissue incubated with the mouse anti-HA antibody did not 
show appreciable immunolabeling (Figure 6C).  
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Figure 6 
 
Figure 6 
α2A-ARs are enriched in the BNST. A) Parasaggital section of the HA α2A-AR 
knockin (KI) mouse showing HA labeling, and corresponding Franklin-Paxinos 
image at 0.96 mm lateral to midline (scale bar = 1 mm).  B) Coronal section of 
the HA α2A-AR KI mouse bed nucleus of the stria terminalis (BNST) showing 
labeled HA (scale bar = 200 µm), and corresponding Franklin-Paxinos image at 
(+) 0.14 mm from bregma. C) Corresponding wildtype C57BL/6J mouse image 
showing lack of labeling with HA antibody (scale bar = 200 µm).  
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The α2A-AR selective agonist guanfacine depresses glutamatergic 
transmission in the dorsal BNST 
Next, we used whole cell patch clamp electrophysiology in slices prepared 
from wildtype mice to assess the likelihood that previously observed effects of α2-
AR agonists in the BNST are mediated by the α2A-AR subtype.  First, we 
replicated previous findings and showed that the α2-AR agonist UK-14,304 (1 
µM) causes an acute depression (51.0 +/- 5.9% from baseline, n = 9, p < .0001, t 
= 9.55, df = 8) of excitatory transmission (Figure 7A-B).  We then examined the 
effects of application of the α2A-AR selective agonist guanfacine.  Guanfacine is 
an α2-AR agonist with 60-fold selectivity for the α2A-AR subtype over α2B-ARs 
(Uhlen and Wikberg, 1991) and 22-fold selectivity over α2C-ARs (Uhlen et al, 
1992).  Guanfacine elicited a concentration-dependent acute decrease in 
excitatory synaptic transmission in BNST (500 nM, 19.1 +/- 7.4% from baseline, n 
= 6, p < .05, t = 2.71, df = 5; 1 µM, 39.9 +/- 5.9% from baseline, n = 9, p < .001, t 
= 6.04, df = 8; 5 µM, 42.2 +/- 6.8% from baseline, n = 10, p < .001, t = 6.13, df = 
9) (Figure 7C, 7F).  The effect of 1 µM guanfacine was blocked by the α2-AR 
selective antagonist atipamezole (n = 4, p > .30, t = 1.19, df = 3) (Figure 7E-F). 
Thus these data further suggest a role for the α2A-AR subtype in modulation of 
glutamatergic transmission in the BNST. 
To begin to assess synaptic mechanisms involved in the effects elicited by 
guanfacine, we assessed paired-pulse responses before and after guanfacine 
application.  Changes in the paired-pulse ratio (PPR) are indicative of alterations 
in the probability of transmitter release.  We observed that PPR of evoked 
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glutamate responses increased after guanfacine application (1 µM, p < .05, t = -
2.55, df = 8; 500 nM, p < .01, t = -4.30, df = 5) (Figure 7D). 
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Figure 7 
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Figure 7 
α2-AR agonists depress excitatory  transmission in the dorsal BNST (dBNST). A) 
Representative experiment showing the effect of 1 µM UK-14,304 on excitatory 
transmission in the dBNST.  pA = pico-amps, HI = holding current, RA = access 
resistance. B) 1 µM UK-14,304 depresses excitatory transmission in the dBNST 
(n = 9).  Inset: representative 5 min average traces pre (black)- and post (red)-
UK-14,304. C) 1 μM guanfacine depresses excitatory transmission in the dBNST 
(n = 9). D) 5 min average paired-pulse ratios pre- and post- 1 µM guanfacine.  E) 
Representative experiment showing the effect of 1 µM guanfacine in the 
presence of 1 μM atipamezole in the dBNST.  F) Dose-response curve for effect 
of guanfacine on excitatory transmission in the dBNST (n = 3 vehicle, n = 9 for 
500 nM, n = 9 for 1 μM, n = 10 for 5 µM), also effect of 1 µM guanfacine in the 
presence of 1 µM atipamezole (n = 4).  
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The α2A-AR is not distributed similarly with noradrenergic terminal markers 
in the BNST 
We used immunohistochemistry in attempt to morphogenically localize the 
α2A-AR in parallel with our functional assessments.  This receptor subtype has 
been proposed to play a role as an autoreceptor at noradrenergic synapses to 
modulate NE release (Altman et al, 1999; Hein et al, 1999; Stewart, 2000; 
Trendelenburg et al, 2001).  However, the acute depression of glutamate 
transmission observed here would most easily be explained by a heterosynaptic 
role of the receptor.  Alternatively, the receptor could be regulating glutamate 
transmission indirectly by regulating endogenous NE release.  The distribution of 
the α2A-AR (as assessed by HA immunoreactivity in the knock-in mouse), 
however, was very distinct from the distribution of immunoreactivity for the NE 
transporter (NET) (Figure 8A-C).  Additionally, the α2A-AR is much more broadly 
distributed throughout the BNST than tyrosine hydroxylase (TH), a marker for 
both dopaminergic and noradrenergic terminals (Figure 8D-F and Figure 9D-F).  
The broad light microscopy level distribution of α2A-AR immunoreactivity outside 
that of TH and NET immunoreactivity suggests that the receptor may indeed 
exist as a heteroreceptor on non-noradrenergic terminals. 
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The α2A-AR is distributed similarly to glutamatergic terminal markers in the 
BNST 
Next, we looked at the co-distribution at the light microscopy level of the 
α2A-AR and immunoreactivity for the glutamatergic terminal marker vesicular 
glutamate transporter 1 (VGLUT1).  VGLUT1 is diffusely distributed throughout 
the BNST in a pattern grossly similar to the α2A-AR (Figure 8G-I, Figure 9A-C).  
Qualitatively, it appears that the α2A-AR colocalizes considerably with VGLUT1 
(Figure 9A-C).  
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Figure 8 
 
Figure 8 
α2A-AR distribution in the BNST is dissimilar to norepinephrine transporter (NET) 
and tyrosine hydroxylase (TH) distribution but is similar to vesicular glutamate 
transporter 1 (VGLUT1) distribution.  (A-I) 2x2 tiles of coronal sections containing 
the BNST, scale bars represent 200 µm.  A) NET labeling in the BNST with inset 
of the NET KO mouse.  B) HA labeling in the BNST.  C) Merge of NET and HA.  
D) TH labeling in the BNST.  E) HA labeling in the BNST.  F) Merge of TH and 
HA. G) VGLUT1 labeling in the BNST.  H) HA labeling in the BNST.  I) Merge of 
VGLUT1 and HA.   
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Figure 9 
 
 
Figure 9 
α2A-AR distribution is in the dorsal lateral BNST is broader than the distribution of 
tyrosine hydroxylase (TH), but is similar to distribution of vesicular glutamate 
transporter 1 (VGLUT1).  (A-F) High power image of coronal sections containing 
the BNST, scale bars represent 5 µm. Inset scale bars are 0.5 µm.  Inset boxes 
measure 6.9 µm (width) x 5.6 µm (height).  A) VGLUT1 labeling in the dBNST.  
B) HA labeling in the dBNST.  C) Merge of VGLUT1 and HA.  D) TH labeling in 
the dBNST.  E) HA labeling in the dBNST.  F) Merge of TH and HA.  
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The α2A-AR selective agonist guanfacine depresses GABAergic 
transmission in the dBNST 
Due to the widespread expression of the α2A-AR in the BNST, we 
examined the ability of guanfacine to regulate fast inhibitory transmission.  Here, 
we examined the ability of the α2A-AR specific agonist guanfacine to regulate 
evoked inhibitory postsynaptic currents (eISPCs) in the dBNST.  We found that 
guanfacine elicited a concentration-dependent acute albeit modest decrease in 
inhibitory synaptic transmission in BNST (500 nM, 0.9 +/- 6.5% from baseline, n 
= 3, p > .8, t = 0.27, df = 2; 1 µM, 23.7 +/- 4.7% from baseline, n = 5, p < .01, t = 
8.35, df = 4; 5 µM, 39.4 +/- 5.5% from baseline, n = 4, p < .01, t = 6.69, df = 3) 
(Figure 10A, 10C).  Interestingly, there was no change in PPR as seen with 
EPSCs, with a trend for a decrease in PPR (Figure 10B).   
We show that guanfacine decreases both excitatory and inhibitory 
transmission in the dBNST.  Whereas 500 nM guanfacine had a significant effect 
on EPSCs, it did not produce a change in IPSCs.  At 1 µM guanfacine, the effect 
on EPSCs was significantly greater than the effect on IPSCs (p < .05, t = -2.19, 
df = 12) (Figure 11).  Therefore, under our recording conditions, it is possible that 
activation of the α2A-AR produces greater changes at excitatory synapses than 
inhibitory synapses, thereby causing an overall reduction in BNST excitability. 
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Figure 10 
 
 
Figure 10 
The α2A-AR agonist guanfacine depresses inhibitory transmission in the dBNST. 
(A) 1 µM guanfacine depresses excitatory transmission in the dBNST (n = 5) 
Inset: representative 5 min average traces pre (black)- and post (red)- 
guanfacine.  B) 5 min average paired-pulse ratios pre- and post- 1 µM 
guanfacine.  C) Dose-response curve for the effect of guanfacine on inhibitory 
transmission in the dBNST (n = 3 for 500 nM, n = 5 for 1 µM, n = 4 for 5 µM). 
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Figure 11 
 
 
 
Figure 11 
Overlay of guanfacine dose-response curves showing increased efficacy of 
guanfacine on excitatory transmission over inhibitory transmission. 
96 
 
Discussion 
 
The HA α2A-AR KI mouse contains normally distributed and functional α2A-
ARs in the mouse brain 
The HA α2A-AR KI mouse contains a 9 amino acid N-terminal 
hemagglutinin tag on the α2A-AR (Lu et al, 2009).  This tag does not grossly alter 
function of the α2A-AR in vitro, and the receptor is grossly normally distributed in 
the mouse brain (Lu et al, 2009).  A parasaggital section of HA α2A-AR KI mouse 
brain demonstrates high levels of α2A-AR in the LC, NTS, hippocampus, and stria 
terminalis, as expected based on previous studies (Glass et al, 2001; Lee et al, 
1998; Milner et al, 1998; Scheinin et al, 1994; Wang et al, 1996).  Moreover, our 
data suggest that these receptors remain functional in the BNST, consistent with 
a previous report on this mouse (Lu et al, 2009). 
 
The HA α2A-AR KI mouse provides a unique method to specifically label 
α2A-ARs in brain tissue 
 HA is an exogenous sequence not found in normal brain tissue, and thus 
should not cross-react with other receptors or proteins in the brain.  As shown in 
Figure 6B-C, mouse anti-HA specifically labels the HA presented on the HA-
tagged α2A-AR and does not show appreciable immunolabeling in the WT mouse.  
Previous studies examining localization of the α2A-AR in rodent brain tissue have 
used antibodies targeting various portions of the α2A-AR.  Studies conducted in 
the NTS by Glass and others took advantage of a goat anti- α2A-AR from Santa 
Cruz (Glass et al, 2001), which is an antibody against the C-terminus of the 
receptor.  Additionally, Milner and others have published studies in the 
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hippocampus and ventrolateral medulla using an antibody developed against a 
47 amino acid chain of the 3rd intracellular loop of the rat α2A-AR fused to GST 
(Milner et al, 1998; Milner et al, 1999).  Our data confirm aspects of the previous 
studies, demonstrating the presence of the α2A-AR in VGLUT1-(+) and TH-(+) 
compartments within the BNST.   
 
The α2A-AR selective agonist guanfacine depresses excitatory transmission 
in the BNST 
Using in vivo microdialysis techniques, Forray and others have shown that 
in the BNST, the α2-AR agonist UK-14,304 depresses extracellular glutamate 
and K+-induced glutamate release, and that the α2-AR antagonist RX821002 has 
opposite effects (Forray et al, 1999).  We previously reported, using field and 
whole-cell electrophysiology approaches, that the α2-AR agonist UK-14,304 
depresses glutamatergic transmission in the BNST (Egli et al, 2005).  This effect 
is absent in the α2A-AR knockout mouse (Egli et al, 2005), implicating the α2A AR 
subtype as potentially responsible for this depression of glutamatergic 
transmission.  It is also possible though, that multiple ARs in the α2A-AR  
knockout mouse are desensitized due to high levels of extracellular NE in this 
knockout mouse, as α1-AR-mediated LTD is also absent in these mice (McElligott 
et al, 2008).  Therefore, we cannot rule out that the α2C-AR contributes to some 
effects seen with UK-14,304 (Trendelenburg et al, 1999).   
Using whole-cell electrophysiology to explore the specific role of the α2A-
AR in modulation of glutamate transmission in the BNST, we applied the α2A-AR 
selective agonist guanfacine to cells in the dBNST.  We found that guanfacine 
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depresses glutamatergic transmission in a dose-dependent manner, and that this 
effect can be blocked with the α2-AR selective antagonist atipamizole.  Thus, in 
total these data strongly suggest that activation of the α2A-AR acutely depresses 
glutamate release in the BNST.   
 
α2A-ARs depress excitatory transmission by presynaptically modulating 
glutamate release 
The α2A-AR is discussed as an autoreceptor modulating NE release 
(Altman et al, 1999; Hein et al, 1999; Stewart, 2000; Trendelenburg et al, 2001), 
and it is conceivable that effects on glutamate transmission are the result of an 
α2A-AR-mediated altered release of NE.  To examine this possibility, we used 
immunohistochemistry to co-label the HA-tagged α2A-AR and markers of 
noradrenergic terminals, NET and TH.  Interestingly, the α2A-AR is much more 
broadly distributed than either NET or TH in the BNST, making modulation of NE 
release by the α2A-AR unlikely to provide the sole, or perhaps even major, 
explanation for the acute effects seen with application of guanfacine.  In fact, the 
α2A-AR has a very similar distribution to the glutamatergic terminal marker, 
VGLUT1. In electrophysiological experiments we observed an increase in the 
paired pulse ratio (PPR) upon application of guanfacine, thus suggesting that the 
α2A-AR regulates glutamate transmission by decreasing glutamate release 
probability.  
Other areas of the extended amygdala, such as the central nucleus of the 
amygdala (CeA), also show heterosynaptic regulation of glutamate transmission 
by α2-ARs, but via a distinct mechanism involving direct interaction of the βγ 
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subunit of the G-protein coupled receptor complex with release machinery 
(Delaney et al, 2007).  In contrast, α2A-AR mediated depression of excitatory 
transmission in the prefrontal cortex has been theorized to be postsynaptic due 
to an absence of effect on PPR, although regulation similar to that seen in the 
CeA cannot be ruled out based on current findings (Ji et al, 2008).  The α2A-ARs 
are also known to presynaptically modulate L-type calcium channels in the retina 
(Dong et al, 2007).  In other areas including the NTS (Glass et al, 2001), 
ventrolateral medulla (Milner et al, 1999), and hippocampus (Milner et al, 1998), 
evidence consistent with expression of heterosynaptic presynaptic α2A-ARs has 
been reported.  Using a combination of various techniques, we demonstrate that 
the α2A-AR is also located heterosynaptically on glutamate terminals and 
modulates excitatory transmission in the BNST by presynaptically altering 
glutamate release, thus adding to findings demonstrating the complex role of the 
α2A-AR in modulation of transmission in the brain.  Our findings are consistent 
with the proposal by Gilsbach and others that many α2A-AR-mediated 
modulations of function in the brain are via α2A-AR heteroreceptors, not 
autoreceptors (Gilsbach et al, 2009).  
 
α2A-ARs modulate GABAergic transmission in the BNST 
NE is known to modulate both inhibitory and excitatory transmission in the 
BNST.  For example, activation of the α1-AR causes LTD at excitatory synapses 
(McElligott et al, 2008), and also increases IPSC frequency at inhibitory 
synapses that are shown to project to the VTA via a retrograde label (Dumont et 
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al, 2004).  Therefore, we must consider the possibility that α2A-ARs regulate 
inhibitory transmission in the BNST in addition to their effects on excitatory 
transmission.  Dumont and Williams saw no effect of the α2-AR agonist clonidine 
or the α2-AR antagonist yohimbine on spontaneous IPSCs in the ventral BNST 
(Dumont et al, 2004).  Also, Forray and others saw no effect of the α2-AR agonist 
UK-14,304 on GABA basal extracellular levels using in vivo microdialysis 
approaches in the BNST (Forray et al, 1999).  Here, however, we show that the 
α2A-AR selective agonist depresses inhibitory transmission in the BNST in a 
dose-dependent manner, but does not alter PPR.  These data suggest that the 
α2A-AR may modulate inhibitory transmission in the BNST through a postsynaptic 
mechanism, although we cannot rule out that there is some direct interaction 
between the α2A-AR and release machinery as seen with excitatory transmission 
in the CeA (Dumont et al, 2004).  Also, at present we cannot rule out the 
possibility that the greater effect of guanfacine on eIPSCs at higher 
concentrations is partially due to recruitment of α2C-ARs in addition to α2A-ARs. 
 
α2A-ARs gate excitatory drive to the BNST, and regulate inhibitory 
transmission in the BNST via distinct mechanisms 
Taken together, our data indicate that the α2A-AR plays a particularly 
important role in modulation of BNST output.  This is not the first instance in 
which α2A-ARs have been suggested to be differentially localized within a region.  
In the NTS, ventrolateral medulla, and hippocampus, α2A-AR-like 
immunoreactivity has been noted on presynaptic autoreceptor and 
heterosynaptic terminals, as well as postsynaptically, and on glial cells (Glass et 
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al, 2001; Milner et al, 1998; Milner et al, 1999).  Here, we find that the α2A-AR is 
broadly associated with at least two compartments, TH(+) and VGLUT(+) 
terminals. 
Based on current findings, guanfacine appears to have a higher potency 
at excitatory than inhibitory synapses.  Excitatory input into the BNST comes 
from insular cortex, infralimbic cortex, the ventral subiculum and the basolateral 
amygdala (Dong et al, 2001a; Massi et al, 2008; Weller et al, 1982), other 
regions known to be involved in stress-reward circuitry, and regions known to 
express mRNA for the α2A-AR (Scheinin et al, 1994; Wang et al, 1996).  Thus, 
the α2A-AR potentially gates these inputs, effectively decreasing excitatory drive 
to the BNST during events known to release NE, such as chronic stressors, 
withdrawal from drugs of abuse, and other social stressors (Aston-Jones et al, 
1999; Cecchi et al, 2002a; Cecchi et al, 2002b; Delfs et al, 2000; Fendt et al, 
2005). 
The main inhibitory projection to the BNST is from a closely related 
structure, the central nucleus of the amygdala (CeA), a region also involved in 
fear and anxiety states.  Whereas the BNST and CeA are very homologous 
structures with similar afferents and efferents, it is hypothesized that the BNST is 
involved in unconditioned prolonged anxiety states (Walker et al, 2003) whereas 
the CeA is involved in conditioned fear to distinct sensory cues (Campeau and 
Davis, 1995; Kim and Davis, 1993; Wilensky et al, 2006).  Others, however, have 
considered that these two structures have more anatomical similarity than 
differences and suggested they be grouped together as the extended amygdala 
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(Dong et al, 2000; Dong et al, 2004a, b; Holstege et al, 1985; Hopkins and 
Holstege, 1978; Veening et al, 1984).  Therefore, the activation of α2A-ARs may 
modulate functional signaling between or within these two parts of the extended 
amygdala. 
Additionally, the BNST is made up of a large network of GABAergic 
interneurons.  Thus, modulation of inhibitory transmission by activation of α2-ARs 
may also influence output of the BNST.  For example, the BNST is thought to 
contain an excitatory projection to the VTA (Georges et al, 2002; Massi et al, 
2008), and Dumont and others’ work has suggested that NE triggers GABAA-
mediated inhibition of these fibers (Dumont et al, 2004). Here, we have 
demonstrated that α2-ARs do modulate inhibitory transmission in this region.   
α2A-AR knockout mice have been shown to have enhanced anxiety and 
depression-related phenotypes (Schramm et al, 2001), leading to the hypothesis 
that the α2A-AR may play a protective role for an animal under stressful 
conditions.  Studies demonstrate that α2-AR activation in the BNST mediates 
inhibition of stress-induced reinstatement to various drugs of abuse (Delfs et al, 
2000; Wang et al, 2001) and inhibition of stress-induced behavior by predator 
odor (Fendt et al, 2005).  These findings support a stress-protective function of 
α2A-ARs in the BNST.  Thus, activation of the α2A-AR may in fact serve to lessen 
the effects of stress by dampening signaling from inputs to the BNST such as the 
infralimbic cortex, insular cortex, and BLA, regions known to be activated under 
stressful events such as withdrawal from drugs of abuse.   
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The BNST may play a role in the therapeutic effects of guanfacine on 
anxiety-related disorders 
Clinical data indicate that stress is a common reason patients relapse to 
using drugs of abuse (Sinha et al, 1999).  Finding therapeutic agents to help 
addicts with anxiety and craving are extremely limited at this time.  Guanfacine, 
an α2A-AR selective agonist, is FDA-approved for treatment of some anxiety 
disorders including post-traumatic stress disorder (PTSD) and chronic Tic 
disorder.  Guanfacine is also prescribed as a centrally-acting hypertensive agent 
to reduce blood pressure in patients struggling with hypertension (Kisicki et al, 
2007), and is used for treatment of patients suffering from schizophrenia 
(McClure et al, 2007).  Guanfacine is currently undergoing clinical trial for its role 
in preventing stress-induced relapse to cocaine, smoking, and alcohol use 
(Clinicaltrials.gov).  Additional clinical trials looking at its efficacy in treating 
PTSD, ADHD, and schizophrenia are also underway (Posey and McDougle, 
2007).   
Guanfacine is a partial agonist at the α2A-AR, and data suggest that partial 
agonism at this receptor subtype results in fewer unwanted side effects such as 
sedation in the potential treatment of anxiety disorders (Tan et al, 2002).  
Additionally, in disorders such as addiction, PTSD, or ADHD, where chronic 
therapeutics are needed, an agonist that does not readily induce desensitization 
of its target may be beneficial.  Guanfacine desensitizes α2A-ARs much less 
readily than clonidine, likely explaining the longer duration of action by 
guanfacine clinically despite the two partial agonists having a similar half-life (Lu 
et al, 2009).  Thus, guanfacine is a promising potential therapy for anxiety 
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disorders and relapse in addiction.  We theorize that the effects of guanfacine on 
α2A-ARs in the BNST are partially responsible for its effectiveness as a 
therapeutic agent in anxiety- and addiction-related behaviors. 
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CHAPTER III 
 
CHARACTERIZATION OF CORTICAL AND AMYGDALAR AFFERENTS 
TO THE BNST IN C57BL/6J MICE 
 
This chapter describes work completed toward the fulfillment of Aim II of 
my thesis project.   
 
Introduction 
The bed nucleus of the stria terminalis (BNST) is a region thought to play 
a key role in general anxiety and stress-induced relapse to drugs of abuse 
(Walker et al, 2003).  The BNST is an important center for processing inputs from 
stressful stimuli and integrating them into the reward and stress circuitry, thereby 
affecting behavior.  Previous anatomical studies in rat brain have shown that the 
BNST receives projections from brain regions involved in processing stress and 
anxiety-provoking stimuli.  These regions include the insular and infralimbic 
cortices, the basolateral nucleus of the amygdala, as well as the hippocampus, 
central nucleus of the amygdala, and nucleus tractus solitarus (Dong et al, 
2001a; Hurley et al, 1991; McDonald et al, 1999; Shin et al, 2008; Takagishi and 
Chiba, 1991; Vertes, 2004; Walker et al, 2003; Weller et al, 1982; Yasui et al, 
1991).   The BNST is reciprocally connected with many of these regions (Dong et 
al, 2001b; Erb et al, 2001).  The BNST sends projections to various regions of 
the hypothalamus (Conrad et al, 1976; Swanson et al, 1979), a region involved in 
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the peripheral stress response; and the ventral tegmental area (VTA) (Georges 
et al, 2002; Swanson et al, 1979), a region involved in reward and motivation.  
Thus, the BNST is highly integrated with stress and reward pathways in rat brain. 
Whereas anatomical studies have been conducted almost exclusively in 
rat, much behavioral work and electrophysiological studies examining BNST 
function have been carried out in mouse (Egli et al, 2005; Grueter et al, 2006a; 
Kash et al, 2008; McElligott et al, 2008; Weitlauf et al, 2004).  The degree to 
which connections within brain regions of the rat are conserved in mouse is 
currently unknown.  Examining afferents to the BNST in the mouse model will 
help confirm conclusions reached using functional data.  In this study, we have 
begun to characterize the inputs to the BNST in mice.  We have chosen to focus 
on select cortical and amygdalar inputs known to innervate the BNST in rat, as 
these inputs are important in the processing and expression of stress and anxiety 
states. 
The BNST receives the densest noradrenergic innervation in the brain 
(Brownstein et al, 1974), and this input arises primarily from the nucleus tractus 
solitarus (NTS) (Aston-Jones et al, 1999).  Numerous studies have shown that 
the NTS is critical for stress-induced relapse to drug-seeking behaviors (Aston-
Jones et al, 1999; Olson et al, 2006; Shalev et al, 2001; Wang et al, 2001).  
Additionally, studies have demonstrated a role for NE in the BNST in the 
mediation of stress-related behaviors.  Injection of β-AR antagonists or α2-AR 
agonists into the BNST can block morphine withdrawal-induced conditioned 
place aversion (CPA) (Delfs et al, 2000), and stress-induced reinstatement of 
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morphine conditioned place preference (CPP) (Wang et al, 2001).  
Electrophysiology studies have implicated α2-ARs in the presynaptic modulation 
of glutamatergic transmission in the BNST (Egli et al, 2005).  There are three 
subtypes of the α2-AR, the α2A-AR, α2B-AR, and α2C-AR, and the α2A-AR and α2C-
AR subtypes are widely expressed in the BNST (Scheinin et al, 1994; Wang et 
al, 1996).  Recent studies have implicated heterosynaptic α2A-ARs as mediating 
alterations in glutamate transmission (see Chapter II).   
In these studies, we use a transgenic knock in mouse model, in which a 
hemagglutinin tagged α2A-AR is knocked into the endogenous α2A-AR, to begin to 
address the potential regulation of specific inputs to the BNST by α2A-ARs. 
 
Experimental Procedures 
 
Animals 
Eight to twenty week-old hemagluttinin-tagged α2A-AR knockin (HA α2A-AR 
KI) male and female mice (bred in-house on a C57BL/6 background, provided by 
Qin Wang at the University of Alabama) were used for the present studies.  The 
HA KI mice have been shown to have normal physiology and anatomy (Lu et al, 
2009)(also see Chapter II, Figures 5 and 6).  No differences between female and 
male animals were noted in the results of the current studies, so results were 
combined.  All animal procedures were conducted according to an approved 
protocol from the Institutional Animal Care and Use Committee of Vanderbilt 
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University, which certifies compliance with the National Institutes of Health and 
the U.S. Department of Agriculture standards for humane animal utilization. 
 
Anterograde Labeling of BNST Neurons 
Mice were anesthetized with tribromoethanol (2.5% solution in saline, 
0.19 ml/10 g, i.p.). Ophthalmic ointment (Puralube Vet) was applied to the eyes 
to prevent corneal damage. The fur on the top of the head was shaved off and 
the exposed skin was scrubbed sequentially with 70% ethanol, 10% povidone 
iodine, and then again with 70% ethanol. The animal was mounted in a 
stereotaxic apparatus (Kopf Instruments) and placed on a warming pad kept at 
39°C. The skin over the skull was cut and deflected enough to expose the 
bregma and lambda sutures. Local anesthetic cream containing benzocaine was 
applied to the wound. The head was leveled with respect to the intersections of 
bregma and lambda with the midline suture. Holes were drilled in the skull 
directly above the right insular cortex, BLA, or infralimbic cortex according to the 
atlas of Franklin and Paxinos. A sterilized glass pipette with a 30-40 µm diameter 
tip was filled with 10% biotinylated dextran amine (BDA) (10,000 MW, lysine 
fixable, Molecular Probes) in .1 M phosphate buffer.  The dura was cut and the 
syringe needle lowered into the insular cortex (AP +0.02, L 3.66, D 4.16), BLA 
(AP -1.34, L 3.45, D 4.67), or infralimbic cortex (AP +1.78, L 0.22, D 2.91).  The 
BDA was iontophoresed over 10 min at 7 sec on/7 sec off at +3.0 µA, and the 
pipette then removed under negative current. After withdrawing the pipette, the 
wound was closed with sutures and the animal was hydrated with a saline 
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injection (1 ml, s.c.) followed by freshly dissolved ampicillin (0.45 mg/0.1 ml per 
animal, s.c.). The animal was kept warm during recovery from anesthesia and 
was given an analgesic when ambulatory (buprenorphen, 0.1 mg/kg, s.c.). 
Postsurgery, animals were housed singly or with other injected littermates, and 
weighed and injected with analgesic twice per day for up to 6 days or until the 
animal gained weight. Animals that lost more than 20% of their body weight or 
showed signs of uncontrolled pain, stress, or dehydration were euthanized. Ten 
days post-surgery, healthy animals were then processed for 
immunohistochemistry. 
 
Fluorescent Immunohistochemistry 
Ten days following injection of BDA, animals were injected with 0.25 ml 
pentobarbital, and once they were unresponsive to foot and tail pinch, were 
transcardially perfused with phosphate-buffered saline (PBS), followed by 4% 
paraformaldehyde.  Brains were post-fixed in 4% paraformaldehyde for 2-3 days 
at 4°C, and were then transferred to 30% sucrose until fully equilibrated. 
Following post-fixation, 30-100 μm coronal sections of brain were sliced on a 
cryostat (Leica CM3050S).  Sections containing the region to be studied were 
then free-floated for immunolabeling.   
Brain sections from BDA injected mice were washed with PBS, then 
incubated with cyanine three conjugated streptavidin for two hours at room 
temperature.  Following three 10 minute washes in PBS, slices were mounted on 
slides, sealed with PolyAquamount, and left overnight to dry. 
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Slices colabeled with VGLUT1 or HA were incubated in the donkey anti-
streptavadin and then washed as described above.  The slices were then 
blocked with 4% normal donkey serum containing 0.2% Triton-X-100 in PBS.   
Slices were then incubated with primary guinea pig anti-the vesicular glutamate 
transporter 1 (VGLUT1) (Chemicon, 1:1000) or primary mouse anti-HA 
(Covance, 1:1000) for 48 hours at 4°C, followed by three 10 minute washes in 
PBS, and then incubated with cyanine dye conjugated donkey anti-guinea pig or 
donkey anti-mouse (Jackson ImmunoResearch) for 24 hours at 4°C. Following 
three 10 minute washes in PBS, sections were mounted on slides, sealed with 
PolyAquamount, and left overnight to dry.   
 
Imaging 
Images were taken with an LSM510 confocal microscope using a 10x 
objective and a 63x/1.4 NA planapochromat objective (Carl Zeiss, Inc.).  
Laser excitation was kept constant between genotypes and primary/no primary 
controls.  High-power (63x) images (optical sections)  were taken at 0.5µm focus 
intervals.  Under conditions identical for those used to obtain sample images, 
we imaged microscopic fluorescent latex beads (Multispeck, Molecular Probes, 
Inc.) with spectral properties similar to the three sample probes (Cy2, Cy3, and 
Cy5) in order to calibrate the three-channel registration and subsequently 
compensate for instrument-induced positional shifts in the data.  Measured shifts 
were minor and used to apply precise offsets to the image data using the 
LSM software, thus providing accurate probe positions to within the diffraction 
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limit of the microscope (less than 0.25 µm in x and y).  Figure 12 was adjusted 
using the Autoequalize feature in CorelDRAW Graphics Suite 12.  Figures 12B, 
12E, and 12H were then increased in brightness by +15 using CorelDRAW 
Graphics Suite 12 in order to illuminate landmarks in the slices more clearly.  
Using ImageJ software, Figures 13 and 14 were subtracted for background and 
were then adjusted in brightness and contrast to allow clear presentation of 
signal. 
 
Results and Discussion: 
 
BDA injections in the insular cortex 
Four mice were successfully injected with BDA into the insular cortex.  
ANG-15 is shown as a representative mouse for the insular cortex injection 
(Figure 12B-C).  All successful injections had a dense BDA deposit in the insular 
cortex.  Previous studies in rat indicate that the dysgranular, but not agranular 
insular cortex projects to the BNST (McDonald et al, 1999).  We cannot make 
this distinction in these mice, as the injection site appears to spread throughout 
both dysgranular and agranular divisions in all mice.  We did, however, see an 
input to the BNST from the insular cortex (Figure 12C), consistent with previous 
studies in rat (McDonald, 1998; McDonald et al, 1999; Shin et al, 2008; Weller et 
al, 1982; Yasui et al, 1991).  Figure 12B shows the injection site in the insular 
cortex, in the same coronal plane as the BNST.  The corresponding Franklin and 
Paxinos atlas image is shown in Figure 12A.  On close inspection, one can see 
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the tracking of fibers from the insular cortex over to the BNST (Figure 12B)  This 
closely resembles previously published data demonstrating the projection track in 
rat (McDonald, 1998). Figure 12C shows fibers projecting to the BNST.  In all 
insular cortex  injected mice, these fibers appeared to be thin and beaded in the 
BNST, consistent with previous studies (Takagishi et al, 1991). 
 
BDA injections in the infralimbic cortex 
Seven mice were injected with BDA into the infralimbic cortex, and 
injection sites were confirmed using the Franklin and Paxinos atlas.  Of these, 5 
mice showed labeling of fibers in the BNST, with heavier projections to the 
ventral BNST and more sparse projections to the dorsal lateral BNST.  Like 
projections from the insular cortex, projections from the infralimbic cortex were 
thin and beaded in appearance.  ANG61 is illustrated as a representative mouse 
with injection of BDA into the infralimbic cortex.  Figure 12E shows the injection 
site in the infralimbic cortex, with the corresponding Franklin and Paxinos coronal 
section in Figure 12D.  Figure 12F shows fibers in the BNST of this same mouse.  
These findings are consistent with previous studies conducted in rat (Dong et al, 
2001a; Hurley et al, 1991; Massi et al, 2008; McDonald et al, 1999; Shin et al, 
2008; Takagishi et al, 1991), as well as cat (Room et al, 1985) and monkey 
(Chiba et al, 2001).  
Additionally, four mice were injected with BDA in the prelimbic cortex, 
which is dorsal to the infralimbic cortex, and none of these mice showed fibers 
projecting into the BNST (data not shown).  This is consistent with studies in rat, 
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which do not show projections from the prelimbic cortex to the BNST, but do 
demonstrate fibers passing through the striatum just lateral to the dBNST as we 
saw in our studies (McDonald et al, 1996; McDonald et al, 1999; Sesack et al, 
1989; Vertes, 2004).  Four mice were injected with BDA ventral to the infralimbic 
cortex, in the dorsal penduncular cortex.  This region has been shown to project 
very lightly to the BNST in rat (McDonald et al, 1999).  Consistent with this, only 
sparse fibers were seen in the BNST in these mice (data not shown).   
 
BDA injections in the BLA 
Four mice contained successful basolateral amygdala (BLA) injections 
without spread of tracer outside the medial/lateral boundaries of the BLA, and 
with minimal spread to the striatum dorsal to the BLA in the injection tract.  
ANG25 is shown as a representative mouse with an injection of BDA into the 
BLA (Figure 12G-I).  The injection site is shown in Figure 12H, with the 
corresponding Franklin Paxinos atlas image in Figure 12G.  The BNST of this 
mouse is shown in Figure 12I.  Projections from the BLA to the BNST go through 
the stria terminalis in rat (McDonald, 1991), and our findings in mouse are 
consistent with this and other previous studies in rat and opossum (Dong et al, 
2001a; McDonald, 1991; McDonald et al, 1986; Shin et al, 2008; Walker et al, 
2003).  Interestingly, these fibers were much thicker and smoother than fibers 
coming from the insular cortex, and did not have the thin beaded appearance like 
those of the insular cortex (see Figure 12C).  Five mice were injected with BDA 
into the dorsal endopiriform cortex, just lateral to the BLA, and two mice were 
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injected with BDA in the striatum just dorsal to the BLA.  These mice did not 
show appreciable fibers projecting to the BNST (data not shown).    
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Figure 12 
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Figure 12 
The insular cortex, infralimbic cortex, and the basolateral amygdala project to the 
BNST.  A) Franklin Paxinos image of coronal plane 30, corresponding to Figure 
12B.  Red sphere indicates insular cortex.  B) Tiled coronal image demonstrating 
injection of BDA into the insular cortex.  Scale bar = 500 μm. C) Tiled image  
illustrating BDA(+) fibers in the BNST projecting from the insular cortex.  Scale 
bar = 50 μm. D) Franklin Paxinos image of coronal plane 15, corresponding to 
Figure 12E.  Red sphere indicates infralimbic cortex.  E) Tiled coronal image 
demonstrating injection of BDA into the infralimbic cortex.  Scale bar = 500 μm. 
F) Tiled image illustrating BDA(+) fibers in the BNST projecting from the 
infralimbic cortex.  Scale bar = 50 μm.  G) Franklin Paxinos image of coronal 
plane 40, corresponding to Figure 12H.  Red sphere indicates basolateral 
amygdala (BLA).  H) Tiled coronal image demonstrating injection of BDA into the 
BLA.  Scale bar = 500 μm. C) Tiled image illustrating BDA(+) fibers in the BNST 
projecting from the BLA.  Scale bar = 50 μm. 
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Projections from the insular cortex, infralimbic cortex, and BLA contain the 
excitatory terminal marker VGLUT1 
The insular cortex, infralimbic cortex, and basolateral amygdala are known 
to carry excitatory projections to the BNST in the rat.  Also, Adamec has shown 
that there is a monosynaptic excitatory projection from the BLA to the BNST in 
the cat (Adamec, 1989).  The vesicular glutamate transporters VGLUT1 and 
VGLUT2 are known to store glutamate in presynaptic terminals, making them 
good markers of glutamatergic fibers and terminals (Boulland et al, 2004; 
Hayashi et al, 2001; Herzog et al, 2001; Takamori et al, 2000).  Cortical regions 
primarily express vesicular glutamate transporter 1 (VGLUT1), with low levels of 
VGLUT2.  Noncortical regions such as the pons, thalamus, and striatum express 
primarily VGLUT2, and have low levels of VGLUT1 (Boulland et al, 2004; 
Fremeau et al, 2001; Islam et al, 2008; Kaneko and Fujiyama, 2002; Varoqui et 
al, 2002).  To confirm that the insular cortex, infralimbic cortex, and BLA are 
glutamatergic, we used VGLUT1 as a glutamatergic marker and colabeled BNST 
sections from BDA injection mice with VGLUT1.  Representative images are 
illustrated from mouse ANG15 (insular cortex), ANG61 (infralimbic cortex), and 
ANG64 (BLA). As shown in Figure 13A-I, each of the three regions studied have 
projections to the BNST that colocalize with VGLUT1, thus confirming that these 
projections are glutamatergic in mouse. 
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Figure 13 
 
 
Figure 13. The insular cortex, infralimbic cortex, and BLA projections to the 
dorsal BNST are VGLUT1-containing.  A-C) BDA projection from insular cortex 
A) BDA fibers  B) VGLUT1  C) Merge  D-F) BDA projection from infralimbic 
cortex  D) BDA fibers  E) VGLUT1  C) Merge  G-I) BDA projection from the BLA.  
G) BDA fibers  H) VGLUT1  I) Merge.  Scale bars = 5 µm.  Insets, scale bars = 1 
µm.   
  
119 
 
Projections from the Insular Cortex, Infralimbic Cortex, and BLA potentially 
contain the α2A-AR 
Recent data suggests that the α2A-AR plays an important role in 
modulation of glutamatergic transmission in the BNST (see Chapter II).  
Functional and immunohistochemical studies indicate that the α2A-AR regulates 
glutamatergic transmission in part via presynaptic heteroreceptors on 
glutamatergic terminals.  Using the HA tagged α2A-AR KI mouse, we have begun 
to examine the potential distribution of α2A-ARs on fibers from the insular cortex,  
infralimbic cortex, and BLA.  Qualitatively, the α2A-AR appears to colocalize on 
insular cortical, infralimbic cortical, and BLA fibers of the BNST (Figure 14A-I).  
Future studies examining localization of the α2A-AR on these projections should 
be conducted to confirm current findings, as the density of the α2A-AR precludes 
us from conducting reliable quantification of our data set.    
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Figure 14 
 
 
Figure 14. The insular cortex, infralimbic cortex, and BLA projections to the 
dorsal BNST are potentially α2AAR-containing.  A-C) BDA projection from insular 
cortex.  A) BDA fibers.  B) HA.  C) Merge.  D-F) BDA projection from infralimbic 
cortex.  D) BDA fibers.  E) HA  C) Merge.  G-I) BDA projection from the BLA.  G) 
BDA fibers H) HA.  I) Merge.  Scale bars = 5 µm.  Insets, scale bars = 1 µm. 
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General Discussion 
 
Insular cortex, infralimbic cortex, and BLA projections to the BNST in 
mouse and rat are phylogenetically conserved 
Our initial studies examining inputs to the BNST in the mouse model 
demonstrate anatomical projections from insular cortex, infralimbic cortex, and 
basolateral amygdala to the BNST in the C57BL/6J background mouse model.  
Additionally, injections made in regions surrounding these three sites, including 
the prelimbic cortex, striatum, and dorsal endopiriform cortex, did not project to 
the BNST.  These findings suggest that projections to the BNST in rat and mouse 
are phylogenetically conserved. This is important, as much behavioral, 
biochemical, and biophysical work has been completed across various rat and 
mouse strains, and many conclusions have been drawn from findings across the 
two rodent models. 
The BNST is a region known to be highly involved in stress and anxiety, 
as well as in relapse behaviors of addiction (Koob, 2008; Walker et al, 2003).  
Others have extensively reviewed studies implicating the BNST in stress and 
anxiety, and addictive behaviors (Choi et al, 2007; Forray et al, 2004; Koob, 
2008; Smith et al, 2008; Stewart, 2000; Walker et al, 2008b; Walker et al, 2003).   
Our current study begins to confirm that projections in rat brain to the 
BNST involved in anxiety and addiction are also present in mice.  These 
projections include the BLA, a region involved in fear learning and extinction of 
learned behavior (Davis, 2006; Quirk et al, 2008; Walker et al, 2008b).   The 
infralimbic and insular cortex are two additional regions known to modulate BNST 
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output in rodent models.  The infralimbic cortex is important in consolidation of 
extinction learning in rodent models and regulates expression of amygdala-
dependent memories [for review, see (Quirk et al, 2008)].  Others have shown 
the infralimbic projection to the BNST is directly involved in regulation of 
dopaminergic signaling in the ventral tegmental area, a critical region in the 
reward pathway that is disrupted by drugs of abuse (Massi et al, 2008).  Here, we 
have begun to characterize the infralimbic projection to the BNST in mouse brain.  
Finally, we have demonstrated that in the mouse, as in rat, the insular cortex 
projects to the BNST.  This region is known to be involved in processing of 
emotional and homeostatic information, and is thought to be involved in drug 
addicts’ negative affective state during abstinence (Contreras et al, 2007).  
Additionally, lesion of the insula in humans has been reported to reduce feelings 
of craving (Naqvi et al, 2007).  Thus, in the mouse model, the BNST receives 
input from regions highly involved in determining emotional significance of 
external stimuli.   
 
The BLA, infralimbic cortex, and insular cortex projections to the BNST 
potentially contain α2A-ARs  
Current studies indicate potential regulation of the insular cortex and BLA 
glutamatergic projections by activation of α2A-ARs. Further studies, however, are 
needed to confirm these findings, likely at the electron microscopy level as the 
density of the α2A-AR at the light microscopy level makes quantification of results 
unreliable in mouse brain tissue.  Qualitative findings, however, indicate that the 
α2A-AR may be localized to fibers projecting from the insular cortex and BLA.  
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Recent data from our lab demonstrate that α2A-ARs regulate glutamate 
transmission in part by heterosynaptically modulating glutamate release at 
presynaptic glutamatergic terminals (see chapter II).   Importantly, we show that 
the α2A-AR colocalizes with VGLUT1 at the light microscopy level (see chapter 
II). Here we show that projections from the insular cortex, infralimbic cortex, and 
BLA are VGLUT1(+), and that the α2A-AR potentially localizes to fibers on 
projections from these regions.  If confirmed, these findings indicate that the α2A-
AR regulates a subset of glutamatergic inputs to the BNST, and therefore is likely 
an important regulator of BNST output under stressful conditions such as during 
withdrawal from drugs of abuse. 
 
Conclusions 
Injections of the anterograde tracer BDA into brain regions involved in 
processing stress and anxiety states, including the infralimbic and insular cortices 
and basolateral amygdala, demonstrate that each of these regions innervates the 
BNST in mouse brain.   Additionally, the infralimbic and insular cortices and BLA 
are VGLUT1-containing.  These anatomical findings support a broad array of 
functional and behavioral data implicating the BNST in stress and anxiety and 
relapse to drug-seeking behaviors in the mouse model. 
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CHAPTER IV 
 
YOHIMBINE DEPRESSES TRANSMISSION IN THE DORSAL BNST VIA AN 
α2-AR INDEPENDENT PROCESS 
 
This chapter describes work completed toward the fulfillment of Aim III of 
my thesis project. 
 
Introduction 
As discussed previously in the thesis introductory chapter, yohimbine is a 
putative α2-AR antagonist that has been widely used to evoke anxiety in rodent 
models.  It is clear that activation of central α2-ARs decreases anxiety during 
withdrawal and can prevent stress-induced relapse to drug-seeking behaviors 
(Morilak et al, 2005).   In agreement with these findings, many studies have 
reported that the α2-AR antagonist yohimbine evokes anxiety in both humans 
(Holmberg et al, 1961; Murburg et al, 1991; Redmond et al, 1979) and animal 
studies (Davis et al, 1979; Holmes et al, 2002; Lang et al, 1963).   Cain and 
others found that yohimbine can facilitate extinction of conditioned fear in mice 
(Cain et al, 2004), while other groups concluded that yohimbine has no effect on 
extinction of conditioned fear (Mueller et al, 2009).  Other studies have shown 
that yohimbine can enhance development of CPP for morphine (Zarrindast et al, 
2002).  Additionally, intraperitoneal (i.p.) injections of yohimbine can reinstate 
methamphetamine-seeking following extinction in the self-administration model 
(Shepard et al, 2004), as well as alcohol-seeking (Le et al, 2005; Marinelli et al, 
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2007; Richards et al, 2009) and cocaine-seeking (Lee et al, 2004).  IP yohimbine 
can also reinstatement food-seeking in animals trained to lever press for food 
(Ghitza et al, 2006).  Thus, yohimbine appears to enhance anxiety-like behaviors 
through its putative action on α2-ARs. 
Other studies, however, have suggested that the anxiogenic effects of 
yohimbine are partially mediated through 5-HT1A receptors.  Powell and others 
have shown that yohimbine disrupts prepulse inhibition of acoustic startle in rats 
through the 5-HT1A receptor, and not α2-ARs, as the effects of yohimbine were 
blocked by a 5-HT1A-R antagonist but not an α2-AR agonist, and the effect of 
yohimbine was not mimicked by the more selective α2-AR antagonist 
atipamezole (Powell et al, 2005).  Studies looking at selectivity of yohimbine 
indicates that yohimbine has about a 10-fold selectivity for the α2A-AR over the 5-
HT1A-R, where as atipamezole has negligible effects on the 5-HT1A-R (Newman-
Tancredi et al, 1998).  Thus, it is likely that blockade of α2-ARs cannot account 
for all of the anxiogenic effects of yohimbine, but further work is needed to 
differentiate the roles of yohimbine and α2-ARs in stress and anxiety. 
Studies to date have looked at the effects of yohimbine on fear extinction, 
but not on reward-related memory.  To further assess the role of yohimbine on 
reward-related memories and behavior, Davis and others looked at the role of 
yohimbine in extinction of reward-related memories formed by exposure to 
cocaine (Davis et al, 2008).  Using a cocaine-induced CPP model, they showed 
that yohimbine impairs extinction of cocaine CPP, and that this effect is 
exacerbated in the α2A-AR knock out mice (Davis et al, 2008).  Additionally, the 
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more selective α2-AR antagonist, atipamezole, does not alter cocaine CPP 
extinction and did not replicate effects of yohimbine on extinction of fear 
conditioning (Davis et al, 2008).  These results contribute to studies suggesting 
that some effects of yohimbine are not mediated through the α2-AR. 
 To further investigate whether the effects of yohimbine are mediated 
solely through the α2-AR, we looked at the actions of yohimbine and atipamezole 
on excitatory transmission in the dorsal BNST.  We found that yohimbine greatly 
depresses excitatory transmission in the BNST, that the effect of yohimbine is 
unaltered in the α2A-AR KO mouse, and that the effect of yohimbine is not 
replicated by atipamezole.  This work was published with the behavioral work 
completed by Adeola Davis and others (Davis et al, 2008). 
 
Experimental Procedures 
Animals 
Experiments on C57BL/6J mice were conducted using males obtained 
from The Jackson Laboratory (Bar Harbor, ME) aged 8–12 weeks. Male α2A-AR 
KO mice were generated as previously described (Altman et al, 1999) and 
backcrossed onto a C57BL/6J genetic background for a minimum of eight 
generations. KO and WT littermate controls were bred from heterozygous 
parents to minimize any potential genotype-related maternal abnormalities 
(Millstein and Holmes, 2007).  Mice were housed on a 12 hour light/ dark cycle in 
groups of two to five with ad libitum access to food and water.  All procedures 
were approved by the Vanderbilt University and NIAAA Animal Care and Use 
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Committees and were in accordance with the Animal Welfare Act and the 
guidelines outlined in “Using Animals in Intramural Research.”  
 
Whole cell recordings 
Brain slices from the dorsal BNST were prepared as previously described 
(McElligott et al, 2008).  Briefly, mice were retrieved from the colony and allowed 
to rest in sound attenuating boxes for a minimum of 1 hour, after which they were 
anesthetized (isofluorane) and decapitated in a separate room.  Three-hundred-
micrometer coronal slices were cut on a VT1000S vibratome (Leica 
Microsystems) in a 1°C–4°C, oxygenated (95% O2, 5% CO2), high-sucrose/low 
Na+ artificial cerebral spinal fluid (ACSF; in mM: 194 sucrose, 20 NaCl, 4.4 KCl, 2 
CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10 glucose, 26 NaHCO3).  
Following slicing, hemisected slices were allowed to rest submerged in a 
holding chamber filled with oxygenated and heated (28°C) ACSF for at least 30 
min. After this incubation time, an individual slice was moved to the recording 
chamber where it was submerged in oxygenated and heated (28°C) ACSF with 
added picrotoxin (25 μM included for the entirety of all experiments) to isolate 
currents evoked by glutamate receptor activation at a rate of 2 mL/min.  A bipolar 
Nichrome (A-M Systems) stimulating electrode was placed dorsally to the 
recording electrode within the dBNST.  Patch electrodes (3–6 MΩ) were pulled 
on a Flaming/Brown microelectrode puller (Sutter Instruments) and filled with 
either cesium (Cs)-gluconate intracellular solution (in mM: Cs-gluconate 135, 
NaCl 5, MgCl2 2, HEPES 10, EGTA 0.6, Na2ATP 4, Na2GTP 0.4).  In all whole-
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cell experiments, cells were clamped at −70 mV throughout and excitatory post-
synaptic currents (EPSCs) were recorded using Clampex 9.2 (Molecular 
Devices).  Series resistance was monitored throughout each experiment, and a 
change greater than 20% resulted in the exclusion of the experiment from the 
data set.  EPSCs were evoked at a frequency of 0.167 Hz, and 100–400 pA 
EPSCs were recorded.  Consistent with the field experiments, drugs were bath 
applied at their final concentrations. 
A 5-10 min baseline was acquired prior to drug application, and all points 
were normalized to minutes 8–10 within each.  Baseline is an average of 2 min 
before drug application, and the experimental value is 24–25 min following drug 
application.  Points are 1-min averages on plotted time course.  
 
Results 
Central NE derives from two primary sources, the VNAB and the DNAB. 
Lesion of the VNAB impairs extinction learning (Cole and Robbins, 1987).  The 
VNAB projections terminate in the lateral hypothalamus and the extended 
amygdala, including the BNST (Aston-Jones et al, 1999).  Thus, we examined 
the effects of yohimbine and atipamezole on glutamatergic transmission in the 
dorsal BNST. We previously reported that the α2-AR agonists clonidine and UK-
14,304 elicit an acute depression of glutamatergic transmission in this region 
(UK-14,304, 41.7 ± 7.7% of baseline, P < 0.05) (Egli et al, 2005). We have 
replicated these data and show a representative experiment for comparison 
(Figure 15A).  Paradoxically, we have shown here that a 30 min 10 μM 
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application of yohimbine in the dlBNST unexpectedly caused a similar decrease 
(31.37% ± 6.90% of baseline; t = 11.10, df = 5, P < 0.001) in glutamatergic 
transmission (Figure 15B).  Further, while the effect of UK-14,304 was absent in 
slices prepared from α2A-AR KO mice (Egli et al, 2005), yohimbine still caused a 
decrease (42.6 ± 7.5% of baseline; t = 5.44, df = 5, P < 0.003) in glutamatergic 
transmission in the dBNST of these mice (Figure 15C). We then compared the 
actions of yohimbine with that of the more selective α2-AR antagonist 
atipamezole. A 30 min 1 μM application of atipamezole did not reproduce the 
effect of yohimbine (P < 0.001) on glutamatergic transmission (atipamezole: 
75.6% ± 4.9% of baseline, n = 10; t = 5.01, df = 9) (Figure 15D).  This 
concentration of atipamezole was sufficient to antagonize effects of UK-14,304 
(85.64% ± 6.82% of baseline; t = 2.59, df = 2, P > 0.12) on glutamatergic 
transmission in the dBNST (Figure 15E).  These experiments suggest that 
yohimbine modulates glutamatergic transmission in the dBNST independent of 
α2-ARs. 
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Figure 15 
 
 
 
Figure 15.  Yohimbine depresses glutamatergic transmission in the BNST 
through a non- α2-AR-dependent mechanism.  EPSCs in the dlBNST: (A) 1 μM 
UK-14,304 (n=1); (B) 10 µM yohimbine (n=10); (C) 10 μM yohimbine in α2A-AR 
KO mouse (n = 6); (D) 1 μM atipamezole (n = 10); (E) 1 μM UK-14,304 in the 
presence of 1 μM atipamezole (n = 3). Error bars, ± SEM. 
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Discussion 
Yohimbine depresses glutamatergic transmission in the dorsal BNST 
through an off-target action 
To address the possible mechanistic basis of the behavioral effects of 
yohimbine and atipamezole, we utilized whole cell patch clamp techniques and 
recorded from dBNST neurons. The BNST receives a dense noradrenergic input 
from the VNAB (Aston-Jones et al, 1999). When the VNAB is lesioned, there is 
an impairment of negative valence-learned extinction (Cole et al, 1987), 
suggesting regions innervated are essential to extinction of learned behaviors.  
We found atipamezole was able to block the depression in excitatory 
transmission caused by the α2-AR agonist UK-14,304.  In contrast, yohimbine 
itself elicited a depression on excitatory transmission, and this effect was not 
replicated by the more selective α2-AR antagonist, atipamezole.  Furthermore, 
we found that in α2A-AR KO mouse slices, the depression caused by yohimbine 
persists. One interpretation is that yohimbine is acting through a non-α2-AR 
mechanism in this brain region, and that this may contribute to impairment of 
extinction in cocaine CPP. 
Yohimbine is known to have a 10-fold selectivity for the α2A-AR over the 5-
HT1A-R (Newman-Tancredi et al, 1998), and its effects on prepulse inhibition of 
acoustic startle in rats have been suggested to be mediated via the 5-HT1A-R 
(Powell et al, 2005).  5-HT causes heterogenous changes in the excitability of 
cells in the BNST, sometimes eliciting a hyperpolarization, hyperpolarization 
followed by depolarization, or a depolarization in whole cell electrophysiology 
recordings under current clamp conditions (Rainnie, 1999).  Further studies by 
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this group demonstrated that a broad spectrum 5-HT1R agonist elicited a 
hyperpolarization in neurons of the BNST that was blocked by a 5-HT1A-R 
selective antagonist.  In vivo injections of the 5-HT1R agonist attenuated the 
acoustic startle response, indicating a role for the 5-HT1R in the BNST for limiting 
anxiety-like responses to stressful stimuli (Levita et al, 2004).  Thus, it is possible 
that the effects of yohimbine on anxiety are partially mediated via the 5-HT 
system. 
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CHAPTER V 
 
GENERAL DISCUSSION 
 
Summary of findings 
Stress is implicated as a major driving force for relapse to drugs of abuse 
in humans and in animal models (Brown et al, 1995; Le et al, 2000).  NE is a 
hormone released in response to stressors known to induce relapse in animal 
models of drug addiction, and is additionally released during withdrawal from 
drugs of abuse in both rodents and humans (Koob, 2008).  The BNST is a region 
of the brain involved in stress and anxiety, and importantly contains the densest 
innervation of NE in the brain (Forray et al, 2004).  Studies show that NE is 
released in the BNST in response to unconditioned and prolonged stressors 
(Cecchi et al, 2002a; Fuentealba et al, 2000).    
α2-AR agonists injected into the BNST consistently decrease measures of 
anxiety-like behaviors and block stress-induced relapse to drug-seeking (Delfs et 
al, 2000; Schweimer et al, 2005; Shaham et al, 2000b; Wang et al, 2001).  
Systemically, α2-AR agonists also lead to decreased anxiety-like behaviors and 
can block stress-induced reinstatement to drug-seeking (Erb et al, 2000; 
Highfield et al, 2001; Le et al, 2005; Morilak et al, 2005; Shaham et al, 2000a; 
Zislis et al, 2007), thus implicating either a global role of the α2-AR to limit the 
stress response, and/or a major role of the BNST in mediating behavioral 
responses to α2-AR agonists. 
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Studies demonstrating a potential heterosynaptic role for actions of the α2-
AR at glutamatergic synapses in the brain (Delaney et al, 2007; Glass et al, 
2001; Milner et al, 1998; Milner et al, 1999), in addition to previous studies in our 
lab demonstrating an acute depression of excitatory transmission by α2-ARs, led 
us to focus on the potential heterosynaptic regulation of glutamate transmission 
by α2-ARs.  Electrophysiology studies show that α2-AR agonists depress 
excitatory transmission in the BNST, and this response is absent in the α2A-AR 
knockout mouse (Egli et al, 2005).  For this reason, we focused our studies on 
the α2A-AR subtype.  As noted in Figure 4 on page 65, the α2A-AR could 
potentially regulate excitatory transmission indirectly as an autoreceptor via 
modulation of NE release at NE terminals, directly as a presynaptic 
heteroreceptor on glutamate terminals regulating glutamate release, or as a 
postsynaptic receptor altering the response to glutamate via modulations at 
postsynaptic sites. 
The goal of this work was to determine the role of the α2A-AR subtype in 
modulation of glutamatergic transmission, and to localize the α2A-AR at the light 
microscopy level.  We additionally sought to examine the potential for the α2A-AR 
to regulate a subset a glutamatergic inputs to the BNST.  Because most 
anatomical studies examining afferents to the BNST have been conducted in rat, 
we sought to confirm that relevant projections to the BNST were phylogenetically 
conserved in the mouse model.  We also examined the specificity of the α2-AR 
antagonist, yohimbine, as several reports have questioned its assumed 
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mechanism of evoking anxiety in humans and rodent models via blockade of the 
α2-AR. 
We have found that the α2A-AR functions in the BNST as a heteroreceptor 
presynaptically regulating glutamate release.  We show that guanfacine, an α2A-
AR selective agonist, dose-dependently depresses excitatory transmission in the 
BNST, and that this effect is blocked by the α2-AR antagonist atipamezole.  
Guanfacine causes a significant increase in the paired pulse ratio of evoked 
EPSCs, indicating that its effects on glutamate transmission may be mediated 
presynaptically.  Using an HA-tagged α2A-AR KI mouse, we show that the 
distribution of the α2A-AR is much broader than that of the noradrenergic markers 
NET and TH.  We show that the distribution of the α2A-AR partially overlaps with 
that of the glutamatergic terminal marker VGLUT1, and that at the light 
microscopy level, the α2A-AR appears to colocalize with VGLUT1.  We 
additionally demonstrate that the α2-AR regulates GABAergic transmission in the 
dorsal BNST in a dose-dependent manner. 
Our tracer studies confirm that the insular cortex, infralimbic cortex, BLA, 
and CeA projections to the BNST are phylogentically conserved from the rat to 
the mouse model.  We provide preliminary evidence that these projections are 
α2A-AR-containing, although future studies are needed to confirm our findings 
due to the density of the α2A-AR at the light microscopy level. 
Finally, we demonstrate that yohimbine depresses glutamatergic 
transmission in the dorsal BNST in non-α2-AR-dependent manner.  The effects of 
yohimbine are not replicated by the more selective α2-AR antagonist, 
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atipamezole.  Additionally, the effects of yohimbine are present in the α2A-AR 
knockout mouse.  This work was done in collaboration with Adeola Davis, who 
demonstrated that yohimbine impairs extinction of cocaine CPP, that this effect of 
yohimbine is exacerbated in the α2A-AR KO mouse, and that the effect of 
yohimbine on extinction of cocaine CPP is not replicated by the more selective 
α2-AR agonist atipamezole (Davis et al, 2008). 
 
Heterosynaptic α2A-ARs in the brain serve critical roles in stress, learning, 
and other behaviors 
α2A-ARs have long been known, along with α2C-ARs,  to function as 
autoreceptors regulating NE release in the brain (Bucheler et al, 2002; Devoto et 
al, 2004; Trendelenburg et al, 1999; Trendelenburg et al, 2001).  Although 
certainly modulation of NE release is a potential and likely mechanism of the 
regulation of stress and relapse behavior in rodents and humans, evidence is 
accumulating that α2-ARs may mediate many of their effects via heterosynaptic 
modulation of other neurotransmitters such as 5-HT, DA, glutamate and GABA.  
Gilsbach and others recently used the DBH promoter to drive expression of the 
α2A-AR exclusively in noradrenergic and adrenergic cells in α2A-AR and α2C-AR 
double knockout mice (Gilsbach et al, 2009).  They found that many functions 
typically attributed to α2-AR autoreceptors, such as analgesia, hypothermia, 
sedation and anesthetic-sparing, were not rescued in mice expressing the α2A-
AR exclusively in adrenergic neurons (curiously, they did not examine potential 
anxiety phenotypes in this report).  They suggest that heterosynaptic α2-ARs 
likely play a significant role in mediating these behaviors (Gilsbach et al, 2009).  
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Studies examining the ultrastructural localization of α2A-AR-like 
immunoreactivity in the rodent brain have found α2A-ARs to be localized to 
various compartments within neurons, including presynaptically on autosynaptic 
and heterosynaptic terminals, as well as postsynaptically and on glial cells in 
regions including the hippocampus, ventrolateral medulla, and NTS (Glass et al, 
2001; Milner et al, 1998; Milner et al, 1999).  These studies also support a 
potential role for heterosynaptic α2A-ARs.  Our studies demonstrate that α2A-ARs 
are distributed in a pattern similar to the glutamatergic terminal marker 
VGLUT1(+), and also have an overlapping albeit broader distribution than the NA 
and DA terminal marker TH, therefore implicating a heterosynaptic role for the 
α2A-AR in the BNST. 
Recent studies have demonstrated a heterosynaptic role of the α2-AR in 
mediating alterations in glutamate transmission (Carey et al, 2009; Delaney et al, 
2007; Yamanaka et al, 2006) and GABA transmission (Yamanaka et al, 2006) in 
the brain.  Our work adds to this body of knowledge by demonstrating a role for 
the α2A-AR in heterosynaptic modulation of glutamatergic and GABAergic 
transmission in the dorsal BNST. 
Studies specifically examining the role of α2-ARs in heterosynaptic 
modulation of synaptic transmission have revealed the importance of this 
receptor in synaptic plasticity and potentially learning.  NE is known to be 
important for allowing focused attention on behaviorally-relevant external stimuli, 
and is also critically involved in the stress response.  Delaney and others have 
shown that heterosynaptic α2-ARs presynaptically regulate glutamate release in a 
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subset of glutamatergic inputs to the central nucleus of the amygdala (Delaney et 
al, 2007).  They observe a depression in excitatory transmission that is mediated 
through α2-AR actions to block fusion of glutamate-containing vesicles with the 
presynaptic terminal via the βγ subunit of the α2-AR-linked GPCR.  They find that 
α2-ARs decrease glutamate release from the basket terminals of the PBN, but do 
not alter glutamate release from the BLA input (Delaney et al, 2007), thus 
implicating the α2-AR in regulation of inputs relaying information about peripheral 
pain. 
Similarly, in the cerebellum, Carey and Regehr have found that 
heterosynaptic α2-ARs decrease presynaptic glutamate release at climbing fiber 
synapses (carrying information from the inferior olivary nucleus) to the Purkinje 
cells, but do not affect glutamate release at parallel fiber synapses (carrying 
information from the spinal cord and brainstem nuclei)  with Purkinje cells (Carey 
et al, 2009).  Importantly, they demonstrate an α2-AR-mediated disruption in 
long-term plasticity at parallel fiber-Purkinje cell synapses that is normally elicited 
via repeated simultaneous stimulation of these synapses and the climbing fiber-
Purkinje cell synapses.  Thus, they suggest that activation of α2-ARs activation 
can disrupt associative motor learning by selectively altering glutamate release at 
climbing fiber synapses (Carey et al, 2009). 
In the BNST, α2-AR agonists also depress excitatory transmission, and 
this response is nearly abolished in the α2A-AR knockout mouse (Egli et al, 
2005).  The current studies expand upon these findings.  We demonstrate a 
heterosynaptic α2A-AR-mediated presynaptic decrease of glutamate release in 
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the dorsal BNST.  Additionally, our work has begun to demonstrate potential 
specificity of regulation at a subset of glutamatergic synapses in the BNST.  We 
show that α2A-ARs are localized to VGLUT1(+) terminals, although our work does 
not allow us to rule out localization to VGLUT2(+) terminals.  Using BDA-tracer 
injections, we were able to demonstrate that the α2A-AR is potentially localized to 
glutamatergic inputs from the BLA, insular cortex, and the infralimbic cortex.  
Fibers anterogradely labeled with BDA from these regions show expression of 
VGLUT1 and the α2A-AR at the light microscopy level, although future studies are 
needed to confirm these preliminary findings due to the density of HA- α2A-AR 
labeling. 
Future studies examining whether the α2A-AR globally regulates 
glutamatergic transmission in the BNST, or is involved in regulating a subset of 
glutamatergic inputs, will be important in understanding how NE elicits behavioral 
responses to stress via its actions through the α2A-AR in the BNST.  EM studies 
combining anterograde tracer work with immunolabeling of the α2A-AR using the 
HA α2A-AR KI mouse, is one way to potentially examine this question.  
Electrophysiology studies using techniques such as those employed by Delaney 
and others to illuminate specific inputs to the BNST are another potential way to 
examine this issue. 
 
Activation of α2-ARs in the dorsal BNST depresses GABAergic 
transmission 
In addition to our work demonstrating heterosynaptic α2A-AR-mediated 
alterations in glutamate release, we also show that activation of α2-ARs dose-
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dependently modulates GABAergic transmission in the dorsal BNST.  Our BDA 
tracer injections in the HA α2A-AR KI mouse suggests potential interaction of the 
α2A-AR with presynaptic fibers or terminals from the CeA, although these are 
preliminary findings in one mouse and have the same caveat as other tracer 
injections co-labeled with the α2A-AR due to the density of this label at the light 
microscopy level.   
In contrast to this apparent presynaptic labeling of CeA fibers, our 
electrophysiology findings show no increase in PPR upon guanfacine application 
in whole-cell electrophysiology recordings.  Additionally microdialysis studies 
examining extracellular GABA levels, and whole-cell electrophysiology studies 
looking at spontaneous inhibitory transmission in the BNST, lead us to suggest 
that actions of the α2-AR on GABAergic transmission may be mediated 
postsynaptically (Dumont et al, 2004; Forray et al, 1999).  Further studies are 
needed, however, to definitely sort out the mechanism behind the depression of 
GABAergic transmission elicited by activation of α2-ARs.   
Importantly, we must consider the possibility that the α2A-AR selective 
agonist guanfacine is eliciting changes in GABAergic transmission at higher 
doses due to actions at the α2C-AR.  Guanfacine shows a 22-fold selectivity for 
the α2A-AR subtype over the α2C-AR (Uhlen et al, 1992), thus at higher 
concentrations of guanfacine we cannot rule out activation of the α2C-AR in 
addition to the α2A-AR.  The potential role of the α2A-AR on CeA fibers in the 
BNST, if this localization is later confirmed, warrants further study. 
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Finally, our studies show that guanfacine has a higher potency on 
glutamatergic than GABAergic transmission in the BNST, suggesting that α2A-
ARs may primarily mediate their effects on BNST output via modulation of 
glutamatergic transmission.  How this difference in potency might affect BNST 
output is hypothesized later in this section. 
 
The α2A-AR potentially mediates some of its effects on glutamatergic and 
GABAergic transmission via modulation of 5HT and DA 
Many studies have demonstrated a role for α2-ARs in regulation of 5-HT 
and DA release via in vitro and in vivo microdialysis (Ansah et al, 2003; Bucheler 
et al, 2002; Gobert et al, 1998; Ihalainen et al, 2002; Maura et al, 1992; 
Numazawa et al, 1995; Scheibner et al, 2001).  Additionally, work completed in 
forebrain synaptosomal preparations suggests that α2-ARs can modulate function 
of the 5-HT transporter, SERT (Ansah et al, 2003).  Therefore, we must consider 
that activation of α2-ARs not only directly regulates glutamate and GABA 
transmission in the BNST, but that some of these effects may be mediated by 
altered endogenous release of 5HT and DA.   
In the frontal cortex, α2-AR agonists can decrease extracellular levels of 
DA and NE (Gobert et al, 1998; Ihalainen et al, 2002), although α2-ARs agonists 
are shown to not regulate DA levels in the NAc (Ihalainen and Tanila, 2004).  The 
BNST receives DA projections from both the VTA and PAG (Hasue et al, 2002; 
Meloni et al, 2006; Zahm et al, 2001).  Our immunohistochemical studies do 
demonstrate the presence of the α2A-AR on TH(+) terminals, potentially 
implicating the α2A-AR as a potential regulator of DA transmission in the BNST.  
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Whole-cell electrophysiology recordings show that DA enhances excitatory 
transmission in the dorsal BNST via D1 and D2 receptors (Kash et al, 2008), and 
it is conceivable that activation of α2-ARs may decrease endogenous DA release, 
leading to a depression of excitatory transmission in the dorsal BNST.  This 
mechanism, however, would require that DA is tonically released in the BNST 
under ex vivo slice recording conditions.  Though we cannot rule this out as 
contributing to the depression in excitatory transmission elicited by activation of 
α2-ARs; the robustness of our effect, localization of the α2A-ARs to VGLUT1(+) 
glutamatergic terminals, and the increase in PPR that we see upon guanfacine 
application, lead us to believe this is not likely the main mechanism behind the 
alteration in glutamate transmission that we see upon guanfacine application. 
Microdialysis studies additionally point to modulation of 5HT release by α2-
ARs in regions such as the hippocampus and prefrontal cortex, (Gobert et al, 
1998; Maura et al, 1992; Numazawa et al, 1995; Scheibner et al, 2001).  We 
must therefore consider that a decrease in 5-HT release may contribute to our 
findings with guanfacine application on transmission in the dorsal BNST.  The 
BNST receives a serotonergic projection from the raphe nucleus (Phelix et al, 
1992a, b).  5-HT in the BNST is concentrated heavily in the medial BNST, 
although Rainnie has shown that cells in the dorsal lateral BNST show alterations 
in excitability in response to 5-HT application (Rainnie, 1999).  Though this 
response is variable, cells in the lateral BNST tend to hyperpolarize in response 
to 5-HT application, and this is likely via activation of the 5-HT1A-R (Rainnie, 
1999).  More work is needed to examine the contributions of 5-HT to alterations 
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in glutamate transmission in the BNST.  5-HT agonists injected into the BNST, 
however, indicate an anxiolytic role of this neurotransmission, similar to activation 
of the α2A-AR (Levita et al, 2004).  Thus, it is unlikely that activation of the α2A-AR 
would decrease 5-HT release and/or enhance 5-HT clearance to coordinate an 
anxiolytic or stress-protective effect of BNST output.   
It seems more likely, that the α2A-AR may enhance 5-HT transmission to 
increase its anxiolytic effects in the BNST.  Studies by Ansah and others suggest 
that activation of α2-AR in the forebrain can inhibit function of the serotonin 
transporter, SERT, thereby elevating 5-HT extracellular levels (Ansah et al, 
2003).  Therefore, we must consider that the effects of α2-AR activation on 
transmission in the BNST may partially be mediated by the ability of the α2-AR to 
inhibit SERT function.  Again, the degree to which this potentially contributes to 
our electrophysiology findings is dependent on the endogenous levels on 5-HT in 
our slice preparation, something we have not yet had the opportunity to examine. 
 
Activation of α2-ARs in the BNST is likely critical in regulation of the stress 
response and relapse to drug-seeking behaviors 
Curiously, we find that activation of α2A-ARs depresses both glutamatergic 
and GABAergic transmission in the BNST under ex vivo whole-cell 
electrophysiology conditions, although the effect on glutamatergic transmission is 
more potent than the effect on GABAergic transmission.  Regulation of both 
glutamatergic and GABAergic transmission by α2-ARs in the BNST complicates 
potential explanations for how activation of α2-ARs in the BNST results in known 
decreased anxiety behaviors and blockade of stress-induced relapse to drug-
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seeking in animal models.  Interestingly, Yamanaka and others similarly see a 
depression in both glutamatergic and GABAergic transmission via activation of 
α2-ARs in whole cell recordings of orexin-(+) neurons of the lateral hypothalamus 
(Yamanaka et al, 2006).  It is likely that α2-AR-mediated depression of 
glutamatergic and GABAergic transmission in the BNST is coordinated to 
regulate BNST output to regions involved in stress and reward such as the PVN 
and VTA. 
Excitatory input into the BNST comes from insular cortex, infralimbic 
cortex, the ventral subiculum and the basolateral amygdala (Dong et al, 2001a; 
Massi et al, 2008; Weller et al, 1982), other regions known to be involved in 
stress-reward circuitry, and regions known to express mRNA for the α2A-AR 
(Scheinin et al, 1994; Wang et al, 1996).  Thus, the α2A-AR potentially gates 
these inputs, effectively decreasing excitatory drive to the BNST during events 
known to release NE, such as chronic stressors, withdrawal from drugs of abuse, 
and other social stressors (Aston-Jones et al, 1999; Cecchi et al, 2002a; Cecchi 
et al, 2002b; Delfs et al, 2000; Fendt et al, 2005). 
The main inhibitory projection to the BNST is from a closely related 
structure, the central nucleus of the amygdala (CeA), a region also involved in 
fear and anxiety states.  Additionally, the BNST is made up of a large network of 
GABAergic interneurons.  Thus, modulation of inhibitory transmission by 
activation of α2-ARs may also influence output of the BNST by modulating 
GABAergic transmission at CeA-BNST synapses, or by altering activity of 
interneurons in the BNST.   
145 
 
The projection from the BNST to the PVN is known to be GABAergic 
(Cullinan et al, 1993; Herman et al, 1994), and activation of the BNST is thought 
to lead to disinhibition of this projection.  Activation of α2A-ARs in the BNST may 
help limit this disinhibition during stressful circumstances.  One potential 
mechanism is that by depressing glutamatergic transmission, α2A-AR activation 
modulates glutamate release onto inhibitory interneurons in the BNST.  These 
interneurons may be activated under stress, therefore mediating disinhibition of 
the BNST.  Thus α2A-ARs may alleviate or limit the disinhibition of the PVN under 
stress.  Similarly, depression of GABAergic transmission on PVN projection 
neurons may also serve to limit the disinhibition of this projection in stressful 
conditions (see Figure 16 for illustration).  
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Figure 16. 
 
 
 
Figure 16. Illustration of one way activation of α2A-ARs could lead to decreased 
inhibitory and excitatory transmission in the dorsal BNST, and thereby limit 
disinhibition of the PVN when glutamatergic inputs are activated under stress. 
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The makeup of the BNST projection to the VTA is controversial.  While 
output of the BNST is typically considered to be GABAergic (McDonald, 1983; 
Sun et al, 1993), recent studies have led researchers to conclude that this 
projection is excitatory (Dumont et al, 2004; Georges et al, 2002), and is CRF(+) 
(Rodaros et al, 2007).  In general though, activation of the BNST is thought to 
lead to activation of the VTA.  For example, Massi and others have demonstrated 
that cannabinoid receptors in the BNST control infralimbic cortex-mediated 
excitation of the VTA (Massi et al, 2008).  Studies demonstrate that α2-AR 
agonists in the BNST block stress-induced reward-seeking behaviors, and this 
data suggests that activation of the α2-AR receptor serves to limit the stress 
response (Delfs et al, 2000; Wang et al, 2001).  Thus, we can imagine that α2A-
ARs in the BNST regulate projections to the VTA by decreasing or limiting 
activation of excitatory BNST projections to the VTA, or augmenting activation of 
inhibitory BNST projections to the VTA. 
Importantly, understanding the physiologic role of the α2A-AR in the BNST 
will be critical for interpreting the findings of this thesis work.  While we 
demonstrate presence of the α2A-AR in the BNST, and show that α2A-AR 
selective agonist guanfacine can heterosynaptically regulate excitatory and 
inhibitory transmission under ex vivo whole-cell electrophysiology conditions, the 
extent to which these receptors are activated by NE under normal physiological 
conditions is unknown.  Our findings demonstrate a widespread distribution of the 
α2A-AR outside that of NET and TH, raising the possibility that NE may not reach 
a significant portion of the heteroreceptor α2A-AR population when low levels of 
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NE are present in the BNST (such as when an animal is at rest or under low-
stress conditions).  It is conceivable that these receptors are activated only in 
response to prolonged or intense stress (and therefore prolonged or greater 
increases in NE levels in the BNST), or that these receptors are rarely activated.  
Future studies examining the extent and result of endogenous activation of α2A-
ARs in the BNST under varying stress-conditions would help elucidate the 
physiological function of α2A-ARs in the BNST.  The presence of α2A-ARs on 
glutamatergic terminals in the BNST as well as the ability of the α2A-AR selective 
agonist guanfacine to depress excitatory transmission in this region, make α2A-
ARs an intriguing target for anti-anxiety therapeutics. 
 
α2A-AR selective agonists may be important therapeutic agents for treating 
anxiety disorders and in preventing stress-induced relapse to drug-seeking 
Effective pharmacological tools for helping addicts with anxiety and 
craving are extremely limited at this time.  Guanfacine, an α2A-AR selective 
agonist, is FDA-approved for treatment of some anxiety disorders including post-
traumatic stress disorder (PTSD) and chronic Tic disorder.  Guanfacine is also 
prescribed as a centrally-acting hypertensive agent to reduce blood pressure in 
patients struggling with hypertension (Kisicki et al, 2007), and is used for 
treatment of patients suffering from schizophrenia (McClure et al, 2007).  
Guanfacine is currently undergoing clinical trial for its role in preventing stress-
induced relapse to cocaine, smoking, and alcohol use (Clinicaltrials.gov).  
Additional clinical trials looking at its efficacy in treating PTSD, ADHD, and 
schizophrenia are also underway (Posey et al, 2007).   
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Guanfacine is a partial agonist at the α2A-AR, and data suggest that partial 
agonism at this receptor subtype results in fewer unwanted side effects such as 
sedation in the potential treatment of anxiety disorders (Tan et al, 2002).  
Additionally, in disorders such as addiction, PTSD, or ADHD, where chronic 
therapeutics are needed, an agonist that does not readily induce desensitization 
of its target may be beneficial.  Guanfacine desensitizes α2A-ARs much less 
readily than clonidine, likely explaining the longer duration of action by 
guanfacine clinically despite the two partial agonists having a similar half-life (Lu 
et al, 2009).  Thus, guanfacine is a promising potential therapy for anxiety 
disorders and relapse in addiction.  We theorize that the effects of guanfacine on 
α2A-ARs in the BNST are partially responsible for its effectiveness as a 
therapeutic agent in anxiety- and addiction-related behaviors. 
 
The presumed α2-AR-mediated mechanism of action of yohimbine in 
evoking anxiety-like behaviors in humans and rodents should be 
reconsidered 
As discussion in chapter IV, yohimbine is a putative α2-AR antagonist that 
has been widely used to evoke anxiety in human and rodents.  Studies 
conducted by Adeola Davis and others demonstrate that the effects yohimbine 
on fear-extinction are not likely mediated via the actions of yohimbine on α2-ARs 
(Davis et al, 2008).  Our electrophysiology work also demonstrates that at the 
slice level, yohimbine elicits alterations in glutamatergic transmission that are not 
due to its actions at the α2-AR.  Whereas short-term application in 
electrophysiology recordings shows no effect of yohimbine in the dorsal BNST 
(Egli et al, 2005), longer application demonstrates an off-target mechanism of 
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action that we theorize to be mediated through the 5-HT1A-R. We show that the 
more selective α2-AR antagonist, atipamezole, does not replicate effects of 
yohimbine in whole-cell voltage clamp recordings in the dorsal BNST. 
Additionally, we demonstrate no loss of effectiveness of yohimbine to depress 
glutamatergic transmission in the α2A-AR KO mouse (Figure 15), a model in 
which α2-ARs are thought to be almost fully desensitized (McElligott et al, 2008).  
Yohimbine has only a 10-fold selectivity for the α2-ARs over the 5-HT1A-R 
(Newman-Tancredi et al, 1998).  Others have shown that the effects of 
yohimbine on acoustic startle are mediated via the 5-HT1A-R, as the effects of 
yohimbine were blocked by a 5-HT1A-R antagonist, but not an α2-AR agonist 
(Powell et al, 2005). 
This work demonstrates the need for reevaluation of results utilizing 
yohimbine as an α2-AR antagonist, and elicits further investigation into the role of 
the 5-HT1A-R in mediating anxiety-related behaviors. 
 
Conclusions 
 
In summary, my thesis work demonstrates an important heterosynaptic 
role for the α2A-AR in mediating glutamatergic and GABAergic transmission in the 
BNST.  We show that the α2A-AR-mediated depression of glutamatergic 
transmission occurs via alterations in presynaptic glutamate release, and that 
α2A-ARs are localized to VGLUT1(+) and TH(+) terminals at the light microscopy 
level.  These findings add to the growing body of evidence implicating the α2A-AR 
as mediating many of its behavioral actions via heterosynaptic regulation of non-
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NE neurotransmitter release, in addition to its role as an autoreceptor regulating 
NE release. 
We additionally have confirmed that several regions involved in stress and 
anxiety, including the infralimbic cortex, insular cortex, BLA, and CeA, show 
phylogenetically conserved projections to the BNST in the rat and mouse model.   
Finally we demonstrate that the reported α2-AR antagonist yohimbine has 
significant α2-AR-independent effects on behavior and synaptic transmission.  
These findings demand more cautious interpretations regarding the mechanism 
of yohimbine in evoking anxiety-like behaviors in human and rodent models. 
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APPENDIX 
 
APPENDIX A 
FURTHER CHARACTERIZATION OF THE α2-ADRENERGIC RECEPTOR AND 
RELATED MARKERS IN THE BNST 
 
Please see Chapter II Experimental Procedures for review of methods. 
Immunohistochemistry 
In the course of my research, I have examined various proteins of interest, 
and their potential co-distribution in the dorsal BNST.  Findings are presented 
below and will be discussed after presentation of the data. 
All labeling was conducted on tissue from the HA α2A-AR KI mouse.  
Primary antibodies used include: guinea pig anti-VGLUT2 from Chemicon 
(1:1000), guinea pig anti-VGLUT1 (1:1000-1:8000); rabbit anti-VGLUT2 from 
Synaptic Systems (1:1000); rabbit anti-GAD65 from Chemicon (1:1000), and 
mouse anti-HA from Covance (1:500-1:1000).  Secondary antibodies are all from 
JacksonImmuno Research and include cy5 donkey anti-guinea pig (1:1000), cy5 
and cy2 donkey anti-rabbit (1:1000), and cy2 donkey anti-mouse (1:1000).  All 
methods for fluorescent immunohistochemitry are as described in chapter II. 
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Figure 17.  Distribution of the vesicular glutamate transporters in the dBNST. 
 
 
Figure 17. VGLUT1 and VGLUT2 do not appear to colocalize in the dorsal lateral 
BNST.  A-C) Scale bar equals 5 μm, inset scale bars are 0.5 µm.  A) VGLUT1 B) 
VGLUT2 (Synaptic systems). C) Merge.  **Note, VGLUT2 antibodies from 
Chemicon and Synaptic Systems show complete overlap in labeling. 
 
 
As described earlier, the vesicular glutamate transporters (VGLUTS) are 
proteins responsible for packaging of glutamate into synaptic vesicles.  VGLUT1 
and VGLUT2 mRNA are known to have a primarily complementary distribution in 
glutamtergic output regions of the brain (Herzog et al, 2001), whereas VGLUT3 is 
found in populations of neurons expression the vesicular monoamine transporter 
(VMAT), the vesicular acetylcholine transporter (VAChT), and the vesicular 
gamma-aminobutyric acid transporter (VGAT) (Boulland et al, 2004).  For this 
reason, VGLUT1 and VGLUT2 are considered glutamatergic markers, whereas 
VGLUT3 is not (Herzog et al, 2004).  VGLUT1 is expressed by cortical neurons, 
neurons in the hippocampus, and olfactory bulb, as well as other nuclei, whereas 
VGLUT2 mRNA is found primarily in the thalamus, hypothalamus, and brainstem. 
Most glutamatergic inputs to the BNST are from cortical or cortical amygdalar 
regions such as the insular cortex, infralimbic cortex, hippocampus, and 
basolateral amygdala, and our data shows potential colocalization of the α2A-AR 
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(see chapter III) with projections from these regions.  Inputs to the BNST such as 
the parabrachial nucleus of the hypothalamus, however, would be expected to 
express primarily VGLUT2 based on previous findings (Herzog et al, 2001).  As 
might be expected based on afferents to the BNST, VGLUT2 distribution is less 
dense than VGLUT1 distribution in the BNST (see Figures 8-9 from Chapter II for 
comparison).  At the light microscopy level, we find little colocalization between 
VGLUT1 and VGLUT2 qualitatively, as expected based on their reported 
complementary distribution (Figure 17). 
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Figure 18. Distribution of the α2A-AR and VGLUT2 in the dBNST. 
 
 
Figure 18. VGLUT2 distribution is similar to, but less dense than HA distribution 
in the dorsal lateral BNST. A-C) Scale bar equals 200 µm. A) VGLUT2 
(Chemicon).  B) HA.  C) Merge.  D-F) Scale bar equals 5 μm, inset scale bars are 
0.5 µm.  D) VGLUT2 (Chemicon). E) HA.  F) Merge.  
 
Interestingly, we see very low levels of colocalization of the α2A-AR with 
VGLUT2 qualitatively (see Figure 18 above), whereas we saw more extensive 
colocalization with VGLUT1 (see Figure 9).  Although additional studies are 
needed to confirm our qualitative light microscopy level findings, it is possible that 
only a subset of glutamatergic inputs to the BNST are regulated by the α2A-AR, 
and we hypothesize that the α2A-AR might regulate glutamate release in the 
VGLUT1(+), but not VGLUT2(+), subset of inputs to the BNST. 
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Figure 19.  Distribution of the α2A-AR and GABAergic marker GAD65 in the 
dBNST. 
 
 
 
Figure 19.  HA surrounds GAD65(+) cell bodies in the dorsal lateral BNST.  A-C) 
Scale bar = 5 µm  A) HA.  B) GAD65.  C) HA-GAD65. D-F) Scale Bar = 2 μm.  D) 
HA.  E) GAD65.  F) HA-GAD65. 
 
Although the density of GAD65 and the α2A-AR make it difficult to assess 
the degree of potential colocalization of these two proteins (and due to variability 
in qualitative colocalization across slices), it is very clear that the α2A-AR 
surrounds GAD65(+) cell bodies of the dorsal BNST.  Because the α2A-AR and 
VGLUT1 are both heavily distributed around these cell bodies of the dBNST, it is 
likely that much of the α2A-AR noted here is presynapic and potentially localized 
to glutamatergic terminals (see Figure 9).  However, these findings also lend 
support to our electrophysiology findings demonstrating α2A-AR-mediated 
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modulation of GABAergic transmission in the dorsal BNST, and confirm studies 
that report a high density of GABAergic interneurons and projection neurons 
(McDonald, 1983). 
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Figure 20.  Distribution of the α2A-AR and CRF in the dorsal BNST.  
 
 
 
Figure 20. CRF distribution is similar to HA distribution in the medial BNST. A-C) 
Scale bar equals 200 µm. A) HA.  B) CRF.  C) Merge.  D-F) Scale bar equals 5 
μm, inset scale bars are 0.5 µm.  D) HA. E) CRF. F) Merge.  
 
As discussed in the introduction, much data exists to suggest a functional 
interaction between NE and CRF.  We have done extensive work at the light 
miscroscopy level to examine a potential colocalization of CRF and the α2A-AR in 
fibers of the stria terminalis, as shown in the figure above.  Unfortunately, due to 
inconsistency of antibodies and even different lots of the same antibody (goat 
anti-CRF S-19 from Santa Cruz; lot #3108 and #1208 do not show stria labeling 
and show a dissimilar pattern of labeling to the lot presented in the images 
above), we cannot yet make any conclusions from the work above.  This 
particular lot of antibody shown above, gave us consistent fiber labeling in the 
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stria that qualitatively colocalizes with the α2A-AR, but we did not have access to 
a CRF-KO animal to examine antibody specificity.  More experiments and 
analysis using an antibody with proper controls are needed to determine a 
potential interaction or co-distribution of CRF and the α2A-AR.  If CRF and the 
α2A-AR are co-localized on terminals in the BNST, this would suggest that 
activation of the α2A-AR may regulate CRF release from these sites.  
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Figure 21.  Distribution of the noradregnergic markers NET and TH in the locus 
coeruleus and BNST. 
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Figure 21.  NET and TH are colocalized in the LC and BNST.  Accepted to BMC 
Neuroscience. Heinrich Matthies et al. 2009 
 
Mouse brain sections were processed for confocal-assisted imaging of 
NET immunoreactivity as described in Materials and Methods. A-C. Coronal 
sections encompassing the locus coeruleus (LC) were doubled-labeled using 
antibodies against both tyrosine hydroxylase (TH, red) (A, D) and NET (B, E, 
green). Panels C and F are merged images of A/B and D/E, respectively. Arrow 
in B identifies a dual labeled LC dendrite. Scale bar in A-C = 200 μm; scale bar in 
D-F = 20 μm. G-I. Projections of six confocal sections (63X) taken from the 
dorsal BNST (dBNST). TH and NET immunoreactivities are shown in panel G 
(red) and panel H (green), respectively. Panel I is the merge of G and H. Insets 
of G-I show a digital zoom to illustrate individual fibers. J-L: Projections of six 
confocal sections (63X) taken from the ventral BNST (vBNST). TH 
immunoreactivity is shown in panel J (red) and NET immunoreactivity is shown in 
panel K and the overlap in panel L. All scale bar = 20 μm. 
 
These data demonstrate that the noradrenergic markers NET and TH are 
heavily colocalized in the locus coeruleus (LC), as would be expected since the 
LC is known to primarily contain noradrenergic cell bodies.  We additionally show 
here that while the NET distribution is much heavier in the ventral BNST than the 
dorsal BNST, there still exists a large amount of NET immunoreactivity in the 
dorsal BNST.  This main source of this NE in the BNST comes from the NTS via 
the VNAB.  NET and TH also colocalize in the dorsal and ventral BNST, 
however, the broader distribution of TH likely demonstrates DA terminals 
innervating the BNST.  Both the PAG and VTA provide dopaminergic innervation 
to the BNST. 
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Whole cell electrophysiology 
 
Figure 22.  The α2-AR agonist UK-14,304 depresses excitatory and inhibitory 
transmission in Swiss-Webster mice. 
 
 
  
Figure 22.  Activation of α2-ARs causes a depression in transmission in the 
dorsal BNST in male Swiss-Webster mice. A)  Excitatory transmission (n = 2-3).  
B) Inhibitory transmission (n = 3-4). 
 
In Swiss Webster mice, activation of α2-ARs in the dorsal BNST leads to a 
depression in both excitatory and inhibitory transmission.  These findings are 
similar to what we find in C57BL/6J mice (see Figure 10 for comparison). 
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Figure 23.  Reboxetine does not alter excitatory transmission in the dorsal BNST 
of WT mice. 
 
 
Figure 23.  The NET blocker reboxetine (100 nM) does not alter excitatory 
transmission in the dorsal BNST of C57BL/6J mice (n = 6). 
 
 Our studies show that the NET blocker reboxetine does not alter excitatory 
transmission in the dorsal BNST, suggesting that there is minimal endogenous 
NE release elicited by our stimulation protocol.  Additionally, it suggests that 
there is little endogenous NE in our ex vivo slice preparation.  Previous studies 
examining the effectiveness of NET blockers to alter excitatory transmission in an 
ex vivo slice preparation, however, typically see loss of their effect within 1 
second (Delaney et al, 2007).  Therefore, it is highly likely that we are missing 
any potential effect of endogenous NE release on excitatory transmission in our 
protocol.   
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Figure 24.  UK-14,304 effects on excitatory transmission are unaltered in NET 
KO mice. 
 
 
Figure 24.  In field electrophysiology recordings, UK-14,304 causes a depression 
of excitatory transmission in the dorsal BNST of WT C57BL/6J mice, and this 
effect is unaltered in NET KO mice.  A) 50 nM UK-14,304, C57BL/6J (red, n = 3), 
NET KO (black, n = 2).  B) 10 μM UK-14,304, C57BL/6J (red, n = 4), NET KO 
(black, n = 4). 
 
 Using field recordings, we demonstrate that even low doses of UK-14,304 
(50 nM) elicit a depression in excitatory transmission of C57BL/6J mice (Figure 
24A).  Moreover, these effects are unaltered in the NET KO mouse at both 50nM 
and 10 μM UK-14,304 (Figure 24A-B).  The NET KO mouse is known to have 
increased NE levels throughout the brain (Xu et al, 2000), and also shows 
upregulation of α2-ARs (Gilsbach et al, 2006).  NET KO mice have been shown 
to behave like anti-depressant treated mice in rodent models of depression, and 
are known to be supersensitive to psychostimulants such as cocaine (Xu et al, 
2000).  These findings demonstrate an important role for NET in maintaining NE 
levels throughout the brain, as well as important behavioral consequences of 
losing this tight regulation of NE in the brain.  Interestingly, α1-AR-mediated LTD, 
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but not mGluR5-mediated LTD, is absent in the NET KO mouse (McElligott et al, 
2008), indicating a disruption of noradrenergic signaling in these mice.  We find 
here, however, that α2-ARs function normally in these mice, suggesting they are 
not subject to desensitization as easily as α1-ARs.  In fact, the upregulation of α2-
ARs throughout the brain of the NET KO mouse suggests that the role of the α2-
AR as an autoreceptor to decrease NE release may be upregulated in these 
mice in attempt to control NE levels throughout the brain and compensate for the 
lack of NET. 
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APPENDIX B 
 
THE CEA PROJECTS TO THE BNST IN THE C57BL/6J 
 
This section examines the projection from the CeA to the BNST.  While 
this projection has been shown numerous times in the rat model, no one has 
anatomically demonstrated whether the projection is phylogenetically conserved 
in the mouse model. 
 
Introduction 
Previous studies in rat and other models indicate a very dense GABAergic 
projection from the central nucleus of the amygdala (CeA) to the BNST (Dong et 
al, 2001a; Krettek and Price, 1978; Price et al, 1981; Shin et al, 2008; Sun et al, 
1991; Weller et al, 1982) that is CRF(+) (Sun et al, 1991).  While the BNST and 
CeA are very homologous structures with similar afferents and efferents, it is 
hypothesized that the BNST is involved in unconditioned prolonged anxiety 
states (Walker et al, 2003) whereas the CeA is involved in conditioned fear to 
distinct sensory cues (Campeau et al, 1995; Kim et al, 1993; Wilensky et al, 
2006).  Work by Erb and others have demonstrated that the projection from the 
CeA to the BNST is critical in stress-induced reinstatement to cocaine seeking 
behaviors (Erb et al, 2001). 
Therefore, we used BDA injections to determine if the projection from the 
CeA to the BNST was upheld in the mouse model. 
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Experimental Procedures 
Methods used are the same as those described in Chapter III Experimental 
Procedures.  BDA injections were made in the CeA (AP -1.34, L 2.4, D 4.53). 
 
Results  
 
BDA injections in the CeA 
One HA α2A-AR KI mouse on a C57BL/6J background was injected with BDA into 
the CeA.  The CeA is known to contain a heavy reciprocal connection with the 
BNST in rat (Dong et al, 2001a; Erb et al, 2001; McDonald, 1991; McDonald et 
al, 1999; Price et al, 1981; Shin et al, 2008; Sun et al, 1991; Weller et al, 1982; 
Zahm et al, 1999), and a similar pattern of labeling from the CeA to the BNST is 
noted here (Figure 6A-C).  Figure 25A contains the Franklin Paxinos atlas image 
corresponding to the injection site shown in Figure 25B.  A coronal section 
containing BNST from this mouse is shown in Figure 25C.  The projection from 
the CeA to the BNST was the densest projection noted in the study of four 
regions (BLA, CeA, infralimbic cortex, insular cortex).  Fibers from the CeA were 
thin and beaded in appearance, as shown in Figure 25B.  Interestingly, the 
projection to the ventral BNST appeared to be denser than the projection to the 
dorsal BNST in all BNST sections examined.  We were not able to differentiate 
injections into various subcompartments of the CeA, as our injection site covered 
several subcompartments.  Therefore, we cannot compare our results with the 
more comprehensive analyses of CeA projections to the BNST done previously 
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by Dong and others in rat (Dong et al, 2001a).  Five mice were injected just 
medial to the CeA, in the globus pallidus, and sparse fibers (likely from minimal 
overlap with the CeA) were noted in the BNST in two of these mice.  The other 
three mice showed no projection to the BNST (data not shown). 
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Figure 25. 
 
 
Figure 25.  The central nucleus of the amygdala (CeA) projects to the BNST.  A) 
Franklin Paxinos image coronal plane 40, corresponding to Figure 25B.  Red 
sphere indicates CeA.  B) 10x tile coronal image demonstrating injection of BDA 
into the CeA.  Scale bar = 500 μm. C) 10x tile illustrating BDA(+) fibers in the 
BNST projecting from the CeA.  Scale bar = 50 μm. 
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Projections from the CeA to the BNST are GAD65(+) 
The CeA projection to the BNST has been shown in multiple studies to be 
GABAergic, and we sought to confirm that this is phylogenetically conserved in 
the mouse model.  Both in the dorsal (Figure 26A-C) and ventral (Figure 26D-F) 
BNST, we observe colocalization of BDA-filled projections from the CeA with the 
GABAergic marker GAD65.  These results suggest that as in the rat model, the 
projection from the CeA to the BNST is GABAergic in nature.  Due to the density 
of GAD65 labeling, however, future studies are needed to confirm findings noted 
here. 
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Figure 26. 
 
Figure 26. The central nucleus of the amygdala projection to the dorsal and 
ventral BNST is GAD65 containing.  A-C) BDA projection to the dBNST.  A) 
GAD65. B) BDA fibers.  C) Merge.  D-F) BDA projection to the vBNST.  D) 
GAD65  E) BDA fibers.  F) Merge.  Scale bars = 5 µm.  Insets, scale bars = 1 µm.   
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Projections from the CeA to the BNST contain α2A-ARs 
Recent data suggests that the α2A-AR plays an important role in modulation of 
GABAergic transmission in the BNST (Chapter II).  Using the HA tagged α2A-AR 
KI mouse, we have begun to examine the potential distribution of α2A-ARs on 
fibers from a main GABAergic input to the BNST, the CeA.  Qualitatively, the α2A-
AR appears to colocalize on CeA inputs to both the dorsal (Figure 27 A-C) and 
ventral BNST (Figure 27D-F).  Future studies examining localization of the α2A-
AR on these projections should be conducted to confirm current findings, as the 
density of the α2A-AR precludes us from conducting reliable quantification of our 
data set.  Data obtained using electrophysiology and microdialysis studies 
indicate that regulation of GABAergic transmission by the α2A-AR might be 
primarily post-synaptic [Chapter II, (Forray et al, 1999) (Dumont et al, 2004)].  
These localization data, however, provide evidence for potential presynaptic 
regulation of GABAergic transmission in the BNST by α2A-ARs. 
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Figure 27. 
 
 
Figure 27. The central nucleus of the amygdala projection to the dorsal and 
ventral BNST is α2A-AR containing.  A-C) BDA projection to the dBNST.  A) HA. 
B) BDA fibers.  C) Merge.  D-F) BDA projection to the vBNST.  D) HA.  E) BDA 
fibers.  F) Merge.  Scale bars = 5 µm.  Insets, scale bars = 1 µm.   
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General Discussion 
The GABAergic projection from the CeA to the BNST appears to be 
phylogenetically conserved between rat and mouse, supporting behavioral data 
implicating this projection as critical in mediating stress-induced behaviors to 
drug-seeking (Erb et al, 2001).  Further studies (larger N) should be conducted to 
confirm findings in this mouse. 
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APPENDIX C 
 
QUANTIFICATION OF BDA LABEL WITH HA-TAGGED 
α2AAR, VGLUT1, AND VGLUT2 
 
Please refer to Chapter III for background and sample confocal images. 
 
We attempted to quantify the degree of colocalization of BDA tracer 
containing VGLUT1, VGLUT2, and the HA-tagged α2AAR to determine whether a 
subset of projections to the BNST contained the α2AAR, and to confirm studies 
demonstrating that cortical projections to the BNST are primarily VGLUT1-
containing.  All findings, however, need to be examined at the EM level due to 
diffuse labeling and background issues as explained below. 
Using Metamorph, one 0.5 μM section of a z-stacked image of the dorsal 
lateral BNST per mouse was separated by channel.  Background was subtracted 
manually.  The pixel by pixel colocalization was then measured as described in 
the tables below.  Results from each mouse receiving a projection in a particular 
region were then averaged and the standard error was calculated. 
VGLUT1 and VGLUT2 are shown to have an overall complementary 
distribution throughout the brain (Hayashi et al, 2001).  Cortical regions are 
shown to have high levels of VGLUT1 mRNA, but express low levels of VGLUT2 
(Fremeau et al, 2001; Herzog et al, 2001).  Therefore, we expected to see 
moderate-high levels of VGLUT1 colocalization with BDA, and our results are as 
expected.  We expected little to no colocalization of VGLUT2 with BDA, however, 
we find that about 13-16% (on average) of BDA(+) pixels from cortical and BLA 
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injections sites also contain VGLUT2(+) pixels.  We theorize that this represents 
false-positive colocalization, or that there is some VGLUT2 protein expressed in 
these primarily VGLUT1-expressing regions.   
We find a consistently high level of α2AAR colocalization with all BDA 
tracer injections from the BLA, insular cortex, and infralimbic cortex.  We 
additionally found that 83.3 +/- 5.7% of BDA contained the α2AAR in the one CeA 
mouse we injected with BDA.  These data imply that the α2AAR may modulate 
glutamatergic transmission in all three glutamatergic input regions studied.  Data 
from the CeA mouse suggest that the α2AAR may also modulate GABAergic 
transmission in this mouse presynaptically, although more work is needed to 
examine and confirm this finding both with anatomical and functional studies. 
Results are displayed in the Tables below.  Preliminary findings confirm 
our hypothesis, but due to the diffuse α2AAR and VGLUT1 labeling, and the 
moderate background seen with the VGLUT2 antibody, all data below need to be 
confirmed and expanded upon at the EM level.  Additional studies examining 
distribution of the α2AAR at the EM level are currently underway. 
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Table 6.  IHC quantifications in the Insular Cortex 
Insular Cortex 
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Table 7.  IHC quantifications in the infralimbic cortex. 
Infralimbic Cortex 
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Table 8.  IHC quantifications in the BLA 
BLA 
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APPENDIX D 
 
YOHIMBINE DEPRESSES EXCITATORY TRANSMISSION IN SWISS-
WEBSTER MICE 
 
 
Methods used are as those described in Chapter IV Experimental 
Procedures. 
 
Figure 28.  Yohimbine depresses excitatory transmission in Swiss-Webster Mice. 
 
Figure 28.  Yohimbine causes a significant depression in the dorsal BNST of 
Swiss-Webster mice (n = 3). 
 
These findings further confirm that our results are similar in both C57BL/6J 
mice and Swiss Webster mice (compare Figure 28 to Figure 15).  As in the 
C57BL/6J mouse, we see a dramatic depression of excitatory transmission upon 
application of the reported α2-AR antagonist yohimbine.   
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